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Abstract 
Rheumatoid arthritis (RA) increases the risk of particularly atherosclerotic cardiovascular 
disease in developed populations.  The sub-Saharan black African population is currently at 
an earlier epidemiological health transition stage.  Consequently, black Africans experience 
a markedly reduced risk of atherosclerotic cardiovascular disease.   
The main objectives of this thesis were to determine whether (1) the atherosclerotic 
cardiovascular risk burden is reduced in black compared to other African patients with RA; 
(2) RA impacts on cardiovascular risk factor profiles and ultrasound determined carotid 
intima-media thickness among black Africans and (3) the atherosclerosis burden and its 
association with traditional and non-traditional risk factors differ in black compared to white 
Africans with RA. 
Black compared to other Africans with RA had more prevalent hypertension and obesity but 
smoked and consumed alcohol less frequently.  However, the overall traditional and non-
traditional atherosclerotic cardiovascular risk burden was as large in black as in other 
Africans with RA.   
      RA was not independently associated with unfavourable traditional and non-traditional 
atherosclerotic risk factors including systemic inflammation among black Africans.  Carotid 
intima-media thickness was similar in black RA and non-RA Africans. 
      The carotid intima-media thickness and plaque prevalence were as large in black 
compared to white African patients with RA.  Blood pressure, dyslipidemia, Framingham 
score, systemic inflammation and extraarticular manifestations were associated with 
atherosclerosis in white but not black African RA patients.  The Arthritis Impact 
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Measurement Scales tension score was consistently related to atherosclerosis in black but 
not white African patients with RA.  
      Black African RA women experienced a markedly larger adiposity burden than their 
white counterparts.  However, body mass index was associated with carotid intima-media 
thickness and waist-to-hip ratio with plaque in white but not black women with RA.   
      The US National Cholesterol Education Program Adult Treatment Panel III metabolic 
syndrome was identified in 30.8% of black compared to 9.7% of white African women with 
RA (p = 0.009).   In white African RA women, the metabolic syndrome definition was 
associated with carotid intima-media thickness and the triglyceride criterion and number of 
metabolic syndrome criteria were associated with plaque.  In black African RA women, only 
the blood pressure criterion was associated with carotid intima-media thickness, which 
represents mostly age and blood pressure induced hypertrophy of medial cells rather than 
atherosclerosis. 
      Reduced estimated glomerular filtration rate was found in 49.1% of black compared 
30.6% of white African patients with RA (p=0.004).  In Receiver Operating Characteristic 
curve analysis, eight of nine evaluated estimated glomerular filtration rate equations were 
associated with carotid artery plaque to a clinically useful extent for cardiovascular risk 
stratification in black but not white African patients with RA.  By contrast, estimated 
glomerular filtration rate was related to the endothelial activation markers of monocyte 
chemoattractant protein-1 and angiopoietin 2 in white but not black African patients with 
RA.   
In conclusion, the overall cardiovascular risk factor and atherosclerosis burden are currently 
as large in black compared to white African patients with RA.  Modifiable traditional risk 
factors and disease characteristics were consistently unrelated to atherosclerosis in black 
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African patients with RA.  Impaired kidney function comprised the only routinely available 
cardiovascular risk factor that was useful in identifying black African RA patients with high 
risk atherosclerosis.Systematic vascular imaging and possibly the use of novel cardiovascular 
risk biomarkers may be required for adequate cardiovascular risk stratification among black 
African patients with RA. 
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CVD  cardiovascular disease 
RA  rheumatoid arthritis 
SCORE  systematic coronary risk evaluation 
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Introduction 
Rheumatoid arthritis (RA) is a prototypic chronic high-grade inflammatory and 
destructive joint disease.  RA increases the risk of mostly atherosclerotic 
cardiovascular events to an extent that is as large as in patients with diabetes 
[1].  A recent meta-analysis of 14 studies among 41 490 patients with RA 
revealed a pooled relative risk for incident cardiovascular disease of 1.48 (95% 
CI 1.36 to 1.62) with a significantly increased risk of myocardial infarction and 
cerebrovascular accidents of 68% and 41%, respectively [2].  In a meta-analysis 
of 24 mortality studies among 111 758 RA patients, the weighted standardized 
mortality rate for cardiovascular disease death was 1.59 (95% CI 1.46 to 1.73) 
with a significantly increased risk of death from ischemic heart disease and 
cerebrovascular accidents of 59% and 52%, respectively [3].  Further, in a 
meta-analysis [4]of 13 studies that compared to the general population, the 
relative risk of a cardiovascular disease event is 2.59 (95% CI 1.77 to 3.79) and 
1.27 (95% CI 1.16 to 1.38) in RA patients <50 years compared to those aged 
>50 years.  The increased risk of cardiovascular events is therefore particularly 
high in young RA patients. 
      The presenting cardiovascular disease manifestationsalso differ in patients 
with RA compared to people without RA.  In this regard, the frequencies of 
silent myocardial infarction, sudden death, death after an acute coronary 
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syndrome and heart failure with preserved ejection fraction are each increased 
in RA [5,6].  
      How RA enhances atherogenesis remains poorly understood.  Traditional 
and non-traditional cardiovascular risk factors as well as genetic factors are 
associated with atherosclerosis as well as incident cardiovascular events in RA 
[7-11].  Amongst non-traditional cardiovascular risk factors, high-grade 
inflammation is particularly implicated in increased atherogenesis among 
patients with RA.  Indeed, high grade inflammation induces cytokine driven 
metabolic abnormalities including impaired glucose metabolism and low HDL 
cholesterol concentrations, the latter through increased catabolism [12,13].  A 
meta-analysis of 15 studies produced a significant 74% increased risk of 
diabetes and reduction in mean HDL cholesterol concentrations of 18 mg/dl 
(0.45 mmol/l) amongst patients with RA [14].  Equally important, high-grade 
inflammation in RA has direct adverse effects on the endothelium [15]. 
      Another important metabolic abnormality induced by increased cytokine 
production as well as corticosteroid use and physical disability related 
inactivity consist of rheumatoid cachexia [13].  This affects up to 60% of RA 
patients and is characterized by loss of lean body and muscle mass, which is 
replaced by fat and, consequently, an overall unchanged body mass index.  The 
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rheumatoid cachexia component of excess body fat content further enhances 
cardiovascular disease risk [13]. 
      The prevention of cardiovascular events in patients with RA remains 
inadequate [1].  In this regard, current algorithms based on traditional risk 
factors that include the Framingham score as well as the Systematic Coronary 
Risk Evaluation (SCORE) were shown to underestimate cardiovascular risk in RA 
[16].  Congruently, evidence was recently reported that a Framingham score of 
~>10% risk for any cardiovascular event and SCORE of ~>1%risk for a fatal 
cardiovascular event represent very high cardiovascular risk as evidenced by 
carotid plaque presence and thereby call for intervention with cardiovascular 
drugs in RA [17].  The respective recommended cut-off values for the 
Framingham score and SCORE are 20% and 5%, respectively, in non-RA 
subjects.  Additionally, the recent European League Against Rheumatism 
recommendations include the application of a 1.5 multiplier upon employing 
risk calculators for cardiovascular disease risk stratification in the presence of 
RA [18].  Whether either of these 2 approaches can improve cardiovascular risk 
management and thereby cardiovascular disease outcomes in patients with RA 
awaits further investigation. 
      There is another major concern in the context of current cardiovascular risk 
stratification strategies that are recommended for use in patients with RA.  
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Indeed, whereas the bulk of information on cardiovascular disease and its 
stratification derives from investigations performed in developed countries, 
80% of cardiovascular events now occur in developing populations [19,20].  
Importantly in the present context, consequent to previous colonialism and 
the subsequent apartheid system that ended in 1994, African black persons 
currently represent a developing population.  African black people are 
undergoing rapid urbanization, which comprises a process that was 
documented to impact substantially on cardiovascular risk factor profiles and 
the frequency as well as nature of associated cardiovascular events.  This 
phenomenon is described as the epidemiological health transition that consists 
of 4 stages as is illustrated in Figure 1 [20].  Whereas developed populations 
are in stage 4 of the respective transition, most sub-Saharan black African 
persons are reportedly in stages 1 and 2.  This results in more frequent 
hypertension and heart failure together with less prevalent atherosclerotic 
cardiovascular disease in black Africans.  It is therefore conceivable that 
reported data on cardiovascular risk and its stratification in RA patients 
originating in developed populations cannot be merely extrapolated to those 
belonging to developed populations.Meanwhile, the prevalence of RA is similar 
in urbanized black Africans to that in persons from developing populations.  
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What is the current cardiovascular disease risk burden in the black African 
population at large? 
      Reliable large scale epidemiological data on cardiovascular disease 
frequencies in African black people are scarce.  Nevertheless, a 2010 South 
African Medical Research Council report listed cerebrovascular disease as fifth 
and coronary artery disease as the eighth most common causes of death [21].  
Also, peripheral arterial disease was found in 29% of outpatients in a South 
African rural community [22].   
      It was amply documented that the black African population is indeed at an 
earlier health transition stage compared to that observed in developed 
populations.  Thus, heart failure that is mostly due to hypertension, and 
idiopathic dilated cardiomyopathy are currently the most commonly diagnosed 
conditions in black African patients presenting with heart disease [23].  
Coronary artery disease is often reported as being distinctively uncommon in 
this population.  Alarmingly however, a recent investigation performed in 
Johannesburg, South Africa, identified coronary artery disease in 10% of black 
African patients presenting with heart disease [23].  Stroke incidence remains 
also lower in the black African population compared to developed population 
but it occurs at a younger age and is possibly associated with increased 
mortality rates in this population [24-26].  Further, the ratio of ischemic to 
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hemorrhagic stroke was recently reported to be similar in black compared to 
white African patients [24].  Overall, the prevalence of atherosclerotic 
cardiovascular disease appears to be still markedly lower in the black African 
population than that seen in developed or high-income countries.  Recently 
reported data indicate however that atherosclerotic cardiovascular disease 
frequencies are increasing in this developing population.  This has crucial 
implications in the planning and application of optimized cardiovascular 
disease prevention strategies in the black African population.  What do 
cardiovascular disease risk factor profiles in black African persons currently 
look like? 
      The low coronary artery disease incidence has been mostly attributed to 
low total and high HDL cholesterol concentrations in the black African 
population [27].  However, more recent studies identified particularly low HDL 
cholesterol concentrations in this population [28].  This finding could further 
account for the low total cholesterol levels in black African people [28].The low 
atherosclerotic cardiovascular disease burden may therefore originate in a 
relatively short lifetime exposure rather than favourable lipid profiles in black 
Africans [29].  This is typical for a population that is undergoing rapid 
urbanization.  Also, hypertension is reportedly highly prevalent in the black 
African population [30].  In fact, apart from low tobacco consumption, the 
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prevalence of all major traditional cardiovascular disease risk factors is large 
and rising in recent studies [31-33].  In addition, large obesity rates were 
documented particularly in black African women [34].  With regard to 
psychosocial stress, the recent World Health Organization Mental Health 
Survey revealed that anxiety and other mood disorders were more prevalent 
and severe in South Africa than in other participating countries [35].  As also 
illustrated in Figure 1, this is again in line with an early epidemiological health 
transition stage.   
Chronic kidney disease is a further potential cardiovascular risk factor that may 
be particularly relevant in the present context.  Chronic kidney disease 
increases the risk of cardiac death up to 20-fold irrespective of age, sex, race 
and diabetes status [36]. The risk of cardiovascular events and mortality is 
enhanced in persons with a glomerular filtration rate below 60 ml/min/1.73m
2
 
and rises incrementally as kidney function declines [36].The frequency of CKD 
is not clearly established in Sub-Saharan Africa but may be much larger than in 
developed countries [37].  To summarize then, atherosclerotic cardiovascular 
disease risk factors may not be as favourable as was perceived until recently in 
black Africans.  Do cardiovascular risk factors impact on cardiovascular disease 
to the same extent in black African persons as in people originating in 
developed countries?         
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The associations of modifiable cardiovascular risk factors with acute 
myocardial infarction were similar in the INTERHEART Africa study compared 
to the overall INTERHEART study.  Smoking, diabetes, hypertension, abdominal 
obesity and dyslipidemia provided a population attributable risk of 89.2% for 
acute myocardial infarction [38].  However, a history of hypertension 
represented a higher myocardial infarction risk in the African black group.  
Hypertension was the most frequently implicated cause of stroke in relatively 
large studies amongst black African patients[24,39].  Noticeably, the potential 
influence of excess adiposity on stroke risk was not reported and the cause 
remained unidentified in 43% of cases [24].  Excess adiposity associates with 
hypertension as well as left ventricular diastolic function and systemic 
inflammation in this population [40,41].  Both systolic and diastolic blood 
pressure are further important determinants of diastolic function in this 
population [42].  With regard to smoking, the risk of tobacco related CVD in 
urban African black persons does not differ from that observed in developed 
populations [43].  Even mild current smoking was strongly associated with 
blood pressure in an African black population study [44].  Psychosocial stress 
but not hypertension is associated with angiopoietin-2 and vascular 
endothelial growth factor-A concentrations in black Africans [45].  The 
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latterare markers of angiogenesis, which associate with vascular dysfunction in 
African black subjects [45]. 
      Taken together, RA has adverse effects on atherosclerotic cardiovascular 
risk factor profiles and enhances cardiovascular event and mortality rates by 
~50% in patients from developed countries.  Persons belonging to developing 
populations have different cardiovascular risk factor profiles and 
cardiovascular disease event presentations consequent to being at an earlier 
epidemiological health transition stage.  It is therefore conceivable that black 
African patients with RA experience disparate atherogenic mechanisms.  This 
has implications in optimal cardiovascular disease risk stratification and 
prevention in black Africans with RA.   
      This thesis comprises 6 manuscripts that explore cardiovascular risk factor 
profiles and their associations with ultrasound determined carotid artery 
intima-media thickness and plaquein African black patients with RA.  The data 
were recorded prospectively in consecutive patients.  Each paper was 
published in a highimpact journal and multivariable analysis was applied 
consistently.    
      The hypothesis that was tested in paper 1 was that atherosclerotic 
cardiovascular disease risk factor profiles are more favourable in black 
compared to other (white, Asian or mixed ancestry) African patients with RA, 
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as reported in non-RA subjects.  The evaluated risk factors included (1) major 
traditional: hypertension, dyslipidemia, smoking and diabetes, (2) other 
traditional: underweight, obesity, metabolic syndrome, chronic kidney disease, 
alcohol consumption, tension, depression and body height, (3) non-traditional: 
rheumatoid factor status and markers of inflammation and (4) arterial 
stiffness: brachial pulse pressure. 
      In paper 2, the tested hypothesis was that RA impacts adversely on 
cardiovascular risk factor profiles and carotid intima-media thickness amongst 
black Africans, as reported in developed populations.  We compared 
traditional cardiovascular risk factors, C-reactive protein and interleukin-6 
concentrations and carotid ultrasound findings between non-RA and RA 
subjects.  Also, the potential determinants of systemic inflammation, the 
impact of systemic inflammation on traditional cardiovascular risk factors and 
the associations of cardiovascular risk factors with atherosclerosis were 
explored.  
      In paper 3, we hypothesized that the atherosclerosis burden is smaller and 
that its association with cardiovascular risk factors differs in black compared to 
white African patients with RA, again in line with reported data in non-RA 
subjects [43].  For this purpose, cardiovascular risk factor profiles and carotid 
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intima-media thickness and plaque were recorded amongst black and white 
Africans with RA.  
      Published data on the influence of adiposity on atherosclerotic 
cardiovascular disease in patients with RA from developed populations are 
contradictory [13,46-49].  As obesity rates are particularly large in black African 
women, this risk factor could be suspected to contribute more to 
atherogenesis in black compared to white African women.  This hypothesis was 
tested in paper 4.  We compared anthropometric measures in black and white 
African women with RA and assessed their associations with carotid artery 
intima-media thickness and plaque.  We also explored the impact of clinical 
adiposity measures on different metabolic risk factors.  Finally, we determined 
whether the anthropometric measure-atherosclerosis relationships were 
explained non-metabolic or/and metabolic cardiovascular risk factors. 
      Current metabolic syndrome definitions describe excess adiposity together 
with its complications.  In paper 5, we hypothesized that the burden of 
metabolic abnormalities is larger and has a greater impact on atherosclerosis 
in black compared to white women with RA.  The relationships ofthe US 
National Cholesterol Education Program Adult Treatment Panel III definition 
and criteria as well as the number of the respective criteria with carotid artery 
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intima-media thickness and plaque were systematically compared between 
black and white African women with RA. 
      The hypotheses that were tested in paper 6 included: (1) kidney function is 
more impaired in black compared to white African patients with RA, and (2) 
impaired kidney function has a larger adverse impact on endothelial activation 
and atherosclerosis in black compared to white Africans with RA.  We 
calculated 9 estimated glomerular filtration rate equations and determined 
their relations with carotid artery intima-media thickness and plaque as well as 
markers of endothelial activation, which represents the earliest stage of 
atherogenesis upon exposure to cardiovascular risk factors.  Patients with RA 
experience particularly interleukin-6 mediated marked endothelial activation 
that regresses upon treatment with disease modifying agents and tumor 
necrosis factor-α inhibition [15,50,51].  The endothelial activation markers that 
were evaluated in paper 6 included E-selectin, vascular cell adhesion molecule-
1, intercellular adhesion molecule-1 and angiopoietin 2.  Receiver operating 
characteristic curve analysis was employed to assess the performance of 
estimated glomerular filtration rate equations and their optimal cut-off values 
in identifying plaque presence. 
      The major outcomes in papers 2 – 6 of this thesis were carotid ultrasound 
determined intima-media thickness and plaque as surrogate markers of 
24 
 
 
atherosclerosis [52-53].  The intima-media thickness was measured in the 
distal common carotid artery and plaque presence was identified throughout 
the extra-cranial carotid artery tree.  Plaque develops most commonly in the 
carotid bulb due to low shear stresses and high oscillations in shear stresses 
[52].  Both carotid intima-media thickness and plaque were validated as 
surrogate markers of true biological vessel wall thickness against histological 
specimens [52].  Nevertheless, intima-media thickening occurs mostly in 
response to blood pressure induced enlargement of the arterial media.  By 
contrast, plaque represents intima thickening engendered by atherogenic 
cardiovascular risk factor exposure.  Indeed, compared to carotid intima-media 
thickness, carotid plaque is a more powerful predictor of incident 
cardiovascular events [52,53].  Congruently, in contrast to carotid plaque, 
intima-media thickness improves the prediction of cardiovascular risk only 
minimally beyond traditional risk factors [52,53].  The use of carotid intima-
media thickness in the identification of patients that require prevention with 
cardiovascular drugs has therefore recently become a matter of controversy 
[52-54].A major purpose of the present work was to quantify atherosclerosis 
extent by determining carotid intima-media thickness and plaque presence. 
      In summary, this thesis evaluates the (1) atherosclerotic cardiovascular risk 
factor profile, (2) impact of RA on atherosclerotic cardiovascular risk factors 
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and carotid intima-media thickness, (3) atherosclerosis burden and (4) 
relationships of traditional and non-traditional atherosclerotic cardiovascular 
risk factors with atherosclerosis in black African patients with RA.  The main 
objective was to elucidate atherogenesis and cardiovascular disease risk 
stratification in black Africans with RA. 
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Paper 1 
      In this initial study, atherosclerotic cardiovascular risk factors were 
compared between black and other (white, Asian and mixed ancestry) Africans 
with RA.  In keeping with being at an earlier epidemiological health transition 
stage, black Africans experienced an increased prevalence of hypertension and 
obesity, and smoked and employed alcohol less frequently.  Concurrent low 
total and HDL cholesterol concentrations resulted in unaltered atherogenic 
indices.  Interestingly, despite increased overall adiposity as represented by 
the body mass index, triglyceride concentrations were lower in black compared 
to other Africans with RA.  In this regard, the frequency of abdominal obesity 
as reflected by the metabolic syndrome waist circumference criterion was 
similar in black and other African RA patients.  Most importantly in the present 
context, the overall traditional atherosclerotic cardiovascular risk burden as 
estimated by high cardiovascular disease risk according to the Framingham 
score and Systematic Coronary Risk Evaluation, having one or more major 
traditional atherosclerotic cardiovascular risk factor, or meeting the criteria for 
the metabolic syndrome definition as well as the number of metabolic 
syndrome features, was consistently similar in black compared to other 
Africans with RA.  Also, pulse pressure as a measure of arterial stiffness did not 
differ by population grouping.  Additionally, non-traditional cardiovascular risk 
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factors or the RA characteristics of rheumatoid factor positivity and markers of 
disease activity and severity were similar in black compared other Africans 
with RA.  Finally, tension and depressive symptoms did not differ between 
black and other Africans with RA. 
      Taken together, this study documents that black African RA patients 
experience an atherosclerotic cardiovascular disease risk factor burden that is 
as large as in their non-black counterparts.  This contrasts to the overall 
findings reported in the non-RA black population.  Our finding therefore calls 
for cardiovascular disease risk evaluation and management irrespective of 
ethnic origin and epidemiological transition stage in Africans with RA.   
Does RA impact on cardiovascular risk in black Africans to the same extent as it 
does in persons belonging to developed populations? 
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Risk Factor Profiles for Atherosclerotic Cardiovascular
Disease in Black and Other Africans with Established
Rheumatoid Arthritis
AHMED SOLOMON, BERENICE F. CHRISTIAN, GAVIN R. NORTON, ANGELA J. WOODIWISS,
and PATRICK H. DESSEIN
ABSTRACT. Objective. Black Africans reportedly experience a distinctly low risk for atherosclerotic cardiovas-
cular disease (CVD). We investigated whether this protection was present among Africans with
established rheumatoid arthritis (RA).
Methods. We determined disparities in CVD risk factor profiles (major conventional: hypertension,
dyslipidemia, smoking, and diabetes; other conventional: underweight, obesity, metabolic syndrome,
chronic kidney disease, alcohol consumption, tension, depression, and body height; nonconvention-
al: rheumatoid factor status and markers of inflammation) and arterial stiffness (brachial pulse pres-
sure) between 291 black and 335 other (229 white, 64 Asian, and 42 mixed ancestry) consecutive
Africans with RA in multivariable regression models.
Results. After adjusting for demographic characteristics and healthcare sector attendance, black
Africans had more prevalent hypertension (OR 1.76, p = 0.01) and diabetes (OR 1.90, p = 0.07),
smoked less frequently (OR 0.12, p < 0.0001), and had concurrent lower total and high-density
lipoprotein cholesterol concentrations that resulted in unaltered atherogenic indices (p = 0.2) than the
other participants in the study. These findings translated into global scores for major conventional
risk factor-mediated future CVD event rates that were not reduced in black patients. Proportions of
individual metabolic syndrome components differed between black and other patients but their total
numbers of metabolic risk factors (p = 0.4) and metabolic syndrome frequencies (OR 1.44, p = 0.1)
were similar. Black ethnicity did not independently associate with rheumatoid factor status, markers
of inflammation, and brachial pulse pressures.
Conclusion. The overall conventional and nonconventional atherosclerotic CVD risk burdens and
arterial stiffness were not reduced in black patients with RA. CVD risk should be assessed and man-
aged independent of ethnic origin and epidemiological transition stage in RA. (First Release March
15 2010; J Rheumatol 2010;37:953–60; doi:10.3899/jrheum.091032)
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The enhanced risk for cardiovascular disease (CVD) in
patients with rheumatoid arthritis (RA) is well estab-
lished1-13. Atherogenesis in RA is mediated by convention-
al cardiovascular risk factors and disease characteristics,
particularly high-grade inflammation1-13. Additionally,
interactions between RA characteristics and conventional
cardiovascular risk factors can accelerate atherogenesis3,5,7.
In subjects without RA, the major conventional cardio-
vascular risk factors of hypertension, dyslipidemia, smok-
ing, and diabetes predict the bulk of future cardiovascular
events14,15. Most information on CVD originates in devel-
oped countries that are largely inhabited by white popula-
tions16. However, 80% of the CVD burden now arises in
middle-income and low-income countries16. The current
increase in incident CVD in poorer populations is attributa-
ble to the epidemiological transition induced by socioeco-
nomic development that consists of the emergence of ather-
osclerotic cardiovascular risk, engendered by nascent hyper-
tension followed by obesity, dyslipidemia, diabetes, and cig-
arette smoking17.
Until 30 years ago, CVD was reportedly less prevalent in
blacks without RA compared to white Americans, but black
Americans currently experience more adverse risk factor
profiles for atherosclerosis and higher cardiovascular event
rates than their white counterparts18-21. Black Africans are
presently considered to be at an earlier stage of the epi-
demiological transition with particularly more favorable
lipid profiles and thereby at lower risk for atherosclerosis
compared to other Africans19,22. Nevertheless, a recent
emergence of risk factors for atherosclerotic CVD has been
well documented in this population22-24 and coronary artery
disease is now diagnosed in 10% of black South Africans
who present to hospital with heart disease25. South Africa is
socioeconomically more developed than other sub-Saharan
African countries but is further characterized by persistent,
vast income and health inequities26.
The INTERHEART investigators recently documented
that conventional cardiovascular risk factors associate with
acute myocardial infarction (MI) to a similar extent in dif-
ferent ethnic groups and geographical locations worldwide
including in Africa16,19. RA is as prevalent in black as in
white urbanized Africans27,28. To our knowledge, whether
ethnic origin and epidemiological transition stage affects
cardiovascular risk in individuals who have developed RA
has not been investigated. As part of a recently initiated
study on atherogenesis in African populations with RA29,
we studied conventional and nonconventional risk factor
profiles for atherosclerosis and arterial stiffness. Our aim
was to determine whether among Africans with RA, black
patients experience a reduced risk burden for atherosclerot-
ic cardiovascular disease.
MATERIALS AND METHODS
We enrolled consecutive patients who met the American College of
Rheumatology criteria for RA30 at a public healthcare center (Charlotte
Maxeke Johannesburg Academic Hospital) and a private one (Milpark
Hospital; Table 1). All invited patients had previously been treated with dis-
ease-modifying agents and agreed to participate. The study was approved
by the Ethics Committee for Research on Human Subjects (Medical) of the
University of the Witwatersrand. Written informed consent was obtained
from each patient.
Assessments. The recorded cardiovascular risk factor profiles are presented
in Table 2 and Figure 1. All patients fasted for at least 8 hours prior to blood
sampling. Hypertension was diagnosed in patients with a blood pressure >
140 mm Hg systolic and/or > 90 mm Hg diastolic, and when antihyperten-
sives were prescribed. Dyslipidemia was diagnosed when the atherogenic
index [total cholesterol/high-density lipoprotein cholesterol (HDL) ratio]
was > 415,31. We assessed current smoking status. Patients with a fasting
plasma glucose ≥ 7 mmol/l, or in whom glucose-lowering agents were pre-
scribed, were diagnosed with diabetes. Patients with a body mass index
(BMI) < 20 kg/m2 were considered to be underweight32. We used the
recently reported RA-specific BMI threshold (> 28 kg/m2)33 in identifying
cases with generalized obesity. Patients were classified as having the
National Cholesterol Education Program Adult Treatment Panel III (NCEP
ATPIII)-defined metabolic syndrome (MetS) using the ethnicity-specific
criteria as recently updated by the American Heart Association and the
National Heart, Lung and Blood Institute34. The glomerular filtration rate
(GFR) was estimated by the Modification of Diet in Renal Disease equa-
tion and chronic kidney disease (CKD) was diagnosed when the GFR was
< 60 ml/min35. We assessed alcohol consumption (a protective cardiovas-
cular risk factor in subjects without RA)16, and depression and tension were
evaluated using the Arthritis Impact Measurement Scales (AIMS)36. Body
height was recorded as a cardiovascular risk factor that originates in envi-
ronmental and genetic factors acting early in life37.
The evaluated RA characteristics considered as potential cardiovascular
risk factors included rheumatoid factor status, C-reactive protein (CRP)
concentrations, the 28-joint Disease Activity Score (DAS28), the Health
Assessment Questionnaire disability index (HAQ-DI), and the number of
deformed joints.
Brachial pulse pressure, a marker of arterial stiffness, was defined as
the difference between systolic and diastolic blood pressure38-40.
Data management and analysis.We grouped the cardiovascular risk factors
into 3 categories. The 1st was the major conventional cardiovascular risk fac-
tors, comprising the modifiable risk factors of hypertension, dyslipidemia,
smoking, and diabetes, which form part of both the Framingham score14 and
the Systematic COronary Risk Evaluation (SCORE)15. These risk factors are
the most established ones in atherogenesis in the population without RA. As
estimates of the overall major conventional cardiovascular risk burden, we
evaluated the mean (SD) number of major risk factors and the proportions of
patients who had at least 1 major risk factor as well as those who were at high
risk (10-year risk ≥ 20%)14,15 for coronary heart disease (established CVD
and/or diabetes and/or a Framingham score of ≥ 20)14 or fatal cardiovascular
disease (established CVD and/or diabetes and/or a SCORE of ≥ 20)15. The
2nd risk category was other conventional cardiovascular risk factors, includ-
ing underweight, generalized obesity, the MetS, alcohol use, CKD, depres-
sion, tension, and body height. The 3rd risk category was nonconventional
cardiovascular risk factors, consisting of rheumatoid factor status and mark-
ers of current (DAS28, CRP, HAQ-DI) and cumulative inflammation
(HAQ-DI and number of deformed joints). Except for alcohol use, tension,
obesity, and body height, each of the assessed risk factors in this investiga-
tion was previously shown to enhance the risk for CVD in not only the gen-
eral population but also in patients with RA1-13,41-43.
Dichotomous variables are expressed as proportions or percentages and
continuous variables as mean (SD). Abnormally distributed characteristics
were logarithmically transformed prior to statistical analysis and for these
variables, geometric means (SD) are given.
Relationships between black ethnicity and CVD risk were investigated
in multivariable logistic and linear regression models as appropriate and
with consistent adjustment for age, gender, and healthcare center atten-
dance. Prescribed antihypertensive therapy and statin use were further
adjusted upon assessing associations with brachial pulse pressure and lipid
values, respectively. Finally, the metabolic cardiovascular risk was further
compared between black and other Africans by using the NCEP ATPIII
MetS criteria definitions34.
Statistical computations were made using the GB StatTM program
(Dynamic Microsystems Inc., Silver Spring, MD, USA). Since many mul-
tivariable analyses were conducted, significance was set at p < 0.01.
RESULTS
A total of 626 patients were investigated, 424 in our public
and 202 in our private healthcare center. Eighty-three per-
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Table 1. Overall African patients with RA by gender and healthcare center.
Patients
Characteristic Black, White, Asian, Mixed,
n (%) n (%) n (%) n (%)
All participants 291 (46.5) 229 (36.6) 63 (10.0) 43 (6.9)
Gender
Women 259 (49.0) 186 (35.1) 49 (9.3) 35 (6.6)
Men 32 (33.0) 43 (44.3) 14 (14.4) 8 (8.3)
Healthcare center
Public 282 (66.5) 61 (14.4) 47 (11.1) 34 (8.0)
Private 9 (4.5) 168 (83.1) 16 (7.9) 9 (4.5)
cent of the patients were either black (46.5%) or white
(36.5%; Table 1). Nine black and 168 white patients were
seen in private healthcare (p < 0.0001 for each group com-
pared to public healthcare attendance). Asian patients and
those of mixed ancestry attended both centers with similar
frequencies (p = 0.1 and p = 0.3, respectively). Black
patients were more often women and on average 2.9 years
younger (Table 2). In all patients, the mean (SD) disease
duration was 9.1 (2.4) years, and disease-modifying agents,
nonsteroidal antiinflammatory agents, prednisone [mean
(SD) dose 4.7 (1.8) mg/day], and statins were currently pre-
scribed in 97.8%, 18.4%, 4.8%, and 6.1% of cases, respec-
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Table 2. Cardiovascular risk factor profiles in black compared to white, Asian, or mixed African patients with
RA. Significant (p < 0.05) associations of black ethnicity with cardiovascular risk factors in logistic regression
models are shown in bold type.
Characteristics Black Africans White, Asian, OR* (95% CI)
(n = 291) or Mixed Africans
(n = 335)
Women 89.0 80.6 —
Major conventional CV risk factors
Hypertension 66.0 54.5 1.76 (1.14–2.74)
T chol/HDL chol > 4 18.3 19.8 0.83 (0.51–1.36)
Smoking 3.4 18.2 0.12 (0.06–0.26)
Diabetes 13.1 6.9 1.90 (0.96–3.78)
≥ 1 major risk factor 71.1 67.5 1.08 (0.69–1.70)
10-year risk for CHD ≥ 20% 14.8 13.1 1.17 (0.67–2.07)
10-year risk for fatal CVD ≥ 20% 14.5 12.5 1.09 (0.62–1.92)
Other conventional CV risk factors
BMI < 20 kg/m2 8.6 11.1 0.59 (0.31–1.13)
BMI ≥ 28 kg/m2 52.5 28.7 2.03 (1.35–3.05)
Metabolic syndrome 31.3 20.3 1.44 (0.92–2.25)
MDRD GFR < 60 ml/min 4.6 9.1 0.46 (0.21–1.04)
Alcohol use 0.7 26.9 0.12 (0.03–0.56)
Nonconventional CV risk factors
Rheumatoid factor-positive 75.6 77.5 0.94 (0.61–1.46)
Continuous variables Black Africans, White, Asian, p*
Mean (SD) or Mixed Africans,
mean (SD)
Age, yrs 54.3 (10.8) 57.2 (12.1) —
Major conventional CV risk factors
T chol, mmol/l 4.57 (0.98) 4.93 (1.05) 0.0002
HDL chol†, mmol/l 1.45 (1.48) 1.54 (1.36) 0.2
T chol/HDL chol† 3.08 (1.47) 3.12 (1.37) 0.2
LDL chol, mmol/l 2.54 (0.86) 2.81 (0.93) 0.003
No. of major risk factors 1.0 (0.8) 1.0 (0.8) 0.7
Other conventional CV risk factors
Triglycerides†, mmol/l 1.01 (1.72) 1.11 (1.66) < 0.0001
AIMS tension 3.9 (1.9) 3.7 (2.0) 0.7
AIMS depression 3.6 (1.9) 2.8 (2.0) 0.7
Height, cm 160 (10) 163 (11) 0.2
Nonconventional CV risk factors
DAS28 3.2 (1.5) 2.7 (1.4) 0.6
CRP†, mg/l 7.6 (3.5) 5.2 (3.6) 0.8
HAQ score 0.78 (0.66) 0.65 (0.64) 0.1
Deformed joints 9 (8) 8 (10) 0.2
Arterial stiffness
Pulse pressure, mm Hg 50 (14) 47 (12) 0.2
T chol: total cholesterol; CV: cardiovascular; CHD: coronary heart disease; CVD: cardiovascular disease; BMI:
body mass index; DAS28: Disease Activity Score in 28 joints; CRP: C-reactive protein; HAQ: Health
Assessment Questionnaire; HDL: high-density lipoprotein; MDRD GFR: Modification of Diet in Renal Disease
glomerular filtration rate; LDL: low-density lipoprotein; AIMS: Arthritis Impact Measurement Scales. * OR and
p value for comparisons between black and white or Asian Africans or those of mixed ancestry after adjustment
for age, gender, and healthcare center as well as lipid-lowering and antihypertensive in models that include lipid
variables and pulse pressure, respectively. † Logarithmically transformed.
tively. None of these characteristics differed in black com-
pared to other patients. However, tumor necrosis factor-α
blockers were used only in non-black patients who were seen
in private healthcare (n = 6), cyclooxygenase inhibitors were
less frequently used in black cases (n = 2 vs 17 in
non-blacks), and antihypertensives were more often taken by
black patients (53.3 vs 38.5%; OR 1.82, 95% CI 1.32–2.50).
Conventional and nonconventional cardiovascular risk fac-
tor profiles and arterial stiffness in black and other African
patients with RA. Table 2 shows that hypertension and dys-
lipidemia were the most prevalent conventional risk factors.
The 11% of subjects who used tobacco smoked 11 (SD 2)
cigarettes daily and in the 15% who consumed alcohol, the
daily intake was 0.9 (SD 0.3) units.
Adjusted for age, gender, and healthcare center atten-
dance, and lipid-lowering agents and antihypertensives
when appropriate (Table 2), black patients sustained more
prevalent hypertension, less smoking, a trend toward higher
diabetes prevalence (OR 1.90, p = 0.07), and lower total and
low-density lipoprotein (LDL) cholesterol concentrations
but similar cholesterol/HDL cholesterol ratios compared to
other Africans. Estimates of the overall major conventional
cardiovascular risk burden were consistently similar in
black and other Africans with RA. Among the other con-
ventional risk factors, triglyceride concentrations were
lower and generalized obesity more prevalent, while the
overall prevalence of the MetS did not differ in black com-
pared to other Africans with RA. Alcohol use was less fre-
quent in black patients. Nonconventional cardiovascular
risk factor profiles were similar in black and other Africans.
Finally, arterial stiffness did not differ in black compared to
other Africans.
Mixed-ancestry Africans without RA reportedly still
experience a somewhat lower risk for coronary heart disease
than white and Asian Africans19. When we repeated these
analyses after exclusion of Africans of mixed ancestry, our
findings were unaltered (Table 3).
When all the analyses in Tables 2 and 3 were repeated
with further adjustment for disease duration, the results were
unaltered (data not shown).
NCEP ATPIII-defined metabolic cardiovascular risk in
black compared to other Africans with RA. The previous
analyses revealed that although black patients with RA
experienced an overall similar prevalence of the MetS, the
individual MetS risk factors of hypertension frequency and
triglyceride concentrations differed in black compared to
other Africans with RA. We further analyzed the data in
order to clarify whether these relationships persisted once
the NCEPATPIII individual MetS criteria definitions34 were
applied. These results are shown in Figure 1. After adjust-
ments for age, gender, and healthcare center attendance,
black African patients experienced more prevalent NCEP
ATPIII-defined hypertension (OR 1.84 to 2.00), less often
elevated triglyceride concentrations (OR 0.37 to 0.43), sim-
ilar frequencies of abdominal obesity (OR 1.12 to 1.19),
reduced HDL cholesterol concentrations (OR 1.46 to 1.71),
and elevated plasma glucose concentrations (OR 1.02 to
1.07). The number of MetS criteria in black patients was 2.0
(1.1) compared to 1.7 (1.2) and 1.6 (1.2) in other patients
before and after exclusion of people of mixed ancestry,
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Figure 1. Proportions of the National Cholesterol Education Program Adult Treatment Panel III-defined meta-
bolic cardiovascular risk factors in black and other Africans (before and after exclusion of subjects of mixed
ancestry) with RA. MetS: metabolic syndrome; BP: blood pressure; HDL: high-density lipoprotein cholesterol;
trig: triglycerides. *Analysis adjusted for age, gender, and healthcare sector.
respectively (p = 0.4 after adjustment for age, gender, and
healthcare center).
DISCUSSION
Our study revealed disparities in several individual conven-
tional risk factor profiles among black and other Africans
with RA. Such findings reportedly reflect different epidemi-
ological transition stages in subjects without RA17,19.
Differences in conventional CVD risk factors included a
higher prevalence of hypertension and lower smoking fre-
quency in black patients that resulted in an unaltered overall
major conventional CVD risk burden relative to other
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Table 3. Cardiovascular risk factor profiles in black compared to white or Asian African patients with RA.
Significant (p < 0.05) associations of black ethnicity with cardiovascular risk factors in logistic regression
models are shown in bold type.
Characteristics Black Africans White or Asian OR* (95% CI)
(n = 291) Africans
(n = 293)
Women 89.0 80.5 —
Major conventional CV risk factors
Hypertension 66.0 53.4 1.76 (1.09–2.84)
T chol/HDL chol > 4 18.3 18.9 0.80 (0.47–1.36)
Smoking 3.4 17.8 0.13 (0.06–0.28)
Diabetes 13.1 6.6 1.76 (0.84–3.71)
≥ 1 major risk factor 71.1 65.8 1.14 (0.70–1.85)
10-year risk for CHD ≥ 20% 14.8 12.3 1.14 (0.61–2.11)
10-year risk for fatal CVD ≥ 20% 14.5 12.0 1.05 (0.57–1.95)
Other conventional CV risk factors
BMI < 20 kg/m2 8.6 10.7 0.70 (0.34–1.42)
BMI ≥ 28 kg/m2 52.5 27.5 2.21 (1.41–3.47)
Metabolic syndrome 31.3 19.5 1.42 (0.87–2.32)
MDRD GFR < 60 ml/min 4.6 8.7 0.44 (0.19–1.04)
Alcohol use 0.7 30.1 0.12 (0.02–0.54)
Nonconventional CV risk factors
Rheumatoid factor-positive 75.6 77.6 0.93 (0.57–1.50)
Continuous variables Black Africans White or Asian p*
Mean (SD) Africans,
mean (SD)
Age, yrs 54.3 (10.8) 56.9 (12.1) —
Major conventional CV risk factors
T chol, mmol/l 4.57 (0.98) 4.96 (1.05) < 0.0001
HDL chol†, mmol/l 1.45 (1.48) 1.56 (1.35) 0.2
T chol/HDL chol† 3.08 (1.47) 3.11 (1.36) 0.2
LDL chol, mmol/l 2.54 (0.86) 2.83 (0.90) 0.0004
No. of major risk factors 1.0 (0.8) 0.9 (0.8) 0.7
Other conventional CV risk factors
Triglycerides†, mmol/l 1.01 (1.72) 1.10 (1.68) < 0.0001
AIMS tension 3.9 (1.9) 3.7 (2.0) 0.6
AIMS depression 3.6 (1.9) 2.7 (2.1) 0.8
Height, cm 160 (10) 164 (11) 0.4
Nonconventional CV risk factors
DAS28 3.2 (1.5) 2.6 (1.5) 0.4
CRP†, mg/l 7.6 (3.5) 4.8 (3.7) 0.5
HAQ score 0.78 (0.66) 0.60 (0.61) 0.5
Deformed joints 9 (8) 7 (9) 0.3
Arterial stiffness
Pulse pressure, mm Hg 50 (14) 47 (12) 0.09
T chol: total cholesterol; CV: cardiovascular; CHD: coronary heart disease; CVD: cardiovascular disease; BMI:
body mass index; DAS28: Disease Activity Score in 28 joints; CRP: C-reactive protein; HAQ: Health
Assessment Questionnaire; HDL: high-density lipoprotein; MDRD GFR: Modification of Diet in Renal Disease
glomerular filtration rate; LDL: low-density lipoprotein; AIMS: Arthritis Impact Measurement Scales. * OR and
p value for comparisons between black and white or Asian Africans after adjustment for age, gender, and health-
care center as well as lipid-lowering and antihypertensive in models that include lipid variables and pulse pres-
sure, respectively. † Logarithmically transformed.
African patients. Similarly, black ethnicity was associated
with a lower prevalence of MetS triglyceride concentrations
and a higher frequency of MetS hypertension that together
translated into a similar overall metabolic risk burden com-
pared to other Africans with RA. Additionally, we found no
disparities in nonconventional risk factor profiles between
black and other African patients. Finally, and in keeping
with an unaltered overall CVD risk burden, arterial stiffness
was not reduced in blacks compared to other patients with
RA.
Although data on atherosclerotic CVD in sub-Saharan
Africa are few19, the increased prevalence of hypertension
in our black patients with RA is reminiscent of what was
published on black Africans without RA as well as on
Americans19,44. Nevertheless, because of factors including a
reduced intake of saturated fat, black subjects without RA in
Africa reportedly have more favorable lipid profiles than
other individuals on that continent19,22,45. It is the low total
cholesterol and high HDL cholesterol concentrations in
black Africans that are believed to account for the current
low prevalence of ischemic heart disease in this popula-
tion22. In our investigation, black patients had lower total
and LDL cholesterol concentrations than other patients with
RA. In the general population, the cholesterol/HDL choles-
terol ratio exceeds total, HDL, and LDL cholesterol concen-
trations in predicting incident CVD31. We found that black
patients with RA experienced not only lower total choles-
terol but also concurrent lower HDL cholesterol con-
centrations and thereby atherogenic indices or total choles-
terol/HDL cholesterol ratios that did not differ from those
found in other Africans with RA. Additionally, although the
prevalence of diabetes is increasing in black Africans, it is
still reportedly lower than in whites living in Africa46.
Among Africans with RA in our study, black patients expe-
rienced a trend (OR 1.76 to 1.90, p = 0.07) toward a higher
prevalence of diabetes in age, gender, and healthcare sector
adjusted analysis. Our results on individual major conven-
tional CVD risk factors translated into an overall risk burden
for atherosclerosis that was similar in black and other
patients with RA, as estimated by the number or presence of
one or more of the respective risk factors or being at high
risk for incident coronary heart disease or fatal CVD.
Importantly in the present context, hypertension is more
strongly associated with acute MI in black Africans than in
other populations19. Our findings suggest that an earlier epi-
demiological transition stage, as manifested by the presence
of lower total and LDL cholesterol concentrations and less
frequent smoking in black Africans with RA, fails to render
immunity to the risk of atherosclerosis as it reportedly does
in the general black African population19,22.
Other conventional risk factors for atherosclerotic CVD
in not only the population at large but also in patients with
RA include the MetS and its components6,9, being under-
weight32, CKD42, and depression41. In our multivariable
analyses, black and other patients with RA exhibited similar
prevalences of underweight and CKD, and AIMS depres-
sion. Except for NCEP ATPIII-defined raised glucose and
reduced HDL cholesterol concentrations and abdominal
obesity, the frequencies of MetS features differed in black
compared to other Africans. This comprised a higher preva-
lence of elevated blood pressure and less frequently
increased triglyceride concentrations. Notably, using the
National Health and Nutrition Examination Survey, Sumner
and Cowie recently reported that, compared to non-Hispanic
whites and Mexican Americans, non-Hispanic blacks were
more likely to be insulin-resistant despite experiencing
lower triglyceride concentrations47. Reduced insulin sensi-
tivity was also found in black Africans without RA48.
Despite different individual metabolic risk factor profiles in
black compared to other Africans with RA, black patients
did not sustain an altered number of MetS criteria and
prevalence of the MetS. Our findings indicate that the over-
all metabolic CVD risk is likely to be similar in black and
other Africans with RA and certainly not lower in black
patients.
The RA characteristics of current and cumulative inflam-
mation markers constitute documented important noncon-
ventional CVD risk factors in RA4,5,13,42. After adjusting for
potential confounders including public healthcare atten-
dance, a surrogate for socioeconomic disadvantage in our
context26,49,50, the inflammatory burden did not differ in
black compared to other Africans with RA. Interestingly,
and in agreement with our findings, Iren and colleagues
recently reported no differences in HAQ-DI and DAS28 in
black compared to white Americans with RA, when adjust-
ed for confounders including socioeconomic status51.
Increased brachial pulse pressure strongly associates
with the prevalence and incidence of CVD, and its risk fac-
tors are generally similar to those for atherosclerosis38-40.
We found that the mean brachial pulse pressure did not dif-
fer between black and other patients in multivariable analy-
sis. These findings substantiate the notion that the overall
risk for atherosclerotic CVD is unlikely to be reduced in
black Africans with RA.
We prospectively evaluated detailed CVD risk factor pro-
files in 626 consecutive patients with RA. We did not per-
form a power analysis prior to the initiation of our study.
However, based on our results, a minimum of 15, 34, 46,
and 158 patients needed to be included in the 2 groups of
African and other patients with RA in order to document a
significant (p < 0.01) difference of 1, 1, 1, and 5 mm Hg in
the number of major conventional CVD risk factors, the
number of MetS components, DAS28, and pulse pressure,
respectively, at 80% power. The cross-sectional design of
our study precludes drawing inferences on the direction of
causality. Also, although an increased brachial pulse pres-
sure reflects arterial stiffness38-40, our current finding of a
higher than expected risk for atherosclerosis in black
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patients with RA calls for the assessment by more direct
measures of subclinical cardiovascular disease in future
investigations that address the effect of ethnic origin on
CVD risk in RA. We are currently addressing these issues.
Although black Africans with RA smoke less frequently
and have lower MetS triglyceride concentrations than other
Africans with this disease, they experience more frequent
hypertension that therefore should be particularly targeted in
CVD risk management. Despite potentially different epi-
demiological transition stages and/or biological factors
among African populations, the overall conventional and
nonconventional risk burdens for atherosclerotic CVD and
arterial stiffness were not reduced in black compared to
other patients with RA in our study. CVD risk should be
comprehensively assessed and managed irrespective of eth-
nic origin in individuals who have contracted RA, including
those in developing populations.
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Paper 2 
      This study assessed whether RA influences atherosclerotic cardiovascular 
risk factors and atherosclerosis in the black African population as it reportedly 
does in developed populations.  The analysis revealed a series of novel and 
unanticipated findings: 
1. Body mass index was reduced in RA by 4.5 kg/m
2
 compared to non-RA   
subjects.  On the other hand, waist-hip ratio was unaltered in RA.   
2. Dyslipidemia was less prevalent in RA but this was no longer the case after 
adjustment for adiposity and chloroquine use. 
3. Hypertension, diabetes and smoking prevalence, and the number of major 
cardiovascular risk factors did not differ by RA status. 
4. Concentrations of C-reactive protein were similar and those of interleukin-6 
were reduced in RA.  This was probably due to the reduced adiposity burden 
in RA.  Indeed, adiposity was most strongly associated with systemic 
inflammation irrespective of RA status. 
5. RA activity and severity were consistently unrelated to systemic 
inflammation. 
6. The carotid intima-media thickness was not different in RA compared to 
non-RA subjects. 
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7. Low density lipoprotein cholesterol concentrations were associated with 
carotid intima-media thickness.  However, this cardiovascular risk factor 
explained a mere 2.3% of the variance in carotid intima-media thickness. 
In summary, each of these findings contrasts to findings reported on the 
impact of RA on atherosclerotic cardiovascular disease risk in developed 
populations.  Our results indicate that an absent release of interleukin-6 into 
the circulation may account for the unaltered cardiovascular disease risk in 
black Africans with compared to those without RA.  Interestingly, extraarticular 
manifestations are also distinctly uncommon in black Africans with RA.  This 
indicates that the inflammatory process in RA may indeed be restricted to the 
joints in this population.   
Is the atherosclerosis burden reduced in black compared to white Africans with 
RA?  Also, is the potential impact of atherosclerotic cardiovascular disease risk 
factors on atherosclerosis similar in black compared to white Africans with RA? 
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Rheumatoid arthritis is associated with reduced
adiposity but not with unfavorable major
cardiovascular risk factor profiles and enhanced
carotid atherosclerosis in black Africans from a
developing population: a cross-sectional study
Patrick H Dessein1*, Angela J Woodiwiss1, Gavin R Norton1 and Ahmed Solomon2
Abstract
Introduction: Rheumatoid arthritis (RA) is characterized by inflamed joint-derived cytokine-mediated high-grade
systemic inflammation that enhances cardiovascular metabolic risk and disease in developed populations. We
investigated the potential impact of RA on cardiovascular risk factors including systemic inflammation and
atherosclerosis, and their relationships in black Africans from a developing population.
Methods: We evaluated demographic features, adiposity indices, major traditional cardiovascular risk factors,
circulating C-reactive protein and interleukin-6 concentrations and ultrasound determined carotid intima-media
thickness (cIMT) in 274 black Africans; 115 had established RA. Data were analyzed in confounder-adjusted mixed
regression models.
Results: The body mass index and waist-height ratio were lower in RA compared to non-RA subjects (29.2 (6.6)
versus 33.7 (8.0), P < 0.0001 and 0.58 (0.09) versus 0.62 (0.1), P = 0.0003, respectively). Dyslipidemia was less
prevalent in patients with RA (odds ratio (OR) (95% confidence interval (CI) = 0.54 (0.30 to1.00)); this disparity was
no longer significant after further adjustment for reduced adiposity and chloroquine use. RA was also not
associated with hypertension, current smoking and diabetes. The number of major traditional risk factors did not
differ by RA status (1.1 (0.8) versus 1.2 (0.9), P = 0.7). Circulating C-reactive protein concentrations were similar and
serum interleukin-6 concentrations reduced in RA (7.2 (3.1) versus 6.7 (3.1) mg/l, P = 0.7 and 3.9 (1.9) versus 6.3 (1.9)
pg/ml, P < 0.0001, respectively). The cIMT was 0.700 (0.085) and 0.701 (0.111) mm in RA and non-RA subjects,
respectively (P = 0.7). RA disease activity and severity parameters were consistently unrelated to systemic
inflammation, despite the presence of clinically active disease in 82.6% of patients. In all participants, adiposity
indices, smoking and converting angiotensin inhibitor non-use were associated with increased systemic
inflammation, which related to more atherogenic lipid profiles, and circulating low density lipoprotein
concentrations were associated with cIMT (partial R = 0.153, P = 0.032); RA did not impact on these relationships
(interaction P ≥0.1).
Conclusions: Among black Africans, patients with established RA experience reduced overall and abdominal
adiposity but no enhanced major traditional risk factor and atherosclerosis burden. This study further suggests that
an absent interleukin-6 release by inflamed RA joints into the circulation may account for this unaltered
cardiovascular disease risk.
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Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory and
potentially destructive joint disorder that is complicated
by enhanced atherosclerosis and incident cardiovascular
event rates similar to diabetes [1-6], as well as cardiovas-
cular mortality [4,7].
In the general population, the bulk of cardiovascular
disease (CVD) is attributable to the traditional risk fac-
tors of hypertension, dyslipidemia, smoking and diabetes
[8,9]. In addition, cytokine-mediated systemic inflamma-
tion as generally estimated by circulating C-reactive pro-
tein concentrations (CRP), contributes to atherogenesis
[10-19]. Systemic inflammation originates mostly in
excess adiposity and smoking, and mediates CVD
through adverse effects on metabolic cardiovascular risk
factors as well as more direct effects at the endothelial
level [10-19].
RA is characterized by circulating CRP concentrations
that are typically increased several fold even when the
disease appears clinically controlled [20,21]. Although,
in RA, adiposity and smoking associate independently
with serum CRP concentrations [22], the inflammation
extent is mostly accounted for by circulating joint
derived cytokines, particularly interleukin-6 [20-22].
Several genetic polymorphisms were recently found
to be associated with CVD in RA [23-27]. Amongst the
modifiable cardiovascular risk factors, it is the chronic
high-grade systemic inflammatory state that is cur-
rently considered to best explain the excess CVD in
RA [20,21,28-31]. Congruent with this paradigm, sys-
temic inflammation is associated with metabolic risk
factors, including insulin resistance and decreased high
density lipoprotein (HDL) cholesterol concentrations in
RA [20,21,32,33]. A recent meta-analysis of traditional
cardiovascular risk factors in RA indeed confirmed the
presence of lower HDL cholesterol concentrations and
an enhanced diabetes frequency [34]. Importantly in
the present context also, high-grade inflammation in
RA is complicated by a reduced lean mass and particu-
larly muscle mass together with increased body fat
accumulation, a condition most often termed rheuma-
toid cachexia [35,36]. Adiposity associates with meta-
bolic risk factors in RA [36-38]. With regard to more
recently identified cardiovascular risk factor pathways,
circulating interleukin-6 concentrations are indepen-
dently associated with endothelial activation [21] that
decreases upon suppression of interleukin-6 production
in RA [39].
Besides systemic inflammation in RA, antirheumatic
agents can modify cardiovascular risk factors. Although
short term glucocorticoid therapy in patients with mark-
edly active RA can enhance insulin sensitivity [20],
chronic use of this intervention associates with insulin
resistance [40], atherosclerosis [41] and cardiovascular
event rates [42]. Chloroquine therapy induces favorable
lipid profiles [43,44] and lowered diabetes risk [45] and
leflunomide use hypertension [46] and dyslipidemia [47].
As applies to the general population, available data on
atherogenesis in RA were generally obtained in subjects
that belong to developed populations, whereas 80% of
CVD now occurs in low income or developing countries
[38,48-52]. In this regard, we recently documented con-
sistent disparities in individual cardiovascular risk factor
profiles including more marked overall adiposity, an
increased prevalence of hypertension and less frequent
alcohol consumption in patients with RA from develop-
ing groups of black African descent compared to their
white counterparts from a developed population, as well
as risk factor-atherosclerosis relationships amongst both
groups [38,51,52]. Non-RA black African subjects
experience not only a very large prevalence of obesity
[53] and hypertension [54,55], but also a strikingly large
systemic inflammation burden [56-58], whereas serum
C-reactive protein concentrations are not increased in
black Africans compared to white patients with RA [52].
Further, cumulative inflammation as estimated by the
number of deformed joints, is independently associated
with decreased overall and abdominal obesity in African
black but not white women with RA [38]. In the present
study, we examined the potential impact of RA on car-
diovascular risk factors, including systemic inflamma-
tion, carotid atherosclerosis and their relationships
amongst 274 African blacks.
Materials and methods
Study participants
The present investigation was conducted according to the
principles outlined in the Helsinki declaration. The Com-
mittee for Research on Human Subjects of the University
of Witwatersrand approved the protocols applied in non-
RA and RA subjects (approval numbers: M02-04-72 and
renewed as M07-04-69 in non-RA subjects and M06-07-
33 in RA subjects). Participants gave informed, written
consent. The present study design has previously been
described [38,50-52,56,59-61]. Briefly, 115 African black
patients who met the 1988 American College of Rheuma-
tology criteria for RA [62] were enrolled at the Charlotte
Maxeke Johannesburg Academic Hospital. All invited
patients agreed to participate. Only two RA subjects used
prednisone and, hence, to avoid confounding of the data
analysis by this intervention, the respective participants
were excluded. All patients used disease modifying agents
for rheumatic disease (DMARDs) at the time of the
study. Age- and sex-matched non-RA subjects were parti-
cipants in a population study on cardiovascular risk and
disease that is also conducted in Johannesburg [56,59-61].
This investigation comprises randomly recruited nuclear
families of black African descent with siblings older than
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16 years. Of the 159 non-RA participants, 124 had CRP
measurements and 92 carotid ultrasound evaluations; the
other recorded variables did not differ in non-RA subjects
with and without CRP and carotid ultrasound assess-
ments. Data were missing in fewer than 5% of any of the
other recorded cardiovascular risk factors in the study
participants.
Baseline characteristics
We recorded demographic features, life style factors
comprising alcohol use (at least one unit per month)
and exercise (at least once per month) that included
time spent in walking, for example, to reach public
transportation, and cardiovascular and non-steroidal
anti-inflammatory drug (NSAID) use. Height, weight
and waist and hip circumference were measured using
standard approaches. Body mass index (BMI) cut-off
points of <20, 20 to 24.9, 25 to 29.9 and >29.9 kg/m2
were employed to identify underweight, normal weight,
overweight and obese status, respectively. Abdominal
obesity indices included waist circumference and waist-
height ratio whereas fat distribution was estimated by
the waist-hip ratio [38]. In patients with RA, we addi-
tionally recorded disease duration, the Clinical Disease
Activity Index (CDAI) [63], the number of deformed
joints (cumulative inflammation or disease severity),
rheumatoid factor status and the use of traditional or
synthetic DMARDs. Patients with RA had no access to
biological DMARD therapy at the time of the study
[38,50-52].
Conventional cardiovascular risk factors
Hypertension was defined as an average systolic blood
pressure ≥140 or/and diastolic blood pressure ≥90
mmHg or/and current use of antihypertensive medica-
tions. Uncontrolled and untreated hypertension were
diagnosed in patients with a systolic blood pressure
≥140 or/and diastolic blood pressure ≥90 mmHg who
used and did not use antihypertensive agents, respec-
tively. Standard laboratory blood tests of renal and liver
function, hematological parameters, lipids and glucose
were performed. Dyslipidemia was diagnosed when the
atherogenic index, that is, the cholesterol-HDL choles-
terol ratio was more than four and proatherogenic
non-HDL cholesterol concentrations were calculated by
subtracting HDL cholesterol from total cholesterol con-
centrations [38,44,50-52]. We documented smoking
habits. Diabetes was identified as the use of glucose low-
ering agents or a fasting plasma glucose ≥7 mmol/l. The
overall major conventional cardiovascular risk factor
burden was estimated by the number and proportion of
patients with one or more of such risk factors that com-
prised hypertension, dyslipidemia, current smoking
status and diabetes, as well as the Framingham 10-year
risk prediction scores for coronary heart disease (myo-
cardial infarction or coronary death) [8] and general
CVD (myocardial infarction, coronary death, coronary
insufficiency, angina, ischemic stroke, hemorrhagic
stroke, transient ischemic attack, peripheral vascular dis-
ease or heart failure) [9].
Systemic inflammation
Serum CRP and interleukin-6 comprised the evaluated
laboratory inflammatory markers in the present investi-
gation. CRP concentrations were determined using
immunoturbidimetric methods. In non-RA subjects,
this was done on the AU analyzer (Olympus, Essex,
UK), the lower detection limit was 0.05 mg/l and the
inter- and intra-assay coefficients of variation were 1.3
and 0.4%, respectively; in RA patients it was performed
on the DxC/LX analyzer (Beckman Coulter, Inc., Brea,
CA, USA), the lower detection limit was 1 mg/l and
the inter- and intra-assay were 2.5 and 5.0%, respec-
tively. In the general population, a CRP concentration
>1 mg/l reportedly predicts increased incident CVD
[16,19]. Seventy-four blood samples from subjects who
did not participate in the present study were tested on
both the AU and DxL/LX systems and the Spearman
correlation coefficient between the obtained CRP
values was 0.994. Interleukin-6 concentrations were
measured using a solid-phase sandwich enzyme-linked
immunosorbant assay (ELISA) (Quantikine®HS, R&D
Systems, Inc., Minneapolis, MN, USA). The lower
detection limit ranged from 0.016 to 0.110 pg/ml and
inter- and intra-assay coefficients of variation were 7.8
and 7.4%, respectively.
Carotid artery atherosclerosis
Carotid artery intima-media thickness (cIMT) measure-
ments were made using a linear array 7.5 MHz probe
attached to a high resolution B-mode ultrasound
machine (SonoCalc IMT, Sonosite, Inc., Bothell, WA,
USA) in both RA and non-RA subjects, as recently
described [38,51,52]. This equipment involves the appli-
cation of a unique semi-automated border detection
program that was previously documented to provide
highly reproducible intra- and inter-rater results in
other as well as our settings [38,51,52,61,64]. Carotid
artery plaque is currently identified in our RA patients
[38,51,52] but not in non-RA subjects and, hence,
results on plaque are not shown in the present report.
Data analysis
Dichotomous variables are expressed as proportions or
percentages and continuous variables as mean (SD).
Non-normally distributed characteristics were logarith-
mically transformed prior to statistical analysis and for
these variables geometric means (SD) are given. The
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selection of confounders in multivariable regression
models was both data driven and based on biological
plausibility.
Disparities in demographic features between RA and
non-RA subjects were compared using the Student’s
t-test and univariate logistic regression analysis as
appropriate. Relationships of RA with baseline recorded
characteristics, major cardiovascular risk factors,
systemic inflammation and atherosclerosis were first
investigated in multivariable logistic and continuous
regression models as appropriate with consistent adjust-
ment for demographic characteristics since age differed
numerically by RA status. The associations between RA
and cardiovascular risk factors, systemic inflammation
and atherosclerosis status were then re-assessed in mod-
els that included additional potential confounders or/
and mediators.
In all participants, the relation of circulating CRP and
interleukin-6 concentrations with potential determinants
of systemic inflammation and metabolic cardiovascular
risk factors were investigated in demographic character-
istic as well as in multiple confounder adjusted models.
The impact of RA on these relationships was deter-
mined by employing interaction terms [38,51,52].
Finally, in patients with RA, the associations of clinical
disease activity and severity variables with systemic
inflammation were investigated in demographic and
multiple confounder adjusted models.
Statistical computations were made using the GB
Stat™ program (Dynamic Microsystems, Inc., Silver-
spring, MD, USA).
Results
Baseline characteristics in African black subjects with and
without RA
Table 1 gives the baseline characteristics in the study
participants. The proportion of women was numerically
larger by 3.4% amongst those with compared to those
without RA. Alcohol was consumed only by non-RA
subjects (17.6%), who also exercised more than their
RA counterparts. The BMI was substantially lower in
RA compared to non-RA subjects (difference in mean
= 4.5 kg/m2). In age and sex adjusted analysis, black
Africans with RA had more frequently a normal BMI
(odds ratio (OR) (95% confidence interval (CI)) = 3.42
(1.69 to 6.95)) and were less often obese (OR (95% CI)
= 0.35 (0.21 to 0.59)) than those without RA. Abdominal
obesity measures (waist and waist-height ratio) were lar-
ger in non-RA subjects whereas RA was not associated
with an altered fat distribution (waist-hip ratio). Hyper-
tension was treated in 72.1% and 61.5% (OR (95% CI) =
1.76 (0.93 to 3.33)) of RA and non-RA cases, respectively.
Antihypertensive agents were more frequently employed
(OR (95% CI) = 1.87 (1.12 to 3.11)) and the mean
number of antihypertensives prescribed was twice as
large in subjects with compared to those without RA; this
was mostly due to a more regular use of angiotensin con-
verting enzyme inhibitors (OR (95% CI) = 10.00 (4.80 to
20.85)) and calcium channel blockers (OR (95% CI) =
4.01 (1.66 to 9.69)). Amongst treated hypertensive partici-
pants, 58.5% of non-RA subjects compared to 67.7% of
RA patients had uncontrolled hypertension (systolic
blood pressure ≥140 or/and diastolic blood pressure ≥90
mm Hg) (OR (95% CI) = 1.49 (0.71 to 3.14)).
In patients with RA, the mean disease duration was
12.5 years, 76.5% tested rheumatoid factor positive,
17.4% experienced clinical remission and 53% moderate
or high disease activity. Methotrexate and chloroquine
comprised the most frequently prescribed DMARDs and
the mean number of DMARDs used was 2.4.
Conventional cardiovascular risk factor profiles in African
black subjects with and without RA
Table 2 shows the conventional cardiovascular risk fac-
tor profiles in black Africans with and without RA. In
age- and sex-adjusted analysis (Model 1 in Table 2), RA
was associated with less frequent dyslipidemia (OR (95%
CI) = 0.54 (0.30 to 1.00)) and consistently more favor-
able individual lipid parameters. Subjects with RA had a
similar frequency of ever smoking but had discontinued
smoking more often than their non-RA counterparts.
Amongst smokers, the mean number (SD) of cigarettes
smoked per day was low at 4.1 (2.3). The overall major
conventional cardiovascular risk factor burden as esti-
mated by the number of major risk factors, the presence
of at least one major risk factor and the 10-year risks
for coronary heart disease and cardiovascular disease
were similar in subjects with and without RA.
Besides disparities in adiposity measures between RA
and non-RA subjects (Table 1), other factors that could
have confounded or mediated our findings in Model 1
(Table 2) included chloroquine [43-45] and leflunomide
use [46,47]. Thus, amongst patients with RA and in age,
sex, cardiovascular drug, obesity measure and lifestyle
factor adjusted analysis, potentially relevant relationships
(P < 0.2) were found between chloroquine and lefluno-
mide use and the cholesterol-HDL cholesterol ratio
(partial R = -0.153, P = 0.13 and partial R = 0.158, P =
0.12, respectively). Leflunomide use also potentially
impacted on systolic blood pressure but this constituted
an inverse relationship (partial R = -0.177, P = 0.08)
thereby arguing against an adverse effect of leflunomide
on blood pressure amongst black Africans with RA. None
of the other RA characteristics (Table 1) were found to be
potential confounders or mediators in the associations
between RA and cardiovascular risk factors (P > 0.2).
The mediating or confounding effects of disparities of
adiposity indices between RA and non-RA subjects,
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Table 1 Baseline characteristics in African black subjects with and without rheumatoid arthritis
Rheumatoid arthritis
Characteristic Present (n = 115) Absent (n = 159) P-valuea
Demographics
Age, years 55.7 (10.3) 56.5 (10.9) 0.5
Female (%) 89.6 86.2 0.45
Lifestyle factors
Alcohol use (%) 0 17.6 -
Units per week, numberb 0 0.27 (1.08) -
Exercise (%) 41.7 42.8 1.0
Hours per week, numberb 0.1 (1.0) 1.7 (2.4) 0.0004
Anthropometric measures
Body mass index 29.2 (6.6) 33.7 (8.0) <0.0001
<20 kg/m2 (%) 5.4 2.5 0.2
20 to 24.9 kg/m2 (%) 25.2 8.8 0.0004
25 to 29.9 kg/m2 (%) 25.2 23.3 0.8
>29.9 kg/m2 (%) 44.1 64.8 0.0001
Waist circumference, cm 93.1 (13.3) 97.5 (15.0) 0.01
Waist/height 0.58 (0.09) 0.62 (0.1) 0.0003
Hip circumference, cm 110 (18) 116 (15) 0.002
Waist/hipb 0.85 (1.14) 0.84 (1.13) 0.4
Cardiovascular drugs
Antihypertensive agents
Use (%) 53.9 40.2 0.02
Number 1.0 (1.1) 0.5 (0.7) <0.0001
>1 agent (%) 36.5 8.8 <0.0001
Diuretic (%) 38.3 39.0 1.0
Angiotensin converting enzyme inhibitor (%) 40.8 6.9 <0.0001
Calcium channel blocker (%) 16.5 5.0 0.002
Beta blocker (%) 3.5 0 -
Angiotensin receptor blocker (%) 0.9 0 -
Glucose lowering agents
Oral glucose lowering agent (%) 13.9 10.1 0.3
Insulin (%) 0.9 2.5 0.3
Statin (%) 19.1 0 -
Nonsteroidal antiinflammatory agent (%) 6.1 4.4 0.6
Rheumatoid arthritis characteristics
Disease duration, years 12.5 (8.8)
Clinical Disease Activity Indexb [58] 8.3 (2.6)
<2.8 or remission (%) 17.4
2.7 to 10 or mild disease activity (%) 29.6
11 to 22 or moderate disease activity (%) 40.0
>22 or high disease activity (%) 13.0
Deformed joints, numberb 6.2 (2.7)
Rheumatoid factor positive (%) 76.5
Disease modifying agents
Methotrexate (%) 92.2
Chloroquine (%) 80.9
Sulphasalazine (%) 25.2
Leflunomide (%) 20.0
Azathioprine (%) 14.8
Tetracyclin (%) 10.4
Cyclophosphamide (%) 6.1
Penicillamine (%) 2.6
Results are expressed as mean (SD) or proportions/percentages. aExcept for associations between rheumatoid arthritis status and demographic characteristics,
adjusted for age and gender; bnon-normally distributed variables for which geometric mean (SD) is given.
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leflunomide and chloroquine use and systemic inflamma-
tion on the associations between RA and cardiovascular
risk factors (Model 1 in Table 2) are shown in models 2
to 5. In Model 2, additional adjustment for anthropo-
metric measures consistently attenuated the inverse
associations between RA and lipid variables. In Model 3,
further adjustment for leflunomide use strengthened the
respective associations thereby confirming an adverse
effect of leflunomide on serum lipid concentrations. In
keeping with the above reported negative borderline rela-
tionship between leflunomide use and systolic blood pres-
sure, the association between RA and hypertension was
also strengthened and, in fact, significant. In Model 4,
additional adjustment for chloroquine use resulted in a
complete lack of association between RA and lipid para-
meters. In Model 5, further adjustment for serum CRP
and interleukin-6 concentrations did not materially alter
the results in Model 4. The same applied when lifestyle
factors were adjusted for (data not shown).
In a separate model, the number of antihypertensives
used (Table 1) remained higher in RA compared to non-
RA subjects independent of demographic characteristics,
life style factors, obesity measures, systemic inflammation
and leflunomide use; amongst patients with RA, none of
the disease characteristics were related to the number of
antihypertensives used (data not shown).
Systemic inflammation in African black subjects with and
without RA
In age and sex adjusted analysis, circulating interleukin-6
concentrations were strongly associated with circulating
CRP concentrations (partial R = 0.396, P < 0.0001) and
the presence of RA did not impact on this relationship
(interaction P > 0.1)
Table 2 further gives serum CRP and interleukin-6
concentrations in the study subjects. Serum CRP
concentrations did not differ and the serum interleukin-6
concentrations were lower in RA compared to non-RA
subjects (P = 0.7 and P < 0.0001, respectively, in age and
sex adjusted analysis) (Model 1 in Table 2). Adjustment
for obesity measures did not materially alter these results
(Model 2 in Table 2). Also, further adjustment for alcohol
use, cigarettes smoked per day and the use of angiotensin
converting enzyme inhibitors that were additional poten-
tial confounders in the present context (see analyses
below), did not materially alter the relationship between
RA and systemic inflammation (data not shown).
The lack of impact of RA on CRP concentrations and
reduced interleukin-6 concentrations in patients with
RA is unexpected. Therefore, we further measured CRP
and interleukin-6 concentrations in 122 African whites
with RA that formed part of an investigation that was
previously reported by us [52]. We used the same assay
as in all subjects and the one employed in non-RA sub-
jects in the present study upon quantifying CRP and
interleukin-6 concentrations (see methods), respectively.
In African white patients with RA, the geometric mean
(SD) CRP and interleukin-6 concentrations were 4.3
(3.7) mg/l and 3.6 (2.2) pg/ml, respectively. CRP concen-
trations were higher in black compared to white patients
(P = 0.002 and 0.03 before and after adjustment for con-
founders (see Table 3)) and those of interleukin-6 were
similar in both groups (P = 0.4 and 0.4 before and after
adjustment for confounders).
Carotid artery atherosclerosis in African black subjects
with and without RA
The carotid artery atherosclerosis burden in African black
subjects with and without RA is also shown in Table 2.
In age and sex adjusted analysis, the cIMT was similar in
both groups (P = 0.7) (Model 1 in Table 2). Further
adjustment for anthropometric measures, leflunomide
Table 3 Associations of potential determinants of systemic inflammation with CRP and interleukin-6 concentrations in
all participants
C-reactive proteina Interleukin-6a
Potential determinant Age and sex adjusted
model
Multivariable adjusted
model
Age and sex adjusted
model
Multivariable adjusted
model
Partial R P Partial R P Partial R P Partial R P
Body mass index 0.240 0.0003 -0.005 0.9 0.227 0.0002 0.148 0.02
Waist circumference 0.318 <0.0001 0.173 0.005
Waist/height 0.302 <0.0001 0.188 0.005 0.182 0.004 -0.001 1.0
Waist/hipa 0.163 0.01 0.054 0.39
Number of cigarettes/daya 0.017 0.8 0.034 0.6 0.128 0.04 0.130 0.04
Alcohol use 0.065 0.3 0.048 0.5 0.162 0.008 0.098 0.1
ACE inhibitor use 0.051 0.4 0.056 0.4 -0.144 0.019 -0.127 0.045
Model 0.350 0.331
Significant associations are shown in bold. aNon-normally distributed variables that were logarithmically transformed. Except for alcohol use (only in participants
without rheumatoid arthritis), none of the relationships differed in black Africans with versus those without rheumatoid arthritis (interaction P = 0.1 to 0.9). CRP,
C-reactive protein.
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and chloroquine use and systemic inflammation did not
alter these results (models 2 to 5 in Table 2).
Factors associated with systemic inflammation in African
black subjects with and without RA
Table 3 gives the significant associations between the
potential determinants of systemic inflammation that
were recorded in subjects with and without RA (charac-
teristics shown in Table 1) and serum CRP and interleu-
kin-6 concentrations. In age- and sex-adjusted analysis,
each anthropometric measure was associated with CRP
concentrations and overall and abdominal obesity mea-
sures as well as the number of cigarettes smoked, alcohol
use and angiotensin converting enzyme inhibitor therapy
were associated with interleukin-6 concentrations. In
additional models in which these characteristics (except
for waist circumference and waist-hip ratio that were
omitted because of co-linearity) were entered together as
independent variables, the waist-height ratio remained
associated with serum CRP concentrations and the BMI,
number of cigarettes smoked per day and angiotensin
converting enzyme inhibitor therapy were independently
associated with interleukin-6 concentrations. None of the
relationships between potential determinants of systemic
inflammation and serum CRP and interleukin-6 concen-
trations differed in black African subjects with compared
to those without RA (interaction P = 0.1 to 0.9).
Table 4 shows the analyses of the associations
between recorded clinical disease activity and disease
severity (deformed joint count) measures and serum
CRP and interleukin-6 concentrations in subjects with
RA. Both in age and sex adjusted models as well as in
models that included additional adjustment for potential
confounders (Table 3), there were no significant rela-
tionships; the same was true when the respective asso-
ciations reassessed in subgroups with no or mild disease
activity (Table 5) and moderate and high disease activity
(Table 7), respectively. In fact, in those with more
marked disease activity, a borderline inverse relationship
between the swollen joint count and interleukin-6 con-
centrations was noted. These results were also unex-
pected. Hence, to ensure that the lack of association
between CRP concentrations and clinical disease activity
and severity measures is specific to African black
patients with RA in our setting, we also assessed the
respective relationships in African whites with estab-
lished RA that formed part of our previously reported
investigation [52]. Indeed, in these patients, upon adjust-
ment for demographic characteristics, the log swollen
joint count (partial R = 0.536, P < 0.0001), log tender
joint count (partial R = 0.429, P < 0.0001), log doctor
disease activity (partial R = 0.628, P < 0.0001), patient
disease activity (partial R = 0.464, P < 0.0001), log CDAI
(partial R = 0.580, P < 0.0001), CDAI >2.7 (partial R =
0.481, P < 0.0001) and log deformed joint count (partial
R = 0.254, P = 0.005) were each strongly associated with
log CRP concentrations. Upon further adjustment for
additional potential confounders (Table 3), these rela-
tionships remained equally strong (partial R = 0.531,
0.425, 0.614, 0.460, 0.516, 0.462 and 0.284 for log swol-
len and log tender joint count, log doctor and patient
disease activity, log CDAI and CDAI >2.7 and log
deformed joint count (P < 0.003 for each), respectively).
Table 7 gives the significant associations of serum CRP
and interleukin-6 concentrations with the recorded cardi-
ovascular risk factors (Table 2) in African black subjects
with and without RA. In age and sex adjusted models,
both inflammatory markers were related to metabolic risk
that comprised lipid variables. None of the associations
between systemic inflammation and cardiovascular risk
factors differed in African black subjects with compared
to those without RA (interaction P = 0.4 to 0.9).
Relationships between cardiovascular risk factors and
carotid artery atherosclerosis in African subjects with and
without RA
In age-, sex- and statin therapy-adjusted models, serum
low-density lipoprotein (LDL) cholesterol concentrations
Table 4 Relationships of disease activity and severity with systemic inflammation in all 115 African RA patients
C-reactive proteina Interleukin-6a
Disease activity variable Age and sex adjusted model Multivariable adjusted modelb Age and sex adjusted model Multivariable
adjusted modelb
Partial R P Partial R P Partial R P Partial R P
Swollen jointsa 0.081 0.4 0.102 0.3 -0.136 0.2 -0.101 0.3
Tender jointsa 0.005 1.0 0.009 0.9 -0.029 0.8 -0.012 0.9
Doctor disease activitya 0.061 0.5 0.057 0.6 0.077 0.4 0.126 0.2
Patient disease activity -0.053 0.6 0.082 0.4 0.101 0.3 0.090 0.4
CDAIa 0.065 0.5 0.049 0.6 0.083 0.4 0.031 0.8
CDAI >2.7 0.069 0.5 0.088 0.4 0.129 0.2 0.163 0.1
Deformed jointsa 0.040 0.7 0.103 0.3 -0.027 0.8 -0.016 0.9
aNon-normally distributed variables that were logarithmically transformed; badditionally adjusted for potential confounders of body mass index, waist:height ratio
and angiotensin converting enzyme inhibitors (see Table 3). CDAI, Clinical Disease Activity Index.
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were associated with cIMT (partial R = 0.153, P = 0.032).
Further adjustment for other traditional risk factors com-
prising hypertension, diabetes and smoking did not mate-
rially alter these associations (R = 0.135, P = 0.06). The
other recorded cardiovascular risk factors (Table 2) were
not associated with cIMT and the relationships between
cardiovascular risk factors and cIMT were consistently
similar in black African subjects with compared to those
without RA (interaction P > 0.2).
Discussion
Among African black subjects from a developing popu-
lation, patients with RA experienced markedly reduced
adiposity compared to their non-RA counterparts. RA
was not independently associated with hypertension,
dyslipidemia, smoking and diabetes and the overall
major traditional risk factor burden was similar in RA
compared to non-RA subjects. Serum CRP concentra-
tions were not increased in RA and further unrelated to
disease activity and severity, a finding that was specific
to African black patients with RA. The carotid artery
atherosclerosis extent did not differ by RA status. To
our knowledge, this is the first study that evaluated the
association of RA with cardiovascular risk factors and
atherosclerosis in African black persons.
In the present study, non-RA subjects experienced an
apparently large systemic inflammation burden with
mean circulating CRP and interleukin-6 concentrations
of 6.7 mg/l and 6.3 pg/ml, respectively. Of likely rele-
vance in the present context, the pro-inflammatory cyto-
kine interleukin-6 IL-6-174 G/G genotype was found
36.5 (95% CI = 8.8 to 159.1) times more frequently in
African compared to white Americans [65]. The most
striking finding in the current investigation was the
Table 5 Relationships of disease activity and severity with systemic inflammation in non- or mildly active RA.
C-reactive proteina Interleukin-6a
Disease activity variable Age and sex
adjusted model
Multivariable adjusted
modelb
Age and sex
adjusted model
Multivariable
adjusted modelb
Partial R P Partial R P Partial R P Partial R P
Swollen jointsa 0.082 0.6 0.063 0.7 -0.189 0.2 -0.147 0.3
Tender jointsa -0.067 0.6 -0.100 0.5 -0.173 0.2 -0.168 0.3
Doctor disease activitya 0.044 0.8 0.017 0.9 -0.126 0.4 -0.027 0.9
Patient disease activity -0.148 0.3 -0.139 0.3 0.070 0.6 0.011 0.9
CDAIa -0.034 0.8 -0.060 0.7 -0.143 0.3 -0.116 0.4
Deformed jointsa 0.071 0.6 0.119 0.4 -0.081 0.6 0.013 0.9
Fifty-four patients had no or mild disease activity (CDAI = 0 to 10). aNon-normally distributed variables that were logarithmically transformed; badditionally
adjusted for potential confounders of body mass index, waist:height ratio and angiotensin converting enzyme inhibitors (see Table 3). CDAI, Clinical Disease
Activity Index.
Table 7 Associations of systemic inflammation with
cardiovascular risk factors in RA and non-RA African
subjects
Cardiovascular risk factor C-reactive proteina Interleukin-6a
Partial R P Partial R P
HDL chola -0.247 0.0002 -0.109 0.08
Chol/HDL chol 0.208 0.002 0.104 0.10
Triglycerides/HDL chola 0.170 0.01 0.147 0.02
LDL chol/HDL chola 0.202 0.002 0.038 0.5
Relationships were assessed in age and sex adjusted models. Significant
associations are shown in bold. HDL, high density lipoprotein; chol, cholesterol;
LDL, low density lipoprotein. None of the relationships differed in black Africans
versus those without rheumatoid arthritis (interaction P = 0.4 to 0.9).
Table 6 Relationships of disease activity and severity with systemic inflammation in moderately or highly active RA
C-reactive proteina Interleukin-6a
Disease activity variable Age and sex
adjusted model
Multivariable
adjusted modelb
Age and sex
adjusted model
Multivariable
adjusted modelb
Partial R P Partial R P Partial R P Partial R P
Swollen jointsa 0.025 0.9 0.113 0.4 -0.260 0.07 -0.246 0.1
Tender jointsa 0.028 0.8 0.014 0.9 -0.131 0.4 -0.120 0.4
Doctor disease activitya 0.100 0.5 0.084 0.6 0.212 0.2 0.232 0.1
Patient disease activity -0.092 0.5 -0.066 0.7 0.222 0.1 0.225 0.2
CDAIa 0.066 0.6 0.111 0.5 0.125 0.4 0.147 0.3
Deformed jointsa 0.041 0.8 0.028 0.8 0.012 0.9 -0.050 0.7
Sixty-one patients had moderate or high disease activity (CDAI > 10). aNon-normally distributed variables that were logarithmically transformed; badditionally
adjusted for potential confounders of body mass index, waist:height ratio and angiotensin converting enzyme inhibitors (see Table 3). CDAI, Clinical Disease
Activity Index.
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absence of increased systemic inflammation in RA com-
pared to non-RA subjects despite the presence of clini-
cally active disease [63] in >80% of the patients. This is
in sharp contrast to the RA associated six- to seven-fold
increase in both CRP and interleukin-6 concentrations
in a study on mostly white patients with RA, as pre-
viously reported by us [21]. In addition, there was an
overall lack of impact of RA on the relationships of cir-
culating interleukin-6 and CRP concentrations with
their potential determinants and metabolic risk factors.
The concentrations of circulating interleukin-6 that con-
stitute the major determinant of hepatic CRP produc-
tion [12,17] were higher in non-RA compared to RA
black Africans even after adjusting for confounders.
However, the full impact of disparities in potential con-
founders including adiposity measures, smoking, alcohol
consumption and angiotensin converting enzyme inhibi-
tor use [16,66-68] on the association of RA status with
circulating interleukin-6 concentrations may not have
been accounted for in multivariable models, particularly
given the cross-sectional design of our study.
Our findings have important implications. First, they
suggest that interleukin-6 produced in inflamed joints is
not released into the circulation in black Africans with
established RA. As well, the very low prevalence of extra-
articular manifestations among black Africans with RA
[52,69] supports the presence of an inflammatory process
that is mostly restricted to the joints. Since race specific
therapeutic responses to interleukin-6 blockade with toci-
lizumab were not observed in randomized controlled
trials that included black patients, interleukin-6 should be
equally important in the pathogenesis of RA induced
synovitis in black compared to other subjects [70].
Second, based on reported consistent results that origi-
nate in patients with RA from developed populations, a
lack of adverse impact of RA on systemic inflammation
would be expected to translate in unaltered cardiovascular
risk factor profiles and disease [20,21,32,33,71,72]. Indeed,
among African black subjects, RA was not related to
adverse metabolic risk and atherosclerosis. Furthermore,
whereas in patients with RA from developed populations,
the associations of traditional cardiovascular risk factors
with CVD are weakened due to the substantial contribu-
tion of systemic inflammation to cardiovascular mortality
[31], in the present study, black Africans with RA experi-
enced similar cardiovascular risk factor-atherosclerosis
associations compared to their non-RA counterparts.
Third, our findings could explain the apparent dispari-
ties in RA-adiposity relationships among our patients
and those that participated in previously reported stu-
dies [35-37,73,74]. Thus, patients with RA from devel-
oped populations sustain reduced lean body mass and
increased adiposity that is mediated mainly by systemic
inflammation and results in an overall unaltered or
increased BMI and waist circumference, together with a
more central fat distribution that enhances cardiovascular
metabolic risk [35-37,73,74]. Accordingly, this condition
has also been termed ‘rheumatoid cachectic obesity’ and
‘hypercytokinaemic cachexia’ [35]. In the present study,
RA in black persons was associated with reduced overall
and abdominal obesity indices and not with an altered fat
distribution as estimated by waist-hip ratio. Waist
circumference is determined by abdominal fat and hip
circumference by lean mass and subcutaneous fat [75,76].
The waist and hip circumference were reduced to a simi-
lar extent in RA compared to non-RA subjects in this
study. Reduced adiposity indices partially explained more
favorable lipid profiles in RA in mixed regression models
and, hence, may protect against CVD. Although systemic
inflammation was not increased in African black patients
with RA, their cumulative joint inflammation was distinc-
tively large with a mean joint deformity count of 9.7. The
joint deformity count is inversely related to BMI, waist
and waist-height but not waist-hip ratio in African black
women with RA [38] and the same relationships were
found in the present investigation (data not shown).
Reported findings together with our results therefore
indicate that high-grade systemic and joint restricted
inflammation may have disparate effects on adiposity and
its distribution in RA.
Last, C-reactive protein concentrations should not be
relied upon when determining the need for DMARD
intensification in African black patients with RA.
Chloroquine, a long standing treatment in rheumatic
diseases, can reduce hepatic cholesterol synthesis and
increase LDL receptor numbers on fibroblasts and
enhances insulin secretion and sensitivity [43-45]. We
found that the associations of RA with a range of serum
lipid concentrations and their ratios, including the tri-
glycerides-HDL cholesterol ratio that is a marker of
insulin resistance [77], were attenuated and no longer
significant once chloroquine use was accounted for. Stu-
dies aimed at determining the true independent impact
of RA on cardiovascular risk factor profiles should con-
sider confounding by RA treatment.
Despite a low smoking prevalence and the small num-
ber of cigarettes consumed daily, the 10-year risk for
CVD was substantial at approximately 10% in black
Africans. These data are reminiscent of an earlier health
transition stage that characterizes developing popula-
tions [49,50].
As previously reported in developed populations, RA
was not associated with an augmented prevalence of
hypertension in the present investigation [34]. Further,
high frequencies of untreated and uncontrolled hyper-
tension were documented earlier in RA [46] and, in
black Africans, these also did not differ by RA status.
Notably, however, despite similar blood pressure values
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to those in non-RA subjects, patients with RA employed
more frequent and twice as many antihypertensive
agents, a disparity that remained unexplained in multi-
variable analysis. Whether and how RA could influence
hypertension responsiveness to antihypertensive therapy
deserves to be determined in longitudinal studies.
The present study has further limitations. Carotid
artery plaques are more strongly associated with coron-
ary heart disease and its risk factors than cIMT that
relates more closely to stroke and its determinants [38].
Nevertheless, both cIMT and plaque predict future car-
diovascular event rates in RA and non-RA subjects irre-
spective of ethnicity [78-81]. Serum LDL concentrations
were independently associated with cIMT that therefore
would be expected to reflect atherosclerosis and coron-
ary heart disease risk in black Africans. As applies to
most studies on CVD, many relationships were evalu-
ated. Our main findings each originated in confounder-
adjusted multivariable models.
Conclusions
RA associates with markedly reduced overall and
abdominal adiposity in black Africans. However, in con-
founder adjusted analysis, RA did not impact on major
traditional cardiovascular risk factor profiles, athero-
sclerosis extent and their relationships in this popula-
tion. An absence of interleukin-6 release by inflamed
RA joints into the circulation may account for this unal-
tered cardiovascular risk.
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Paper 3 
      In this paper, we compared the (1) atherosclerosis burden and (2) 
associations of traditional and non-traditional cardiovascular risk factors with 
atherosclerosis measures between black and white African patients with RA.  
The atherosclerosis burden was as large in black compared to white African RA 
patients with a similar carotid intima-media thickness as well as plaque 
prevalence.   
      Interaction and stratified analysis produced consistent disparities in 
cardiovascular risk factor-atherosclerosis relations among black and white 
African patients with RA.  Thus, in white African RA patients, systolic blood 
pressure was related to both carotid intima-media thickness and plaque; 
further, the total cholesterol-high density lipoprotein cholesterol ratio and C-
reactive protein concentrations were associated with carotid intima-media 
thickness and extraarticular manifestations were related to carotid plaque.  
The Framingham score explained 22% of the variation in intima-
mediathickness values.  By contrast, in black African RA patients, the Arthritis 
Impact Measurement Scales tension score was associated with both the 
carotid intima-media thickness and plaque; non-steroidal anti-inflammatory 
agent use was also related to plaque prevalence in this group but as only 7.4% 
of them employed the respective medication, this finding needs further 
38 
 
 
investigation.  The Framingham score explained a non-significant (p = 0.06) 
mere 3.2% of the variation in carotid intima-media thickness. 
      Taken together, traditional and non-traditional cardiovascular risk factors 
were associated with atherosclerosis in white African RA patients as previously 
reported in developed populations.  By contrast, tension symptoms comprised 
the only cardiovascular risk factor that was consistently related to 
atherosclerosis in black African patients with RA.  Again, this finding is 
reminiscent of the presence of an early epidemiological transition stage.  These 
findings argue strongly against the extrapolation of recommendations on 
cardiovascular disease risk stratification in RA patients from developed 
populations to those of black African ancestry.  Our findings on the 
Framingham score-atherosclerosis relationships further support this 
interpretation.  The systematic use of vascular imaging may be needed in order 
to obtain adequate cardiovascular risk stratification in black African RA 
patients at the present stage.  
      As the prevalence of excess adiposity is particularly large in black African 
women, what is the potential contribution of adiposity as assessed by different 
anthropometric measures, to atherosclerosis in black compared to white 
Africans with RA? 
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The Carotid Artery Atherosclerosis Burden and Its
Relation to Cardiovascular Risk Factors in Black and
White Africans with Established Rheumatoid Arthritis:
A Cross-sectional Study
AHMED SOLOMON, ANGELA J. WOODIWISS, ABU T. ABDOOL-CARRIM, BELINDA A. STEVENS, 
GAVIN R. NORTON, and PATRICK H. DESSEIN
ABSTRACT. Objective. Black Africans currently experience a distinctly low frequency of atherosclerotic cardiovas-
cular disease. Whether this protection persists in those with rheumatoid arthritis (RA) is unknown. We
compared the carotid atherosclerosis burden and its relationships with cardiovascular (CV) risk factors
between Africans with RA from a developing black and developed CV population.
Methods. We performed high resolution B-mode ultrasonography and assessed CV risk factors in 243
patients with established RA, of whom 121 were black and 122 white. Data were analyzed in age, sex,
and healthcare center-adjusted regression models.
Results. The mean ± SD common carotid intima-media thickness (cIMT) was 0.694 ± 0.097 mm in
black and 0.712 ± 0.136 mm in white patients (adjusted p = 0.8). Plaque prevalence was also similar in
black compared to white cases (35.5% and 44.3%, respectively; adjusted OR 0.83, 95% CI 0.32–2.20,
p = 0.7). Interactions between population grouping and several CV risk factors were independently
associated with cIMT and plaque. In stratified analysis, that is, in each population group separately, risk
factors associated with cIMT or/and plaque comprised the systolic blood pressure (p = 0.02), serum
cholesterol/high-density lipoprotein cholesterol ratio (p = 0.004), C-reactive protein concentrations 
(p = 0.01), and the presence of extraarticular manifestations (p = 0.01) in whites but, contrastingly, the
Arthritis Impact Measurement Scales tension score (p = 0.04) and use of nonsteroidal antiinflammato-
ry agent (p = 0.03) in black patients. The Framingham score was significantly associated with athero-
sclerosis only in whites (p < 0.0001).
Conclusion. The carotid atherosclerosis burden is similar in black compared to white Africans with RA,
but relationships between modifiable CV risk factors and atherosclerosis vary substantially among
Africans with RA. (First Release July 1 2012; J Rheumatol 2012;39:1798–806; doi:10.3899/
jrheum.120073)
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Rheumatoid arthritis (RA) is a chronic inflammatory and
destructive joint disease that is recognized to enhance the risk
for atherosclerotic cardiovascular disease (CVD) events about
2-fold1. The standardized CV mortality ratio is increased by
50% in RA and thereby accounts for most of the excess over-
all mortality caused by this disease2.
CVD in RA is brought about by traditional and nontradi-
tional CV risk factors or disease characteristics, particularly
inflammation3,4,5,6,7,8,9,10. Importantly also in this context,
whereas genetic factors contribute substantially to CVD in the
population at large11, the same likely applies in RA. Indeed,
genetic polymorphisms that are implicated in inflammatory
pathways such as the TNFA-308 (rs1800629)12 and the
CCR5∆32 variant13 and metabolic pathways including the
acid phosphatase locus 1*C allele14 were recently shown to be
associated with CVD in patients with RA. Further, genes that
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influence RA susceptibility can influence CVD15 and its con-
ventional risk factors in RA16. These findings may enable elu-
cidation of the molecular mechanisms involved, discovery of
new therapeutic targets, and optimization of risk assessment
in RA-related CVD.
Our knowledge of CVD in the general population and even
more in persons with chronic inflammatory diseases such as RA
largely derives from studies that were performed in developed
populations17,18. However, ~80% of CVD now arises in middle
and low-income groups or in developing countries17. Further,
the effect of individual CV risk factors on CV events may differ
in the developing compared to the developed nations18,19,20.
South Africa, a sub-Saharan country with 50 million inhab-
itants, has become the most unequal society in the world21. A
minority of South Africans follow a westernized lifestyle, live
in modern cities, and represent a developed and mostly white
population, whereas the majority still follow a more tradition-
al lifestyle, live outside these cities, and typify a developing
and predominantly black population20,22,23. Accordingly,
these populations are at different stages of the epidemiologi-
cal health transition, and the incidence of CVD is still dis-
tinctly uncommon in black compared to white sub-Saharan
Africans18,20,22. However, whether this protection is present in
black Africans in the face of established RA is unknown. The
South African Heart Association recommends the European
Society of Cardiology and European Atherosclerosis Society
guidelines on CV risk assessment and management irrespec-
tive of population grouping or socioeconomic factors24. In
keeping with an earlier epidemiological transition stage, we
recently identified several disparities in individual CVD risk
factor profiles between blacks and other Africans with RA
(whites, Asians, and people of mixed ancestry) but the overall
traditional and nontraditional CVD risk burden was similar in
both populations18. In our present study, we compared the
ultrasonographically determined carotid atherosclerosis bur-
den, a predictor of CVD events in the general population and
in patients with RA24,25,26, in black and white Africans with
RA. Additionally, we investigated whether disparities exist in
the relationships of modifiable CVD risk factors with carotid
atherosclerosis between the 2 populations.
MATERIALS AND METHODS
Study populations. We enrolled patients during the period March 23 to
November 25, 2009, who met the American College of Rheumatology crite-
ria for RA27, at the Charlotte Maxeke Johannesburg Academic Hospital (pub-
lic healthcare) and Milpark Hospital (private healthcare) in Johannesburg
(Table 1). None of the recorded data have been reported previously. Only
patients that had used disease-modifying agents were included; 4 invited
patients refused to participate and those known to be infected with the human
immunodeficiency virus (HIV) were excluded. Considering the aims of the
investigation, we also excluded patients of mixed ancestry and Asians with
RA because they are not consistently at the same epidemiological transition
stage as either black or white Africans20. The HIV prevalence in South
Africans aged 50 years and older is currently 5.7%28; and Asians and people
of mixed ancestry comprise 11% and 8%, and 8% and 5% of patients with RA
in our public and private healthcare centers, respectively18.
Whereas patients attending South African public healthcare centers cur-
rently have no access to use of biological agents for RA, this intervention was
employed in 10 private-care patients (tumor necrosis factor-α blockade in 9
and rituximab in 1), all whites. Biological and nonbiological disease-modify-
ing antirheumatic drugs (DMARD) were grouped into the same single vari-
able for the purpose of our data analysis. Nonsteroidal antiinflammatory
drugs (NSAID) used in black and white patients comprised nonselective
cyclooxygenase (COX) inhibitors (indomethacin and ibuprofen) in the former
and both traditional NSAID (ibuprofen, diclofenac, and meloxicam) and
selective COX-2 inhibitors (celecoxib and etoricoxib) in the latter.
The study was approved by the Ethics Committee for Research on Human
Subjects (Medical) of the University of the Witwatersrand. Written informed
consent was obtained from each patient.
Assessments. CV risk factors that were assessed are presented in Table 2. Data
were missing in < 5% for any of the recorded characteristics. All patients fast-
ed for at least 8 h prior to blood sampling. Hypertension was defined as aver-
age systolic blood pressure ≥ 140 mm Hg or/and diastolic blood pressure ≥ 90
mm Hg or/and current use of antihypertensive medications. Serum total cho-
lesterol and low and high-density lipoprotein (LDL, HDL) concentrations
were determined by enzymatic assays, serum triglyceride concentrations by
the glycerol phosphate oxidase method, and C-reactive protein (CRP) con-
centrations by nephelometry. Dyslipidemia was diagnosed when the athero-
genic index, i.e., cholesterol/HDL cholesterol ratio, was > 4, and the
proatherogenic non-HDL concentrations were calculated by subtracting HDL
cholesterol from total cholesterol concentrations18,29,30. Current smoking sta-
tus was assessed. Diabetes was defined as plasma glucose concentration ≥ 7
mmol/l or/and use of glucose-lowering agents. We recorded alcohol use (at
least 1 unit per month), exercise (at least once per month and including time
spent in walking, that is, to reach public transport), marital status, education
level (years of education), body mass index (BMI), waist circumference, and
the waist-hip ratio. Symptoms of tension and depression were estimated by
the Arthritis Impact Measurement Scales (AIMS)31.
RA characteristics evaluated as potential CV risk factors comprised the
rheumatoid factor status, extraarticular manifestations (see below), use of
antirheumatic agents including NSAID, prednisone, and number of pre-
scribed DMARD, RA duration, the Disease Activity Score in 28 joints
(DAS28), serum CRP concentrations, the Stanford Health Assessment
Questionnaire Disability Index, and the number of deformed joints18,32.
Extraarticular manifestations included current or previously recorded (hospi-
tal record review) presence of pericarditis, pleuritis, Felty’s syndrome, cuta-
neous vasculitis, neuropathy, scleritis or episcleritis, retinal vasculitis,
glomerulonephritis, vasculitis affecting other organs, amyloidosis, keratocon-
junctivitis sicca, xerostomia, Sjögren’s syndrome, pulmonary fibrosis, bron-
chiolitis obliterans organizing pneumonia, cervical myelopathy, and subcuta-
neous nodules and rheumatoid nodules in other locations32,33.
Two authors (BAS, AS) performed the carotid artery ultrasound measure-
ments in private and public healthcare patients, respectively. Both operators
obtained images of at least 1-cm length of the distal common carotid arteries
for measurement of the intima-media thickness of the far wall from an opti-
mal angle of incidence, defined as the longitudinal angle of approach where
Table 1. African patients (n = 243) with RA by sex and healthcare center.
Black, White, p
n (%) n (%)
All participants 121 (49.8) 122 (50.2) —
Sex
Women 108 (89.3) 95 (77.9)
Men 13 (10.7) 27 (22.1) 0.02
Healthcare center
Public 117 (96.7) 22 (18.0)
Private 4 (3.3) 100 (82.0) < 0.0001
RA: rheumatoid arthritis.
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Table 2.  Cardiovascular risk factor profiles in black compared to white patients with RA. Dichotomous vari-
ables are expressed as proportions or percentages and continuous characteristics as mean ± SD. Significant asso-
ciations are shown in bold type.
Characteristics Black, White, OR* (95% CI)
n = 121 n = 122
Female sex 89.3 77.9 —
Major conventional CV risk factors
Hypertension 71.9 45.9 2.43 (1.00–5.94)
T chol/HDL chol > 4 22.2 15.8 1.78 (0.56–5.64)
Smoking 3.3 9.9 0.22 (0.05–1.05)
Diabetes 16.5 7.4 1.78 (0.47–6.65)
Other conventional CV/predisposing risk factors
Alcohol use 2.5 38.0 0.05 (0.01–0.15)
Exercise 39.7 33.3 0.93 (0.39–2.18)
Marital status
Unmarried 38.0 7.4 2.88 (0.92–9.05)
Married 37.2 75.4 0.52 (0.22–1.26)
Divorced 8.3 9.0 0.82 (0.19–3.42)
Widowed 16.5 8.2 1.56 (0.38–6.39)
Nonconventional CV risk factors
Rheumatoid factor-positive 50.5 48.3 1.02 (0.38–2.75)
Extraarticular manifestations 2.5 12.3 0.19 (0.05–0.67)
Antirheumatic agent used
NSAID 7.4 27.0 3.18 (0.56–18.16)
Prednisone 1.7 3.3 0.50 (0.09–2.78)
Continuous variables, mean ± SD p*
Age, yrs 55.8 ± 10.1 58.2 ± 11.4 —
Major conventional CV risk factors
Systolic blood pressure 140 ± 24 128 ± 17 0.5
Diastolic blood pressure 86 ± 15 79 ± 9 0.02
T chol, mmol/l 4.7 ± 0.9 5.0 ± 1.1 0.03
HDL chol†, mmol/l 1.48 ± 1.34 1.61 ± 1.03 0.05
T chol/HDL chol 3.2 ± 1.1 3.2 ± 1.0 0.6
LDL chol, mmol/l 2.6 ± 0.8 2.8 ± 0.9 0.2
Non-HDL chol, mol/l 3.1 ± 0.9 3.3 ± 1.0 0.2
Pack-year history of smoking†, yrs 0.1 ± 1.7 2.8 ± 5.2 0.008
Major risk factors, n 1.2 ± 0.8 0.8 ± 0.7 0.1
Framingham score† 2.6 ± 3.0 2.9 ± 3.0 0.5
Other conventional CV/predisposing risk factors
Exercise†, hours per wk 0.6 ± 2.0 0.6 ± 2.1 0.2
Education, yrs 7.4 ± 4.1 13.0 ± 2.7 0.0002
BMI, kg/m2 29.4 ± 6.6 25.6 ± 4.7 0.003
Waist circumference, cm 93.4 ± 13.4 88.8 ± 13.0 0.08
Waist/hip† 0.85 ± 3.65 0.86 ± 1.11 0.6
Triglycerides†, mmol/l 1.08 ± 1.71 1.08 ± 1.51 0.6
AIMS tension† 3.8 ± 1.5 2.8 ± 1.7 0.1
AIMS depression† 3.2 ± 1.5 1.8 ± 1.7 0.1
Nonconventional CV risk factors
Disease duration, yrs 12.8 ± 9.2 14.3 ± 9.3 0.5
DAS28 4.1 ± 1.3 3.6 ± 1.6 0.3
CRP†, mg/l 7.0 ± 3.1 4.3 ± 3.7 0.9
HAQ score† 0.54 ± 0.41 0.37 ± 0.43 0.5
Deformed joints† 6 ± 2 4 ± 4 0.08
No. DMARD 2.5 ± 1.0 2.2 ± 0.9 0.4
CV: cardiovascular; T: total; chol: cholesterol; BMI: body mass index; AIMS: Arthritis Impact Measurement
Scales; DAS28: Disease Activity Score in 28 joints; CRP: C-reactive protein; HAQ: Health Assessment
Questionnaire; DMARD: disease-modifying antirheumatic drugs; RA: rheumatoid arthritis; HDL: high-density
lipoprotein; NSAID: nonsteroidal antiinflammatory drug; LDL: low-density lipoprotein.  * OR and p value for
comparisons between black and white Africans after adjustment for age, sex, and healthcare center as well as
lipid-lowering and antihypertensive agents in models that include lipid and systolic and diastolic blood pressure
variables, respectively. † Logarithmically transformed variables for which geometric means (SD) are given.
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both branches of the internal and external carotid artery are visualized simul-
taneously34. They used high-resolution B-mode ultrasound (Image Point,
Hewlett Packard, Andover, MA, USA, and SonoCalc IMT, Sonosite Inc.,
Bothell, WA, USA; used by BAS and AS, respectively) with linear array
7.5-MHz probes. Details of the methodology used by BAS were as reported3.
The equipment used by AS involved application of a unique semiautomated
border detection program that was found to provide highly reproducible
results34. The intima-media thicknesses in the left and right common carotid
artery were measured; carotid intima-media thickness (cIMT) was defined as
the mean of these. Carotid artery plaque was defined as a focal structure that
encroaches into the arterial lumen by at least 0.5 mm or 50% of the surround-
ing intima-media thickness value, or demonstrates a thickness of > 1.5 mm as
measured from the media-adventitia interface to the intima-lumen interface35.
Both operators were blinded to the CV risk profiles of the patients. Repeat
ultrasound examinations by both operators on 23 patients revealed Spearman
correlations between repeat cIMT measurements of 0.983 for BAS and 0.956
for AS, and the correlation between measurements made by BAS and AS was
0.926. Both operators identified carotid artery bulb or/and internal carotid
artery plaque in 11 of these 23 patients with full agreement.
Statistical methods. We grouped the CV risk factors into 3 categories18 (Table
2): (1) the major modifiable conventional risk factors of hypertension, dys-
lipidemia, smoking, and diabetes that feature in the Framingham score; (2)
other CV conventional risk or predisposing factors including alcohol use,
exercise, marital status, education level, BMI, waist circumference, waist-hip
ratio, serum triglyceride concentrations, and the AIMS tension and depression
scores; and (3) nonconventional risk factors consisting of RA characteristics.
Dichotomous variables are expressed as proportions or percentages and
continuous variables as mean ± SD. Non-normally distributed characteris-
tics were logarithmically transformed prior to statistical analysis and for
these variables geometric means ± SD are given. The selection of potential
confounders in multivariate regression models was based on biological
plausibility.
Relationships between population grouping, or in the present context, also
ethnic grouping (EG) and CV risk factors were investigated in multivariable
logistic and linear regression models as appropriate and with consistent
adjustment for age, sex, and healthcare center attendance. Prescribed antihy-
pertensive therapy and statin use were further adjusted for when assessing
associations with blood pressure and lipid variables, respectively.
The mean ± SD cIMT was compared between black and white patients by
the Student t test and in age, sex, and healthcare center-adjusted linear multi-
variate logistic regression analysis; plaque prevalence was compared in uni-
variate and age, sex, and healthcare center-adjusted multivariate logistic
regression models.
To determine whether there were disparities in the relationships of modi-
fiable CV risk factors with atherosclerosis in black compared to white
patients, we assessed the associations of interactions between EG and the
recorded risk factors with cIMT and plaque in multivariable regression mod-
els in which age, sex, and healthcare center and the individual terms were
adjusted for, and subsequently performed stratified analysis.
The study was 95% powered to detect a significant (p < 0.01) difference
in mean cIMT of 0.100 mm (the expected increase per 10-year age incre-
ment36) in multiple regression analysis with inclusion of 3 covariates between
black and white Africans with RA. Statistical computations were made using
the GB StatTM program (Dynamic Microsystems, Silver Spring, MD, USA).
RESULTS
Patient characteristics. Patient characteristics are shown in
Tables 1 and 2. A total of 243 patients comprising 121 blacks
and 122 whites were investigated. Black patients were more
often women (p = 0.02) and were on average 2.4 years
younger (p = 0.08) than their white counterparts. About 97%
of black patients and 82% of whites were seen in public and
private care, respectively.
Antihypertensives were used more frequently in black
patients (54.6% vs 41.8%; OR 1.67, 95% CI 1.00–2.78) and
statins more often in whites (36.1% vs 19.0%; OR 2.40, 95%
CI 1.33–4.33). In confounder-adjusted analysis (Table 2),
compared to whites, black patients experienced a higher
prevalence of hypertension and had a higher diastolic blood
pressure, but smoked less; their mean serum total cholesterol
concentration was lower, but with concurrent numerically
lower HDL cholesterol concentrations the total
cholesterol/HDL cholesterol ratio was similar. These results
translated into an overall major conventional CV risk burden,
as estimated by the number of major risk factors and the
Framingham score, that was similar in black and white
patients. Disparities in other conventional CV/predisposing
risk factors (Table 2) included a higher BMI, less frequent
alcohol use, and a lower education level in black compared to
white patients.
Among the nonconventional or predisposing CV risk fac-
tors shown in Table 2, black patients experienced extraarticu-
lar manifestations less often than their white counterparts.
Although the geometric mean CRP concentrations were sub-
stantially higher (2.7 mg/l) in black compared to white
patients (p = 0.002 in univariate analysis), this difference was
not significant (p = 0.9) in age, sex, and healthcare
center-adjusted analysis.
Carotid atherosclerosis in black and white Africans with RA.
The mean cIMT was 0.694 ± 0.097 mm in black and 0.712 ±
0.136 mm in white patients with RA (p = 0.3). Forty-three of
the black (35.5%) and 54 white patients (44.3%) had plaque
(p = 0.3). As illustrated in Figure 1, these results were unal-
tered after adjustment for age, sex, and healthcare center and
after further adjustment for disease duration and prednisone
use as well as CV risk factors that differed between black and
white patients (Table 2) and included hypertension, total and
HDL cholesterol, pack-year smoking history, alcohol use,
presence of extraarticular manifestations, education level,
BMI, and number of deformed joints. The latter models in
Figure 1 may be overfitted because 14 independent variables
were entered, and hence any real difference between the mean
cIMT and plaque prevalence between black and white patients
could be disguised. However, when we entered disease dura-
tion, prednisone use, hypertension, total and HDL cholesterol,
pack-year smoking history, alcohol use, the presence of
extraarticular manifestations, education level, BMI, and num-
ber of deformed joints as potential confounders, each sepa-
rately and together with age, sex, and healthcare center in dif-
ferent models, the results remained consistently unaltered: the
cIMT remained similar in blacks compared to whites (p = 0.6
to 1.0) and population or ethnic grouping (EG) remained
unassociated with plaque (OR 0.79 to 0.96, 95% CI
0.32–0.96, 95% CI 1.96–2.62, p = 0.5 to 0.9) in each of the
models. 
Disparities in relationships of modifiable CV risk factors with
carotid atherosclerosis in black compared to white patients
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with RA. In age, sex, and healthcare-adjusted analysis in all
patients, these factors were associated with the cIMT: hyper-
tension [partial correlation coefficient in multivariable linear
regression model (pr) = 0.13, p = 0.04)], log HDL cholesterol
concentrations (pr = –0.16, p = 0.01), LDL cholesterol con-
centrations (pr = 0.15, p = 0.02), non-HDL cholesterol con-
centrations (pr = 0.13, p = 0.04), BMI (pr = 0.13, p = 0.04),
and DAS28 (pr = 0.13, p = 0.04). No CV risk factors were
associated with plaque in all patients.
Interactions between EG and recorded individual CV risk
factors (Table 2) that were associated with cIMT in all patients
independent of confounders and individual terms are shown in
Table 3; they comprised EG × systolic blood pressure, EG ×
total cholesterol/HDL cholesterol ratio, EG × CRP concentra-
tion, and EG × AIMS tension score. In stratified analysis, the
systolic blood pressure, total cholesterol/HDL cholesterol, and
CRP concentration were associated with the cIMT in white
but not in black patients; conversely, the AIMS tension score
was related to the cIMT in black but not in white patients. In
an additional model, systolic blood pressure (pr = 0.21, p =
0.03), total cholesterol/HDL cholesterol (pr = 0.21, p = 0.03),
and CRP concentration (pr = 0.21, p = 0.03) were associated
with cIMT in whites, independent of one another and of con-
founders; further, the association of the AIMS tension score
with cIMT among black patients with RA was materially unal-
tered (pr = 0.18, p = 0.07) after adjustment for socioeconom-
ic factors as potential confounders and comprising marital sta-
tus, education, alcohol use, and pack-year smoking history.
Figure 1. The carotid artery atherosclerosis burden in black and white Africans with rheumatoid arthritis (RA). A. Carotid inti-
ma-media thickness (cIMT) in black compared to white patients with RA. B. The association of population or ethnic group-
ing with carotid artery plaque. Results are expressed as mean (SD) and the corresponding p value in univariate analysis
(Student t test) as well as p values in confounder-adjusted linear regression models in panel A, and as OR (95% CI) and the
corresponding p values in univariate and confounder-adjusted logistic regression models in panel B. *Adjusted for age, sex,
and healthcare center. †Further adjusted for disease duration and prednisone use as well as cardiovascular risk/predisposing
factors that differed between black and white patients (Table 2) and included hypertension, total and HDL cholesterol, pack-
year smoking history, alcohol use, presence of extraarticular manifestation, education, body mass index, and number of
deformed joints.
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Interactions between EG and CV risk factors that were
independently associated with carotid artery plaque are shown
in Table 4; they comprised EG × systolic blood pressure, EG
× extraarticular manifestations, EG ×AIMS tension score, and
EG × NSAID use. In stratified analysis, systolic blood pres-
sure and presence of extraarticular manifestations were asso-
ciated with plaque in white but not black patients; converse-
ly, the AIMS tension score and NSAID use were related to
plaque in black but not white patients. In additional models,
systolic blood pressure (OR per 10-mm Hg increase = 1.37,
95% CI 1.03–1.82, p = 0.03) and the presence of extraartic-
ular manifestations (OR 5.83, 95% CI 1.34–25.39, p = 0.02)
in white patients and the AIMS tension score (0 to 10 scale;
OR 1.42, 95% CI 1.05–1.92, p = 0.02) and NSAID use (OR
6.75, 95% CI 1.57–39.33, p = 0.03) in black patients were
associated with plaque, independent of one another and con-
founders. Further, among black patients, the association of
the AIMS tension score with plaque with RA was materially
unaltered (OR 1.31, 95% CI 1.00–1.74, p = 0.05) after
adjustment for socioeconomic factors as potential con-
founders and comprising marital status, education, alcohol
use, and pack-year smoking history, and the association of
NSAID use with plaque was independent of prednisone and
DMARD use.
The analysis revealed that major conventional CV risk fac-
tors were related to the cIMT in white but not in black
patients. This was confirmed upon assessment of whether the
association of overall major conventional CV risk as estimat-
ed by the Framingham score with cIMT differed by ethnic
group. Thus, the interaction term EG × Framingham score was
associated with the cIMT independent of healthcare center
and individual terms (p = 0.002; age and sex were not adjust-
ed for in the respective model since these characteristics are
used in calculating the Framingham score). In stratified analy-
sis, the Framingham score was significantly associated with
cIMT in white (pr = 0.47, p < 0.0001) but not in black (pr =
0.18, p = 0.06) patients.
DISCUSSION
We found the carotid artery atherosclerosis burden sustained
by black Africans with established RA was similar to that in
whites. An increased cIMT in the presence of hypertension
may reflect arterial medial-layer hypertrophy rather than
atheroma37. The cIMT was, however, similar in African black
and white patients independent of a diagnosis of hypertension.
Additionally, we found a marked variation in the independent
associations between modifiable CV risk factors and athero-
sclerosis among black and white patients with RA. Our main
findings each originated in several multivariable regression
models adjusted for confounders. To our knowledge, this is
the first study that simultaneously assessed and directly com-
pared the atherosclerosis burden and its relationships with CV
Table 3. Associations of modifiable CV risk factors with common carotid intima-media thickness (cIMT) in
black and white patients with RA separately. Significant associations are shown in bold type.
Stratified Analysis
CV Risk Factor Black and White Blacks Whites
Patients Combined Partial R* p Partial R* p
Interaction p
Systolic blood pressure 0.005 –0.06 0.4 0.24 0.01
Total chol/HDL chol 0.01 0.05 0.6 0.26 0.004
C-reactive protein† 0.01 0.11 0.2 0.24 0.01
AIMS tension† 0.005 0.19 0.04 0.06 0.5
CV: cardiovascular; chol: cholesterol; AIMS: Arthritis Impact Measurement Scales;  HDL: high-density lipopro-
tein.  * Partial correlation coefficients in multivariable regression models in which age, sex, and healthcare cen-
ter were entered as potentially confounding variables. † Log transformed.
Table 4. Associations of modifiable CV risk factors with carotid artery plaque in black and white patients separately. Significant associations are shown in
bold type.
Stratified Analysis
CV Risk Factor Black and White Blacks Whites
Patients Combined OR (95% CI)* p OR (95% CI)* p
Interaction p
Systolic blood pressure/10, range 9–21.3 in black and 9.8–19 in white patients 0.01 0.88 (0.74–1.05) 0.2 1.38 (1.04–1.84) 0.02
Extraarticular manifestations, yes vs no 0.05 0.72 (0.05–9.89) 0.8 5.88 (1.42–24.45) 0.01
AIMS tension†, range 0–10 0.04 1.41 (1.04–1.90) 0.02 0.99 (0.92–1.06) 0.9
NSAID use, yes vs no 0.02 5.97 (1.60–23.85) 0.03 1.00 (0.97–1.02) 0.4
CV: cardiovascular; AIMS: Arthritis Impact Measurement Scales; NSAID: nonsteroidal antiinflammatory drug.  * Adjusted for age, sex, and healthcare cen-
ter. † Log transformed and normalized to a 0 to 10 range.
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risk factors between patients with RA that belong to a devel-
oping and a developed population.
The acquisition of western lifestyles resulting in emerging
CVD risk factors and events was recently documented in
non-RA black Africans18,22. Nevertheless, CVD is still con-
firmed in only 6% of black South Africans that present to hos-
pital with heart disease38. Our finding of a similar atheroscle-
rosis burden in black and white patients with RA confirms that
in the presence of RA, protection against CVD, mediated by
the earlier epidemiological transition stage, may be absent in
black Africans18.
Because hypertension was more frequent and the mean
atherogenic index and CRP concentrations were similar in
black compared to white patients in our study, it is particular-
ly striking that the respective risk factors as well as the
Framingham score were associated with atherosclerosis in
whites only. This finding has 2 potential implications. First,
major conventional CV risk factors and systemic inflamma-
tion may not be reliable in estimating CVD risk in black
Africans that have developed established RA. This is in sharp
contrast with reported findings in studies that were performed
in developed populations and are congruous with our current
results obtained in whites3,4,5,6,7,8,9,10. Because ultrasono-
graphically identified atherosclerosis including both carotid
cIMT and plaque was shown to predict CVD events not only
in non-RA subjects but also in patients with RA and inde-
pendent of population origin25,26,39, our results suggest that
the use of direct vascular imaging may be more frequently
indicated in optimal CV risk assessment in patients with RA
from developing populations. Second, atherogenesis in black
Africans with RA needs further investigation. The absence of
associations of hypertension and dyslipidemia with athero-
sclerosis among black Africans with RA in our analysis does
not exclude a role of major conventional risk factors in athero-
genesis. Rather, because black Africans are currently under-
going a rapid socioeconomic transition18,20,22, upon reaching
a mean age of 56 years as applied to those enrolled in our
study, they are likely to sustain a shorter lifetime exposure to
unhealthy lifestyles that could have contributed to our find-
ings. Equally relevant, we recently reported that, compared to
British white subjects, non-RA black Africans experience
much greater aortic reflective waves and hence possibly
greater aortic blood pressure values for a given brachial blood
pressure40, and black Africans have reduced nocturnal blood
pressure dipping that may produce target organ effects inde-
pendent of conventional blood pressure41. Finally, we found
that CRP concentrations were associated with atherosclerosis
only in white Africans with RA. Interestingly, we recently
documented prevalent high CRP concentrations in non-RA
black Africans that were also not independently related to
CVD risk as assessed by increases in aortic pulse pressure, the
component waves, or the determinants of central pulse pres-
sure42. Taken together, the potential contributions of major
conventional risk factors and systemic inflammation to
atherogenesis in black Africans with RA require assessment in
future longitudinal studies and possibly central rather than
brachial blood pressure evaluation40, the use of ambulatory
24-hour day and night blood pressure recording41, and direct
measurement of inflamed joint-derived circulating cytokine
concentrations43,44,45.
We found that the presence of extraarticular manifestations
that reflect RA severity46 was independently associated with
atherosclerosis in whites only. This disease characteristic was
previously shown to be associated with atherosclerosis47 and
to predict CV mortality in RA46. However, in keeping with an
earlier report48, extraarticular disease was distinctly uncom-
mon in black Africans with RA (2.5% vs 12.3% in whites;
adjusted OR 0.19), and therefore a larger study may be
required to adequately assess its potential influence on athero-
genesis in patients with RA from this population.
Vascular reactivity to psychological stress is enhanced in
black compared to white subjects and is associated with an
increased susceptibility to atherosclerosis and incident CV
events49,50,51. Stress reduction was shown to reduce carotid
atherosclerosis and CV mortality in black Americans52. In our
investigation, the AIMS tension score was independently
associated with both the cIMT and plaque in black Africans
with RA and not in whites; and in multivariable analysis, mar-
ital status, low education level, and smoking and alcohol use
did not materially alter this relationship. Our results support
the presence of an enhanced interconnectedness between
mental and physical health23 that should be considered in opti-
mal CVD prevention in black Africans with RA.
Selective COX-2 inhibition can enhance thrombosis risk
and the development of hypertension53. However, the use of
both traditional NSAID and selective COX-2 inhibitors
increases CV event rates54. Variable effects of these agents in
terms of atheroma development were reported in animal stud-
ies53. In our cohort, traditional NSAID use independently
increased the OR for plaque 6-fold in black Africans with RA.
In addition to an earlier epidemiological health transition
stage in black compared to white Africans, genetic differences
between patients with RA from the 2 ethnic groups may alter-
natively or additionally support our findings. Indeed, in stud-
ies that included black and white populations, a different eth-
nic distribution of genetic polymorphisms that are associated
with CVD, hypertension, and circulating lipid and CRP con-
centrations was found55,56,57,58,59,60. Further, specific patterns
of associations between genetic variations in beta-adrenore-
ceptors and not only cold and but also psychological stress
have been reported in young black individuals61. Finally, the
potential importance of documented variations in CVD-relat-
ed COX polymorphisms among white and black Americans62
deserves further study.
Compared to their white counterparts, black Africans with
RA experience a similar burden of carotid atherosclerosis.
These findings call for intensive CV risk management irre-
spective of epidemiological transition stage or population ori-
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gin in patients with RA. However, relationships between
cross-sectionally recorded modifiable risk factors and athero-
sclerosis vary considerably among Africans with RA.
Longitudinal studies and possibly other than conventional CV
risk factor evaluations are needed to further elucidate athero-
genesis and optimal CV risk assessment in black Africans
with RA. 
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Paper 4 
      A range of anthropometric measures and their association with 
atherosclerosis were compared between black and white African RA women in 
paper 4.  The atherosclerosis burden was similar in both groups.  The body 
mass index and waist-to-height ratio were markedly larger in black African RA 
women.  Irrespective of population origin, body mass index was associated 
with blood pressure whereas abdominal adiposity measures were related to 
lipid concentrations; both generalized and abdominal adiposity measures were 
associated with fasting plasma glucose levels.  
      Upon interaction and stratified analysis, consistent disparities in adiposity 
measures-atherosclerosis relations were found.  In white African women, body 
mass index was associated with carotid intima-media thickness and waist-to-
hip ratio related to plaque.  These associations were explained metabolic risk 
factors.  Interestingly in this regard, carotid intima-media thickness relates to 
stroke and its risk factors whereas waist-to-hip ratio is associated with 
ischemic heart disease and its risk factors.   
      In contrast to our findings in whites,none of the anthropometric measures 
were associated with atherosclerosis in black African RA patients.  In fact, the 
odds ratio was 1.00 to 1.03 with extremely narrow confidence intervals for the 
adiposity-carotid plaque relations in black African patients with RA. 
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This study revealed a large excess adiposity burden but this did not translate 
into any association with atherosclerosis in black African RA women.  We also 
showed for the first time that body mass index and waist-to-hip ratio can assist 
in atherosclerotic cardiovascular risk stratification in white women with RA. 
      The National Cholesterol Education Program Adult Treatment Panel III 
metabolic syndrome definition summarizes excess adiposity together with its 
complications.  What is its potential impact on atherosclerosis in black 
compared to white African women with RA? 
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Obesity and carotid atherosclerosis in African
black and Caucasian women with established
rheumatoid arthritis: a cross-sectional study
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Abstract
Introduction: Reported findings on the relationship between adiposity and atherosclerotic cardiovascular disease
(ACVD) risk in rheumatoid arthritis (RA) are contradictory and originate in developed populations. Approximately
80% of ACVD now occurs in developing countries. We aimed to ascertain the associations of clinical obesity
measures with metabolic cardiovascular risk and atherosclerosis in African women with RA from a developing black
and developed Caucasian population.
Methods: The associations of body mass index (BMI) as an indicator of overall adiposity and waist circumference
and waist-to-height and waist-to-hip ratios as abdominal obesity indices with metabolic risk factors and high
resolution B-mode ultrasound-determined carotid artery atherosclerosis were assessed in multivariate regression
models in 203 African women with established RA; 108 were black and 95 Caucasian.
Results: BMI and waist-to-height ratio were higher in African black compared to Caucasian women (29.9 (6.6)
versus 25.3 (4.9) kg/m2, P = 0.002 and 0.59 (0.09) versus 0.53 (0.08), P = 0.01, respectively). Interactions between
population origin and anthropometric measures were not related to metabolic risk factors but were associated
with atherosclerosis, independent of confounders and individual terms. In all patients, BMI was related to systolic
and diastolic blood pressure but not with serum lipid concentrations whereas abdominal obesity indices were
associated with serum lipid concentrations but not with blood pressure values; obesity measures that were
associated with plasma glucose concentrations comprised BMI, waist circumference and waist-to-height ratio (P <
0.05 in multiple confounder adjusted analysis). In African Caucasian women, BMI was associated with common
carotid artery intima-media thickness (standardized b (95% confidence interval (CI)) = 0.21 (0.03 to 0.38)) and waist-
to-hip ratio with plaque (odds ratio (OR) (95% CI) = 1.83 (1.03 to 3.25) for one standard deviation (SD) increase).
These relationships were independent of multiple non-metabolic risk factors and explained by metabolic risk
factors. In African black women with RA, none of the obesity measures was related to atherosclerosis.
Conclusions: Obesity in women with RA from developing groups of black African descent does not as yet
translate into atheroma. In Caucasian women with RA that belong to developed populations, BMI and waist-to-hip
ratio should be considered in ACVD risk assessment.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory and
potentially destructive joint disease that enhances the
risk for atherosclerotic cardiovascular disease (ACVD)
event rates two fold [1]. ACVD death rates are increased
by 50% and responsible for most of the excess mortality
in RA [2]. Traditional and nontraditional cardiovascular
risk factors as well as genetic polymorphisms were each
reported to be associated with cardiovascular disease in
RA [3-12].
The role of excess adiposity in ACVD and cardiovascu-
lar risk assessment among persons with RA has become a
controversial issue. Whereas adiposity as assessed by the
body mass index (BMI) and waist circumference was
shown to be independently associated with enhanced
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metabolic cardiovascular risk [13,14], a paradoxical
inverse relationship between the BMI and ACVD and
overall mortality were reported in RA [15,16]. The
increased ACVD risk associated with a low BMI in
patients with RA could be explained by chronic inflam-
mation and inactivity mediated reduced lean mass and
particularly muscle mass in the presence of increased
body fat accumulation, a condition known as rheumatoid
cachexia [15-17]. Alternatively, Stavropoulos-Kalinoglou
and colleagues recently proposed that a paradoxical epi-
demiological association between survival outcomes and
cardiovascular risk factors such as obesity as well as ana-
lytical deficiencies in some of the previous studies may
account for the reported seemingly contradictory obser-
vations on the potential impact of adiposity on cardiovas-
cular risk in RA [18]. Importantly in the present context,
BMI constitutes the only obesity measure in RA studies
on cardiovascular morbidity and mortality [18]. However,
BMI does not discriminate between body fat percentage
and lean mass [19] and predicts cardiovascular disease
less effectively than measures of central obesity [20-22]
in non-RA subjects. To the best of our knowledge, the
relative role of different clinical obesity measures in the
assessment of ACVD risk in RA has not been reported.
Reported data on atherogenesis in the general popula-
tion and diseases such as RA derive almost exclusively
from developed populations [23,24]. Nevertheless,
approximately 80% of ACVD now arises in low income or
developing countries. In South Africa, a sub-Saharan
country, a minority of citizens consist of an overall afflu-
ent, developed and mostly Caucasian population whereas
the majority are socially and economically disadvantaged,
at an earlier epidemiological health transition stage with
consequent different cardiovascular risk factor profiles and
disease presentation and mostly of black African ancestry
[25-27]. A markedly high prevalence of obesity has been
increasingly reported especially in black South African
women [28,29]. Still, ACVD event rates remain distinctly
low in black Africans [25-27,30]. These findings suggest
that in populations that are at an earlier epidemiological
transition stage, obesity may not as yet translate into
atheroma. Whether this apparent lack of association
between excess adiposity and ACVD is present in persons
with RA from developing populations, is currently
unknown. In the present study, we determined disparities
in the relationships of obesity measures with atherosclero-
sis between women with RA from a developing black com-
pared to a developed Caucasian population. In addition,
we examined the potential role of different clinical obesity
measures including BMI, waist circumference and waist-
to-height and waist-to-hip ratios in assessing metabolic
cardiovascular risk and ultrasonographically determined
carotid artery atherosclerosis among women with RA.
Materials and methods
Study populations
We enrolled African black and Caucasian patients who
met the American College of Rheumatology criteria for
RA [31] at the Charlotte Maxeke Johannesburg Academic
Hospital (public healthcare) and Milpark Hospital (private
healthcare) in Johannesburg. None of the data have been
reported previously. Four invited patients refused to enroll.
Only 13 black African men with RA participated and
hence to avoid confounding of the data analyses by gender
differences between black and Caucasian patients with RA,
the data analysis was performed in women only. Patients
who had used disease modifying agents, that is, persons
with established RA, were included and those known to be
infected with HIV were excluded. The study was approved
by the Ethics Committee for Research on Human Subjects
(Medical) of the University of the Witwatersrand. Written
informed consent was obtained from each patient.
Assessments
Using methods previously reported by us [3,14], we
assessed sociodemographic characteristics, lifestyle fac-
tors, systolic and diastolic blood pressure, serum lipid
and glucose concentrations, RA characteristics, markers
of systemic inflammation including the erythrocyte sedi-
mentation rate (ESR) and C-reactive protein (CRP) con-
centrations and other potential cardiovascular risk
factors comprising years of education, thyroid status and
hormone replacement therapy. Exercise included hours
spent in walking (for example, to reach public transporta-
tion). Data were missing in fewer than 5% for any of the
recorded variables. Serum lipid and plasma glucose con-
centrations were determined on fasting blood samples
using standard laboratory methods.
BAS (see acknowledgements) and AS performed the
carotid artery ultrasound measurements in private and
public healthcare patients, respectively. Both operators
obtained images of at least 1 cm length of the distal com-
mon carotid arteries for measurement of the intima-
media thickness of the far wall from an optimal angle of
incidence defined as the longitudinal angle of approach
where both branches of the internal and external carotid
artery are visualized simultaneously [32] and with high
resolution B-mode ultrasound (Image Point, Hewlett
Packard, Andover, MA, USA and SonoCalc IMT, Sono-
site Inc, Bothell, Wash, USA used by BAS and AS,
respectively) employing linear array 7.5 MHz probes. The
details of the methodology used by BAS were reported
previously [3]. The equipment used by AS involves the
application of a unique semi-automated border detection
program that was previously found to provide highly
reproducible results [32]. The intima-media thicknesses
in the left and right common carotid artery were
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measured and the carotid intima-media thickness (cIMT)
was defined as the mean of these. Carotid artery plaque
was defined as a focal structure that encroaches into the
arterial lumen of at least 0.5 mm or 50% of the surround-
ing intima-media thickness value, or demonstrates a
thickness of > 1.5 mm as measured from the media-
adventitia interface to the intima-lumen interface [33].
Both operators were blinded to the cardiovascular risk
profiles of the patients. Repeat ultrasound examinations
by both operators on 23 patients revealed Spearman cor-
relations between repeat cIMT measurements of 0.983
and 0.956 for BAS and AS, respectively, and the correla-
tion between measurements made by BAS and AS was
0.926. Both operators identified carotid artery bulb or/
and internal carotid artery plaque in 11 of these 23
patients with full inter-observer agreement.
Height and weight were measured with participants
wearing light clothing and no shoes and the BMI was cal-
culated using these parameters. Waist circumference was
measured at the umbilical level and hip at the level of the
largest circumference. The adiposity measures included in
our main data analysis comprised BMI as an indicator of
overall obesity and waist circumference and waist-to-
height and waist-to-hip ratios as abdominal obesity
indices, respectively [20-22]. The relationships between
waist-to-height ratio and incident ACVD and diabetes are
reportedly most consistent across different population
groups [22].
Statistical analysis
Continuous variables are reported as mean (SD) and
categorical variables as proportions or percentages. Non-
normally distributed characteristics were logarithmically
transformed prior to statistical analysis and for these
variables geometric means (SD) are given.
Disparities in sociodemographic features between
African black and Caucasian women were compared using
the Student t-test and univariate logistic regression analy-
sis as appropriate. Relationships of population grouping
(PG) with baseline characteristics, cIMT and carotid artery
plaque and anthropometric measures were investigated in
multivariate logistic and linear regression models as
appropriate and with consistent adjusting for age and
healthcare center attendance as well as lipid lowering,
antihypertensive and glucose lowering agents in models
that included lipid, systolic and diastolic blood pressure
and glucose variables, respectively.
Disparities in the relationships of obesity measures with
metabolic risk factors and with atherosclerosis in African
black compared to Caucasian women were identified by
assessing the associations of interactions between PG and
obesity measures with metabolic risk factors and cIMT
and plaque, respectively, in confounder and individual
term adjusted multivariate regression models; when
significant interactions were present, stratified analysis
was performed.
Finally, we determined whether associations of obesity
measures with carotid atherosclerosis as identified in the
above mentioned analyses were independent of multiple
non-metabolic risk factors and explained by metabolic risk
factors in additional multivariate regression models.
Statistical computations were made using the GB
Stat™ program (Dynamic Microsystems, Inc, Silver-
spring, Maryland, USA).
Results
Baseline characteristics and atherosclerosis in African
black compared to Caucasian women with RA
Baseline characteristics and carotid atherosclerosis in Afri-
can black and Caucasian women with RA are shown in
Table 1. African black women were on average 2.1 years
younger (P = 0.2) than their Caucasian counterparts.
Approximately 97% of African black women and 80% of
Caucasian women attended the public and private health-
care center, respectively (P < 0.0001). As compared to
African Caucasian women and in confounder adjusted
analysis, black women with RA had a smaller pack year
history of smoking, used alcohol less often, exercised less,
had lower total and HDL cholesterol concentrations but
similar LDL cholesterol, triglycerides and non-HDL cho-
lesterol concentrations as well as cholesterol÷HDL choles-
terol and triglycerides÷HDL cholesterol ratios, higher
plasma glucose concentrations, more deformed joints,
higher ESRs and lower educational levels. Ever prednisone
use was similar in African black and Caucasian women in
univariate (P = 0.94) and adjusted analysis (P = 0.08, see
Table 1). The small proportion of current prednisone
users reflects our previously reported increasing avoidance
of this intervention [24].
Anthropometric measures in African black compared to
Caucasian women with RA
The anthropometric measures in African black and Cau-
casian women with RA are shown in Table 2. In age and
healthcare center adjusted analysis, African black women
had higher body weight, BMI and waist-to-height ratio
compared to their Caucasian counterparts; by contrast,
height, waist circumference, hip circumference and the
waist-to-hip ratio were similar in both groups.
Relationships of obesity measures with metabolic risk
factors in African black and Caucasian women with RA
The relationships between obesity measures and meta-
bolic risk factors in all women with RA are shown in
Table 3. Potentially confounding characteristics that
were included as independent variables in the respective
regression models comprised age, healthcare center, life-
style factors (smoking variable was pack-year history of
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Table 1 Baseline characteristics and atherosclerosis in Caucasian and black women with RA
Characteristic Caucasian women
(n = 95)
Black women
(n = 108)
Pa
Sociodemographics
Age, years 57.5 (11.7) 55.4 (10.0) ...
Public healthcare (%) 18.9 97.2 ...
Lifestyle factors
Pack year history smoking, n 2.4 (5.0) 0.1 (1.5) 0.003
Current smoking (%) 9.6 1.9 0.04
Never smoking (%) 90.7 58.5 0.01
Former smoking (%) 31.9 8.4 0.01
Alcohol use (%) 34.0 1.9 < 0.0001
Exercise, hours per weekb, n 0.7 (2.1) 0.6 (1.9) 0.04
Blood pressure
Systolic blood pressure, mmHg 128 (17) 140 (24) 0.5
Diastolic blood pressure, mmHg 78 (9) 85 (15) 0.1
Lipids
Total cholesterol, mmol/l 5.1 (1.0) 4.7 (0.9) 0.02
LDL cholesterol, mmol/l 2.8 (0.9) 2.6 (0.8) 0.5
HDL cholesterolb, mmol/l 1.7 (1.3) 1.5 (1.3) 0.002
Cholesterol÷HDL cholesterol 3.1 (1.0) 3.3 (1.1) 0.1
Triglyceridesb, mmol/l 1.1 (1.5) 1.1 (1.7) 0.8
Triglycerides÷HDL cholesterolb 0.6 (1.8) 0.7 (2.1) 0.1
Non-HDL cholesterol 3.3 (1.0) 3.2 (0.9) 0.5
Glucoseb, mmol/l 4.7 (1.2) 5.2 (1.4) 0.02
Diabetes mellitus (%) 4.2 16.7 0.3
RA characteristics
Disease duration, years 12.7 (9.1) 14.8 (9.4) 0.6
Rheumatoid factor positive (%) 73.4 75.9 0.8
DAS28 3.5 (1.5) 4.1 (1.3) 0.5
Deformed jointsb, n 4 (4) 7 (3) 0.05
Prednisone use ever (%) 43.2 42.6 0.08
Current prednisone use (%) 4.2 1.9 0.07
Current DMARD, n 2.1 (0.9) 2.5 (1.0) 0.4
Current methotrexate use (%) 77.9 91.7 0.9
Current chloroquine use (%) 47.4 77.8 0.2
Systemic inflammation
Erythrocyte sedimentation rateb, mm/hr 7 (3) 21 (3) 0.007
C-reactive proteinb, mg/l 3.9 (3.6) 7.5 (3.1) 0.5
Cardiovascular drugs
Antihypertensive agent use (%) 43.2 55.6 0.07
Oral glucose lowering agent use (%) 4.2 13.9 0.03
Insulin use (%) 1.1 2.0 0.6
Statin use (%) 36.8 18.5 0.03
Ezetimibe use (%) 2.1 0 ...
Other
Education, years 12.7 (2.7) 7.5 (4.1) 0.002
Hypothyroidismc (%) 34.7 6.5 0.2
Hormone replacement therapy (%) 17.9 5.6 0.8
Atherosclerosis
cIMT, mm 0.689 (0.117) 0.691 (0.099) 0.6
Plaque (%) 36.8 35.2 0.5
Results are expressed as mean (SD) or proportions/percentages. aP for comparison between black and Caucasian women with RA after adjustment for age and
healthcare as well as lipid lowering and antihypertensive agents in models that include lipid and blood pressure variables, respectively; bnon-normally distributed
variable for which geometric mean (SD) is given; c includes subclinical and overt hypothyroidism and diagnosed when serum thyrotropin level was > 4.94 mU/L
or when thyroid hormone replacement therapy was used. cIMT, common carotid artery intima-thickness; DAS28, Disease Activity Score in 28 joints; DMARD,
disease modifying agents for rheumatic disease; n, number of; RA, rheumatoid arthritis.
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smoking), current disease activity (DAS28), cumulative
disease activity (deformed joints), prednisone use,
hypothyroidism and hormone replacement therapy as
well as antihypertensive, lipid and glucose lowering
agents upon entering of blood pressure, lipid and glu-
cose parameters, respectively. Interactions between PG
and obesity measures were consistently unrelated to
metabolic risk factors and therefore no stratified analysis
was performed. BMI was associated with blood pressure
variables but not with serum lipid concentrations. By
contrast, waist circumference and waist-to-height and
waist-to-hip ratios were related to serum lipid concen-
trations but not to blood pressure values. Obesity mea-
sures that were associated with plasma glucose
concentrations comprised BMI, waist circumference and
waist-to-height ratio.
The selection of confounders modeled in the analysis
shown in Table 3 was based on biological plausibility and
not data driven. The associations of these characteristics
with obesity measures in African black and Caucasian
women are shown in Table 4. Age, smoking history,
deformed joints and cardiovascular drugs were each asso-
ciated with obesity measures in African black or/and
Caucasian women. Additionally, there were several dispa-
rities in these relationships between African black and
Caucasian participants. Age was associated with a high
waist-to-hip ratio and smoking with a high BMI, waist
circumference and waist-to-height ratio in African Cau-
casian but not in black women. By contrast, the number
of deformed joints was associated with a low BMI, waist
circumference and waist-to-height ratio in African black
but not in Caucasian women.
Relationships of obesity measures with carotid artery
atherosclerosis in African black and Caucasian women
with RA
Due to consistent differences in the relationships of obesity
measures with cIMT and carotid artery plaque between
African black and Caucasian women with RA (see below),
the respective measures were not associated with athero-
sclerosis upon analysis of the data in all patients or African
black and Caucasian women combined.
Results of age and health care adjusted stratified analyses
for cIMT are shown in Figure 1. The association of waist-
to-height ratio with cIMT differed in African black com-
pared to Caucasian women (P for interaction < 0.003).
BMI was significantly related to cIMT in African Cauca-
sian women. By contrast, none of the obesity measures
were associated with cIMT among African black women.
Results of age and health care adjusted stratified ana-
lyses for plaque are shown in Figure 2. The associations
of each obesity measure with carotid artery plaque dif-
fered in African black compared to Caucasian women
(P for interaction < 0.05). Waist-to-hip ratio was signifi-
cantly related to carotid artery plaque in African Cauca-
sian women whereas none of the obesity measures were
associated with carotid artery plaque in black women.
Impact of adjustment for multiple non-metabolic and
metabolic risk factors on anthropometric measure -
atherosclerosis relations in African Caucasian women
with RA
As shown in the Figures, upon adjustment for age,
healthcare center and non-metabolic risk factors includ-
ing lifestyle factors (smoking variable was pack-year
Table 2 Anthropometric measures in Caucasian and black
women with RA
Anthropometric
measures
Caucasian
women
(n = 95)
Black
women
Pa
(n =
108)
Height, cm 163 (7) 159 (7) 0.08
Body weight, kg 67.2 (15.2) 75.8 (16.3) 0.03
BMI, kg/m2 25.3 (4.9) 29.9 (6.6) 0.002
Waist circumference, cm 87 (13) 94 (14) 0.06
Waist÷height 0.53 (0.08) 0.59 (0.09) 0.01
Hip circumferenceb 101 (1) 110 (1) 0.2
Waist÷hip 0.84 (0.08) 0.85 (1.12) 0.4
Results are expressed as mean (SD). aP-value adjusted for age and healthcare
center; b non-normally distributed variable for which geometric mean (SD) is
given. BMI, body mass index; RA, rheumatoid arthritis.
Table 3 Associations between obesity measures and metabolic risk factors in 203 African women with RA
Metabolic risk factor Obesity measure
BMI Waist Waist÷height Log waist÷hip
Systolic blood pressure 0.23 (0.09 to 0.37)a 0.11 (-0.01 to 0.25) 0.09 (-0.06 to 0.24) -0.05 (-0.16 to 0.07)
Diastolic blood pressure 0.29 (0.15 to 0.43)b 0.13 (-0.13 to 0.28) -0.05 (-0.18 to 0.26) 0.10 (-0.05 to 0.09)
Log triglycerides 0.11 (-0.06 to 0.25) 0.27 (0.14 to 0.41)b 0.28 (0.13 to 0.43)b 0.14 (0.00 to 0.29)
Log HDL cholesterol -0.02 (-0.19 to 0.14) -0.22 (-0.33 to -0.08)b -0.20 (-0.36 to -0.04)a -0.21 (-0.35 to -0.07)b
Log glucose 0.16 (0.02 to 0.27)a 0.15 (0.01 to 0.30)a 0.18 (0.04 to 0.33)a 0.02 (-0.10 to 0.13)
Results are expressed as standardized regression coefficients (95% confidence interval) in multivariable models in which age, healthcare center, lifestyle factors,
current disease activity (DAS28), cumulative disease activity (log deformed joints), prednisone use, hypothyroidism and hormone replacement therapy as well as
antihypertensive, lipid and glucose lowering agents upon entering of blood pressure, lipid and glucose parameters as independent variables, respectively, were
controlled for. Significant associations are shown in bold. aP-value < 0.05; bP-value < 0.01. BMI, body mass index; HDL, high-density lipoprotein; Log,
logarithmically transformed.
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Table 4 Associations between obesity measures and non-metabolic risk factors in African black and Caucasian women with RA
Non-metabolic risk factor Obesity measure
BMI Waist Waist÷height Log waist÷hip
Black Caucasian Interaction Black Caucasian Interaction Black Caucasian Interaction Black Caucasian Interaction
P-value P-value P-value P-value
Age -0.09 -0.10 0.9 -0.10 -0.01 0.4 -0.04 0.10 0.6 -0.09 0.38b 0.004
Public healthcare -0.05 0.07 0.4 -0.08 -0.01 0.3 -0.04 0.13 0.4 -0.07 -0.04 0.5
L py history smoking -0.16 0.22a 0.03 -0.14 0.27a 0.05 -0.15 0.25a 0.048 0.08 0.18 0.6
Alcohol use 0.07 0.05 0.08 0.06 0.07 0.04 0.03 0.06 0.08 -0.08 -0.02 0.5
Exercise -0.00 -0.07 0.7 0.05 -0.12 0.2 0.06 -0.16 0.1 -0.03 -0.04 0.9
DAS28 -0.06 0.19 0.2 0.03 0.11 0.5 0.03 0.16 0.4 -0.04 0.07 0.4
L deformed joints -0.25a -0.15 0.2 -0.32b -0.06 0.01 -0.28b -0.08 0.036 -0.11 -0.10 0.2
Prednisone use -0.10 -0.07 0.6 -0.15 0.02 0.2 -0.16 -0.05 0.5 -0.09 0.05 0.4
Hypothyroidism -0.11 0.16 0.1 0.04 0.08 0.9 -0.04 0.11 0.4 0.05 0.03 0.7
HRT 0.04 -0.06 0.6 -0.02 -0.07 0.8 -0.04 -0.07 0.9 -0.09 -0.04 0.5
Anti-HTA use 0.15 0.35b 0.5 0.23a 0.30† 0.5 0.19 0.29b 0.6 0.00 0.23a 0.039
Statin use 0.10 0.30b 0.4 0.10 0.29b 0.8 0.05 0.28b 0.2 0.06 0.06 0.8
Ezetimibe use ... 0.17 ... ... 0.08 ... ... 0.11 ... ... 0.02 ...
OHA use 0.27b 0.25a 0.5 0.31b 0.25a 0.5 0.29b 0.26a 0.7 0.00 0.14 0.3
Insulin therapy 0.25b -0.05 0.06 0.26a -0.03 0.07 0.30b -0.05 0.042 0.09 0.03 0.6
Results are expressed as standardized regression coefficients in univariate analysis for the relationships between obesity measures and age and public healthcare and in age and public healthcare adjusted analysis
for the associations between obesity measures and the other non-metabolic risk factor measures. Significant associations are shown in bold. aP-value < 0.05, bP-value < 0.01. BMI, body mass index; DAS28, Disease
Activity Score in 28 joints; HRT, hormone replacement therapy; HTA, hypertensive agent; Log, logarithmically transformed; L, logarithmically transformed; OHA, oral hypoglycemic agent; py, pack year.
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history of smoking), current disease activity (DAS28),
cumulative disease activity (deformed joints), prednisone
use, hypothyroidism, hormone replacement therapy and
use of cardiovascular drugs, the associations of BMI
with cIMT (Figure 1) and of waist-to-hip ratio with car-
otid plaque (Figure 2) were not materially altered. By
contrast, upon adjusting for sociodemographic charac-
teristics and metabolic risk factors comprising systolic
-0.6 -0.4 -0.2 -0.0 0.2 0.4 0.6
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0.17 (-0.01-0.25)    0.07
-0.10 (-0.28-0.09)   0.3       0.5
0.17 (-0.03-0.37)    0.1
-0.12 (-0.29-0.10)   0.3
0.07 (-0.10-0.30)    0.5
-0.19 (-0.54-0.01)   0.06
0.17 (-0.01-0.34)    0.07
-0.17 (-0.34-0.03)   0.09    0.003
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0.01 (-0.18-0.20)    0.9
-0.15 (-0.33-0.03)   0.1       0.1
-0.02 (-0.20-0.17)   0.8
-0.18 (-0.37-0.01)   0.07
-0.11 (-0.30-0.09)   0.3
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Figure 1 Obesity measure - carotid intima-media thickness relations in African women with RA. Disparities in the relationships of obesity
measures with ultrasonographically determined carotid artery intima-media thickness between black and Caucasian women with RA after
adjustment for age and healthcare (model 1), age, healthcare and non-metabolic risk factors including lifestyle factors, current disease activity
(DAS28), cumulative disease activity (deformed joints), prednisone use, hypothyroidism, hormone replacement therapy and cardiovascular drug
use (model 2) and age, healthcare center and metabolic risk factors comprising systolic and diastolic blood pressure and HDL cholesterol,
triglyceride and glucose concentrations (model 3). Open and closed circles and their horizontal crossing lines represent the odds ratios and 95%
confidence intervals for the relationships in Caucasian and black women, respectively. BMI, body mass index; CI, confidence interval; cIMT, carotid
intima-media thickness; DAS28, Disease Activity Score in 28 joints; HDL, high density liporotein; ht, height; RA, rheumatoid arthritis; Sb,
standardized regression coefficient.
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and diastolic blood pressure and HDL cholesterol, trigly-
ceride and glucose concentrations, the associations of
BMI with cIMT and waist-to-hip ratio with plaque were
markedly attenuated. Further, in African black women, a
high waist-to-height ratio was significantly associated
with a small cIMT (Figure 1).
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1.03 (0.96-1.10)     0.5       0.007
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1.02 (0.95-1.09)     0.5
1.33 (0.71-2.48)     0.4
1.01 (0.98-1.15)     0.9
Odds Ratio (95% CI)
Figure 2 Obesity measure - carotid plaque relations in African women with RA. Disparities in the relationships of obesity measures with
ultrasonographically determined carotid artery plaque between black and Caucasian women with RA after adjustment for age and healthcare
(model 1), age, healthcare and non-metabolic risk factors including lifestyle factors, current disease activity (DAS28), cumulative disease activity
(deformed joints), prednisone use, hypothyroidism, hormone replacement therapy and cardiovascular drug use (model 2) and age, healthcare
center and metabolic risk factors comprising systolic and diastolic blood pressure and HDL cholesterol, triglyceride and glucose concentrations
(model 3). Open and closed circles and their horizontal crossing lines represent the odds ratios and 95% confidence intervals for the
relationships in Caucasian and black women, respectively. BMI, body mass index; CI, confidence interval; DAS28, Disease Activity Score in 28
joints; HDL, high density liporotein; ht, height; OR, odds ratio; RA, rheumatoid arthritis.
Solomon et al. Arthritis Research & Therapy 2012, 14:R67
http://arthritis-research.com/content/14/2/R67
Page 8 of 12
Discussion
In this study, African black women with RA that form
part of a developing population sustained a markedly
increased adiposity burden compared to their Caucasian
counterparts. The associations of obesity measures with
metabolic risk factors were as strong in African black
compared to Caucasian women with RA. By contrast,
obesity measures were not related to carotid athero-
sclerosis in African black women with RA whereas BMI
and the waist-to-hip ratio were associated with athero-
sclerosis among Caucasian women who belong to a
developed population and these relationships were
explained by metabolic risk factors.
Relationships between adiposity measures and cardio-
vascular risk and disease could be expected to be stronger
in patients with RA compared to non-RA subjects. In
non-RA subjects, a high BMI can reflect an increased
body fat mass or a large muscle mass, factors that are each
associated with opposite outcomes in cardiovascular dis-
ease [19]. However, Stavropoulos-Kalinoglou and collea-
gues recently reported that patients with RA experience a
4.3% increase in body fat mass for a given BMI compared
to healthy individuals [34]. This is most probably attributa-
ble to the presence of rheumatoid cachexia that affects
nearly two thirds of patients with RA [15-17,34].
The most striking finding in our analysis was revealed
upon analyzing the associations of obesity measures with
carotid artery plaque among African black women with
RA. For each of the adiposity measures, the OR for plaque
per 1 SD increase in obesity measure was between 1.00
and 1.03 and the 5 to 95% confidence intervals were very
small (see Figure 2). This evident consistent lack of rela-
tionships between obesity measures and atherosclerosis
could not be attributed to reduced metabolic cardiovascu-
lar risk in African black women with RA. Indeed, BMI and
waist-to-height ratio were higher in African black com-
pared to Caucasian women and the associations of obesity
measures with metabolic risk factors were similar in both
groups. Ultrasonographically determined carotid artery
plaque is associated with a 10-year cardiovascular event
rate risk of 39% in non-RA subjects [35] and reportedly
predicts incident ACVD in patients with RA irrespective
of population origin [36,37]. Our findings indicate that
excess adiposity in patients with RA from developing
groups of black African descent does not as yet translate
in severe atherosclerosis as reflected by the presence of
plaque (see below). Alternatively or additionally, genetic
differences between the African black and Caucasian
populations may underlie our findings. Indeed, in studies
that included African black and European subjects, a dif-
ferential ethnic distribution of genetic polymorphisms that
are associated with obesity [38] as well as those related to
cardiovascular disease [39] were found. Either way, our
results are congruous with the distinctly low ACVD event
rates despite highly prevalent obesity as reported in non-
RA African black women [25-30]. Further, the data analy-
sis in the present study indicates that the presence of RA
does not alter this current absence of adiposity related
atheroma.
Our observation that obesity measures were also not
associated with increased cIMT among African black
women with RA further substantiates the absence of
excess adiposity-related atherogenesis in this patient popu-
lation. In addition, the waist-to-height and waist-to-hip
ratios tended (P = 0.09 and 0.1, respectively) to be nega-
tively associated with cIMT and the waist-to-height ratio
was significantly (P = 0.02) and negatively associated with
cIMT upon adjustment for metabolic risk factors. This
finding is reminiscent of the reported paradoxical inverse
relationships between BMI and ACVD mortality as
reported in patients with RA from developed populations
[15]. Important potential confounders in this context are
smoking and the use of cardiovascular drugs [18]. The lat-
ter variables did not alter the relationships of waist-to-
height and waist-to-hip ratios with cIMT in the present
investigation.
The burden of atherosclerosis was as extensive in Afri-
can black compared to Caucasian women with RA in
this study. These results indicate that systematic cardio-
vascular risk assessment should be performed irrespec-
tive of adiposity extent in African black women with
RA.
Published reports on the associations between obesity
measures and atherosclerosis in patients with RA, even in
those that form part of developed populations, are limited.
In African Caucasian women with RA, we found relation-
ships of obesity measures with cIMT and internal carotid
artery and carotid artery bulb plaque. cIMT and plaque
constitute different phenotypes of atherosclerosis and are
biologically and genetically distinct [40-45]. The cIMT
constitutes approximately 80% media and approximately
20% intima [41]. Intima-media thickening results mostly
from adaptive responses of medial cells to blood pressure
and age [41] and is associated with stroke risk factors and
stroke prevalence [43-45]. On the other hand, carotid
artery plaque occurs as a consequence of intimal pathol-
ogy [40] and reflects an advanced stage of atherosclerosis
that is more closely related to coronary artery disease risk
factors and coronary heart disease prevalence [41,43].
Importantly also in the present context, the INTER-
HEART study investigators found that waist-to-hip ratio
was more strongly associated with myocardial infarction
than BMI [21] whereas in another recent large study per-
formed in Finland and reported by Hu and colleagues,
BMI but not waist-to-hip ratio enhanced the risk for
stroke among female participants [46]. Our results in
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African Caucasian women with established RA are in
keeping with these reported findings in that BMI was asso-
ciated with blood pressure and cIMT whereas waist-to-hip
ratio was related to lipids and plaque. In addition, meta-
bolic cardiovascular risk factors explained the relationships
of adiposity measures with carotid atherosclerosis thereby
supporting the presence of an obesity effect. A differential
effect among the individual metabolic risk factors on the
associations of BMI with cIMT and waist-to-hip ratio with
plaque could not be assessed as lipid characteristics and
blood pressure variables were collinear (data not shown).
Taken together, our results indicate that in patients with
established RA from a developed population, BMI and
waist-to-hip ratio are associated with different metabolic
risk factor profiles, reflect different aspects of carotid
artery atherosclerosis and, therefore, both can be helpful
in ACVD risk assessment.
Our study has further limitations. Our patients were
exclusively women and the cross-sectional design of our
investigation precludes drawing inferences on the direc-
tion of causality. Further, characteristics that can be
important in the present context and were not recorded
include menopausal status and cumulative prednisone
dose. Also, clinical measures of abdominal obesity do not
distinguish between visceral and subcutaneous fat. Ima-
ging studies (for example, computerized tomography) will
be needed to determine the relative impact of visceral as
compared to deep and superficial subcutaneous fat at the
abdominal level on atherogenesis in patients with RA
[47,48]. Visceral fat is particularly strongly associated with
ACVD risk [20-22]. Circulating triglyceride concentrations
reflect visceral fat mass [29] and these did not differ in
African black compared to Caucasian women with RA in
the current investigation. Finally, as applies in previously
reported investigations on cardiovascular risk in non-RA
as well as RA subjects, many relationships were evaluated.
However, our main findings each originate in confounder
adjusted multivariable regression models.
Conclusions
Although women with established RA from developing
groups of African descent experience a larger obesity bur-
den compared to their Caucasian counterparts, this is cur-
rently not as yet associated with enhanced carotid
atherosclerosis. Additionally and contrastingly, we report
for the first time evidence that supports the use of clinical
obesity measures including BMI and waist-to-hip ratio in
the assessment of ACVD and risk among Caucasian
women with established RA from a developed population.
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Paper 5 
      Metabolic syndrome definitions and their components are associated with 
atherosclerosis in patients with RA from developed populations.  The 
metabolic syndrome as presently defined comprises abdominal obesity and its 
metabolic complications.  In paper 5, we used this tool to further investigate 
whether the metabolic risk burden and its association with atherosclerosis 
differs among black and white African women with RA. 
      The metabolic syndrome prevalence was 30.8% and 9.7% in black and white 
African women with RA, respectively (p = 0.009).  The mean number of 
metabolic syndrome criteria was 2.1 in black compared to 1.3 in white Africans 
with RA (p = 0.03).  Except for the triglyceride criterion, all other criteria were 
numerically more prevalent in black African RA women; the difference in the 
metabolic syndrome high density lipoprotein cholesterol concentration 
criterion prevalence was statistically significant (p = 0.036).  
      In white African RA women, the metabolic syndrome definition was 
associated with carotid intima-media thickness and the triglyceride criterion 
and number of criteria were associated with plaque. 
      In black African RA women, only the blood pressure criterion was 
associated with carotid intima-media thickness.  Moreover, arterial intima-
42 
 
 
media thickening represents mostly age and blood pressure induced 
hypertrophy of medial cells rather than atherosclerosis. 
      Taken together, compared to their white counterparts, black African 
women with RA currently experience a much larger metabolic risk burden, 
which is further also not associated with atherosclerosis.  Cardiovascular risk 
management should be applied irrespective of metabolic risk factor profiles in 
this RA population.  
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Abstract
Objectives
 The impact of metabolic risk factors on atherosclerotic cardiovascular disease (ACVD) in patients with rheumatoid 
arthritis (RA) from developing populations is currently unknown. We examined the relationships of the metabolic syndrome 
(MetS) and its components with carotid artery atherosclerosis in African women with rheumatoid arthritis (RA) from a 
developing black and developed Caucasian population.
Methods
 We assessed the associations of the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) defined 
MetS and its criteria with high resolution B-mode ultrasound determined common carotid artery intima-media thickness 
(cIMT) and carotid artery plaque in multivariable regression models in 104 black and 93 Caucasian women with RA.
Results
 The MetS prevalence was 30.8% in black compared to 9.7% in Caucasian women with RA (adjusted odds ratio [95% 
confidence interval]=10.11 [1.76–58.03] [p=0.009]). Population origin impacted on the relationships of metabolic risk 
factors with atherosclerosis. In Caucasian women, the MetS was associated with cIMT (p=0.036) and MetS triglycerides 
and the number of MetS criteria were each associated with both cIMT (p=0.01 and p=0.028, respectively) and plaque 
(p=0.049 and p=0.02, respectively); by contrast, in black women, MetS blood pressure was related to cIMT (p=0.04).
Conclusion
 A high overall metabolic cardiovascular risk burden as disclosed by markedly prevalent MetS in women with RA from 
developing groups of black African descent was not associated with atherosclerosis. This calls for systematic rigorous 
cardiovascular risk management irrespective of metabolic risk factor profiles in African black women with RA.
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2Metabolic syndrome in black Africans with RA / P.H. Dessein et al.
Patrick H. Dessein, MD, FCP(SA), 
    FRCP (UK), PhD 
Gavin R. Norton, MBBCh, PhD 
Barry I. Joffe, DSc 
Abu T. Abdool-Carrim, MBBCh, FRCS 
Angela J. Woodiwiss, PhD 
Ahmed Solomon, MBBCh, FCP
Please address correspondence to: 
Dr P.H. Dessein,  
P.O. Box 1012, 
Melville 2109, 
Johannesburg, South Africa.
E-mail: dessein@telkomsa.net
Received on January 11, 2012; accepted 
in revised form on March 16, 2012.
© Copyright CLINICAL AND 
EXPERIMENTAL RHEUMATOLOGY 2012.
  
Funding: this study was supported by a 
South African Medical Research Council 
Grant. 
Competing interests: none declared.
Introduction
Rheumatoid arthritis (RA) is a chronic 
inflammatory disease that doubles the 
risk for atherosclerotic cardiovascular 
disease (ACVD) events (1). ACVD 
death rates are increased by 50% and 
account for most of the excess overall 
mortality in RA (2).  
Conventional and non-conventional 
cardiovascular risk factors or RA char-
acteristics and genetic polymorphisms 
are associated with ACVD in RA (3-
15). Additionally, the RA characteris-
tics of disease activity and treatment 
with traditional disease modifying 
drugs, biological agents and corticos-
teroids can impact on the metabolic 
syndrome (MetS) and its features in-
cluding insulin resistance, visceral 
adiposity and circulating lipid concen-
trations (16-26). We and others have 
recently reported that metabolic risk 
factors are independently associated 
with both carotid and coronary artery 
atherosclerosis in RA (18, 20, 27).  
Our knowledge on atherogenesis in RA 
originates almost exclusively in devel-
oped populations (28, 29). However, 
developing populations are not im-
mune to RA (29) and ~80% of ACVD 
now arises in middle and low income 
or developing countries (28) in which 
ACVD risk factor profiles and their 
impact on atherogenesis are dissimi-
lar (29, 31, 32). Optimal strategies in 
ACVD risk assessment and prevention 
in patients with RA from developing 
populations await delineation.  
South Africa is a sub-Saharan country 
that has become the most unequal so-
ciety in the world (33). A minority of 
its inhabitants represents an overall 
affluent, developed and mostly Afri-
can Caucasian population, whereas 
the majority is socially and economi-
cally disadvantaged, at an earlier epi-
demiological health transition stage 
with consequent different cardiovas-
cular risk factor profiles and disease 
presentation and consists mostly of an 
African black population (32, 34, 35). 
A distinctly high prevalence of obes-
ity that further impacts substantially 
on blood pressure and glucose and li-
pid metabolism has been increasingly 
documented particularly in black South 
African women (36, 37). Despite this, 
ACVD event rates remain distinctly 
low in black Africans (32, 34) with 
ischemic heart disease currently being 
confirmed in only 6% of South African 
black patients that present to hospital 
with heart disease (38). These findings 
suggest that in populations that are at 
an earlier epidemiological health tran-
sition stage, metabolic cardiovascular 
risk factors may not as yet translate into 
atherosclerosis. Furthermore, whether 
this apparent lack of association be-
tween metabolic cardiovascular risk 
and ACVD is present in persons from 
developing populations that have RA, 
is currently unknown.  
The MetS is a multidimensional risk 
factor for ACVD and diabetes (39). 
The US National Cholesterol Educa-
tion Program (NCEP) describes the 
MetS as the metabolic complications 
of obesity (39). In the present study, 
we examined whether or not dispari-
ties exist between the relationships 
of the NCEP-MetS and its individual 
components with ultrasonographically 
determined carotid atherosclerosis (18, 
27, 40, 41) in women with RA from a 
developing black compared to a devel-
oped Caucasian population.
Materials and methods
Study populations
Study participants comprised con-
secutively recruited African black and 
Caucasian women with RA (42, 43) at 
the Charlotte Maxeke Johannesburg 
Academic Hospital (public healthcare) 
and Milpark Hospital (private health-
care) in Johannesburg. None of the data 
were previously reported. Only 13 Af-
rican black men with RA participated 
and, hence, to avoid confounding of 
the data analysis by gender differences, 
our research question was addressed in 
women only. We included women that 
had used disease modifying agents and, 
therefore, had established RA. Four in-
vited patients refused to participate and 
those known to be infected with Hu-
man Immunodeficiency Virus  (HIV) 
were excluded. Whereas HIV infec-
tion status is currently systematically 
recorded in our African black patients 
with patient refusal rates of ~1%, this 
is not done routinely in our Caucasian 
patients in view of the distinctly low 
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prevalence of HIV infection in such 
subjects. The study was approved by 
Ethics Committee for Research on 
Human Subjects (Medical) of the Uni-
versity of the Witwatersrand. Written 
informed consent was obtained from 
each patient.  
Assessments
Using methods as previously reported 
by us (18, 29, 35, 43, 44), we assessed 
sociodemographic characteristics, life-
style factors, body mass index (BMI), 
systolic and diastolic blood pressure, 
diabetes mellitus status, RA character-
istics, markers of systemic inflamma-
tion including the erythrocyte sedimen-
tation rate (ESR) and serum C-reactive 
protein concentrations (CRP) and other 
potential cardiovascular risk factors 
comprising years of education, the 
Arthritis Impact Measurement Scales 
(AIMS) depression score, thyroid sta-
tus and hormone replacement therapy. 
Exercise included hours spent in walk-
ing (e.g. to reach public transport). 
Data were missing in less than 5% of 
any of the recorded variables. Serum 
lipid and plasma glucose concentra-
tions were determined on fasting blood 
samples and using standard laboratory 
methods (18, 29, 35, 43, 44).  
B.A. Stevens (BAS) (see Acknowledge-
ment) and A. Solomon (AS) performed 
the carotid artery ultrasound measure-
ments in private and public healthcare 
patients, respectively. Both operators 
obtained images of at least 1cm length 
of the distal common carotid arteries 
for measurement of the intima-media 
thickness of the far wall from an opti-
mal angle of incidence defined as the 
longitudinal angle of approach where 
both branches of the internal and exter-
nal carotid artery are visualised simul-
taneously (45) and with high resolu-
tion B-mode ultrasound (Image Point, 
Hewlett Packard, Andover, MA, USA 
and SonoCalc IMT, Sonosite Inc, Both-
ell, Wash, USA used by BAS and AS, 
respectively) employing linear array 7.5 
MHz probes. The details of the meth-
odology used by BAS were reported 
previously (3). The equipment used by 
AS involves the application of a unique 
semi-automated border detection pro-
gramme that was previously found to 
provide highly reproducible results 
(45). The intima-media thicknesses in 
the left and right common carotid artery 
were measured and the carotid intima-
media thickness (cIMT) was defined 
as the mean of these. Carotid artery 
plaque was defined as a focal structure 
that encroaches into the arterial lumen 
of at least 0.5 mm or 50% of the sur-
rounding intima-media thickness value, 
or demonstrates a thickness of >1.5 mm 
as measured from the media-adventitia 
interface to the intima-lumen interface 
(46). Both operators were blinded to 
the cardiovascular risk profiles of the 
patients. Repeat ultrasound examina-
tions by both operators on 23 patients 
revealed Spearman correlations be-
tween repeat cIMT measurements of 
0.983 and 0.956 for BAS and AS, re-
spectively, and the correlation between 
measurements made by BAS and AS 
was 0.926. Both operators identified ca-
rotid artery bulb or/and internal carotid 
artery plaque in 11 of these 23 patients 
with full agreement.
We classified patients as having the 
NCEP-MetS using the criteria as up-
dated by the American Heart Associa-
tion and the National Heart, Lung and 
Blood Institute in 2005 (39). The NCEP 
identifies women as having the MetS 
when 3 or more of the following crite-
ria are present: a) waist circumference 
≥88 cm; b) triglycerides ≥1.7 mmol/l 
or drug treatment for elevated triglyc-
erides; c) HDL-cholesterol <1.3 mmol/
l or drug treatment for reduced HDL-
cholesterol; d) systolic blood pressure 
≥130 mm Hg or/and diastolic blood 
pressure ≥85 mm Hg or drug treatment 
for hypertension; and e) fasting glu-
cose >5.5 mmol/l or drug treatment for 
elevated glucose.
Statistical analysis
Continuous variables are reported as 
mean (SD) and dichotomous variables 
as proportions or percentages. Non-
normally distributed characteristics 
were logarithmically transformed prior 
to statistical analysis and for these vari-
ables geometric means (SD) are given.
Differences in sociodemographic fea-
tures between black and Caucasian Af-
ricans were compared using the Student 
t-test and univariate logistic regression 
analysis as appropriate. Relationships 
between population grouping (PG) and 
baseline characteristics, the cIMT and 
carotid artery plaque and the metabolic 
syndrome and its components as well as 
the associations of the MetS definition 
with baseline characteristics in black 
and Caucasian women with RA were 
investigated in multivariable logistic 
and linear regression models as appro-
priate and with consistent adjusting for 
age and healthcare centre attendance.   
To determine whether there were dis-
parities in the relationships of meta-
bolic risk factors with atherosclerosis 
in African black compared to Cauca-
sian patients, we assessed the associa-
tions of interactions between PG and 
the respective risk factors with cIMT 
and plaque in age, healthcare centre and 
individual term adjusted multivariate 
regression models and, subsequently, 
performed stratified analysis.
Statistical computations were made 
using the GB StatTM programme (Dy-
namic Microsystems, Inc, Silverspring, 
Maryland, USA).  
Results
Baseline characteristics and 
atherosclerosis in African black 
compared to Caucasian women with RA
Baseline characteristics and carotid 
artery atherosclerosis in African Cau-
casian and black women with RA are 
shown in Table I. Black women were 
on average 1.9 years younger (p=0.2) 
than Caucasian women. Approximate-
ly 97% of black women and 83% Cau-
casians were seen in public and private 
care, respectively (p<0.0001). As com-
pared to their Caucasian counterparts 
and in sociodemographic character-
istic adjusted analysis, black women 
with RA had a smaller pack year his-
tory smoking, used alcohol less often 
and had a higher BMI and lower serum 
total and HDL cholesterol concentra-
tions but similar total cholesterol÷HDL 
cholesterol ratios, a higher ESR and 
lower educational level. The athero-
sclerosis burden was similar in black 
and Caucasian patients with RA. Anti-
hypertensive medications, oral glucose 
lowering agents, insulin, statins and 
ezetimibe were used in 43.0 and 54.8 
(p=0.1), 4.3 and 14.4 (p=0.02), 1.1 and 
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1.9 (p=0.6), 36.6 and 19.2 (p=0.007) 
and 2.2 and 0% of Caucasian and black 
women, respectively. 
Metabolic risk factors in African black 
compared to Caucasian women with RA
The metabolic syndrome character-
istics in African black and Caucasian 
women with RA are shown in Table 
II. The MetS prevalence was 9.7% in 
Caucasians and 30.8 % in black women 
with RA. Each of the individual MetS 
components was numerically markedly 
more prevalent in black compared to 
Caucasian women. In age and health-
care centre attendance adjusted analy-
sis, black women with RA sustained an 
odds ratio for having MetS HDL cho-
lesterol and meeting sufficient criteria 
for the NCEP MetS definition of 6.1 
and 10.1, respectively. Moreover, the 
number of metabolic syndrome criteria 
was significantly larger in black com-
pared to Caucasian Africans with RA.
Characteristics of African black 
and Caucasian women with RA 
by MetS status
The characteristics in African black and 
Caucasian women with RA who had 
and who did not have MetS are shown 
in Table III. Sociodemographic charac-
teristics did not significantly differ in 
both black and Caucasian women with 
and without the MetS (p≥0.08). In so-
ciodemographic characteristic adjusted 
analysis, the MetS was associated with 
the BMI, serum triglyceride and non-
HDL cholesterol concentrations and the 
total cholesterol÷HDL cholesterol and 
triglyceride÷HDL cholesterol ratios in 
black and Caucasian women; the MetS 
was further associated with a high pack 
year history smoking, systolic and di-
astolic blood pressure, the DAS28 and 
AIMS depression score in Caucasian 
women and with low serum HDL cho-
lesterol concentrations in black women 
with RA.        
Relationships between metabolic 
risk factors and carotid artery 
atherosclerosis in African black 
and Caucasian women with RA
In sociodemographic characteristic 
adjusted analysis, MetS blood pres-
sure and the number of metabolic syn-
drome criteria were associated with the 
cIMT in all African women with RA 
(standardised [S] β [95% CI]=0.18 
[0.04–0.31], p=0.01 and S β=0.14 
[0.00–0.35], p=0.04, respectively). The 
metabolic syndrome and each of its 
components were not associated with 
carotid artery plaque in all black and 
Caucasian women with RA.  
Interactions between PG and metabolic 
syndrome features that were associated 
with cIMT in all women with RA inde-
pendent of age, healthcare centre and 
individual terms comprised PG x the 
MetS triglycerides (p=0.034) and PG 
x the MetS definition (p=0.02). Dis-
parities in the relationships of meta-
bolic cardiovascular risk with cIMT in 
black compared to Caucasian women 
in stratified analysis are shown in Table 
Table I. Recorded characteristics in African Caucasian and black women with RA.
Characteristics Caucasian women Black women p-value*
 (n=93) (n=104)
Sociodemographics 
   Age, years 57.3 (11.8) 55.4 (10.0)    …
   Public healthcare (%) 16.7  96.6     …
Lifestyle factors
   Pack year history smoking†, n 2.5 (4.0) 0.1 (1.5)   0.002
   Alcohol use (%) 34.8  1.9  <0.0001
   Exercise, hours per week†, n 0.7 (2.1) 1.6 (1.9)   0.01
BMI, kg/m2 25.4 (4.9) 30.0 (6.6)   0.0008
Blood pressure
   Systolic blood pressure, mm Hg 129 (17) 140 (24)   0.8
   Diastolic blood pressure, mm Hg 78 (9) 85 (14)   0.2
Lipids
   Total cholesterol, mmol/l   5.1 (1.0) 4.7 (0.9)   0.03
   LDL cholesterol, mmol/l 2.8 (0.9) 2.6 (0.8)   0.5
   HDL cholesterol†, mmol/l 1.7 (1.3) 1.5 (1.3)   0.002
   Total cholesterol÷HDL cholesterol 3.1 (1.0) 3.3 (1.1)   0.1 
   Triglycerides†, mmol/l 1.1 (1.5) 1.1 (1.7)   0.9
   Triglycerides÷HDL cholesterol† 0.6 (1.8) 0.7 (2.1)   0.1
   Non-HDL cholesterol 3.3 (1.0) 3.2 (1.0)   0.1
Diabetes mellitus (%) 4.3   17.3    0.5
RA characteristics
   Disease duration, years 14.6 (8.7) 12.9 (9.2)   0.9
   Rheumatoid factor positive (%) 73.9  76.0    1.0
   DAS28 3.5 (1.5) 4.2 (1.3)   0.5
   Deformed joints†, n 3 (4) 7 (3)   0.1
   Prednisone ever (%) 41.9  43.3    0.2
   Current DMARD, n 2.1 (1.0) 2.5 (1.0)   0.3
   Current methotrexate use (%) 78.5  92.3    0.7
   Current chloroquine use (%) 46.2  77.9    0.1
Systemic inflammation
   Erythrocyte sedimentation rate†, mm/hr 7 (3) 21 (3)   0.007
   C-reactive protein†, mg/l 3.8 (3.5) 7.5 (3.1)   0.2
Other 
   Education, years 12.8 (2.7) 7.5 (4.1)   0.002
   AIMS depression† 1.9 (1.8) 3.3 (1.6)   0.07
   Hypothyroidism‡ (%) 35.5  5.8    0.1
   Hormone replacement therapy (%) 18.3  5.8    0.9
Atherosclerosis
   CIMT, mm 0.689 (0.118) 0.691 (0.096)   0.7
   Plaque (%) 35.5  35.6    0.2
Results are expressed as mean (SD) unless indicated otherwise.
*p-value for comparisons between African black and Caucasian women after adjustment for age and 
healthcare as well as lipid lowering and antihypertensive agents in models that include lipid and blood 
pressure variables, respectively. †Non-normally distributed variable for which geometric mean (SD) 
is given. ‡It includes subclinical and overt hypothyroidism and diagnosed when thyrotropin level was 
>4.94 mU/L or when thyroid hormone replacement therapy was used. RA: rheumatoid arthritis; BMI: 
body mass index; DAS28: disease activity score in 28 joints; DMARD: disease modifying agents for 
rheumatic disease; AIMS: arthritis impact measurement scales; CIMT: common carotid artery intima-
media thickness.
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IV. MetS triglycerides, the MetS defi-
nition and the number of MetS criteria 
were associated with cIMT in Cauca-
sian women, whereas MetS blood pres-
sure was associated with cIMT in black 
women with RA.  
Interactions between PG and metabolic 
syndrome features that were associated 
with plaque in all women with RA in-
dependent of age, healthcare centre and 
individual terms comprised PG x the 
MetS waist (p=0.01), PG x the number 
of Mets criteria (p=0.02) and PG x the 
MetS definition (p=0.05). Disparities in 
the relationships of metabolic cardio-
vascular risk with plaque in black com-
pared to Caucasian women in stratified 
analysis are shown in Table V. MetS 
triglycerides and the number of MetS 
criteria were associated with plaque in 
Caucasian women, whereas none of the 
metabolic risk factors was related to 
plaque in black women with RA.
Baseline recorded characteristics that 
are potential non-metabolic risk factors 
and differed between African black 
and Caucasian women with RA (Table 
I) included life style factors (pack year 
history smoking, alcohol use and exer-
cise), the ESR and years of education. 
In separate models amongst African 
Black women with RA and in which 
age and healthcare centre together with 
these characteristics were adjusted for, 
MetS waist, MetS HDL cholesterol, 
MetS triglycerides, MetS glucose and 
the MetS definition and number of 
MetS criteria remained unrelated with 
cIMT (S β=-0.05, p=0.6, S β=0.09, 
p=0.4, S β=0.03, p=0.8, S β=-0.10, 
p=0.3, S β=-0.07, p=0.5 and S β=0.06, 
p=0.6, respectively) and plaque (odds 
ratio [OR] [95% confidence inter-
val CI]=1.02 [0.93–1.11], p=0.8 ,OR 
(95%CI)=0.46 [0.13–1.63], p=0.5 ,OR 
(95% CI)=1.23 [0.36–4.21], p=0.8, OR 
(95%CI)=1.23 [0.39–4.20], p=0.7 , OR 
(95%CI)=0.63 [0.21–1.86], p=0.4 and 
OR [95%CI]=0.78 [0.50–1.24], p=0.3, 
respectively), whereas MetS blood 
pressure remained associated with 
cIMT (S β=0.19, p=0.049) and unasso-
ciated with plaque (OR [95%CI]=1.97 
[0.47–8.24], p=0.4).
In patients with RA from developed 
populations, systemic inflammation can 
explain the association of metabolic risk 
with atherosclerosis (20). In additional 
models amongst Caucasian women 
with RA in which age and healthcare 
centre together with the DAS28, C-re-
active protein concentrations and the 
ESR were adjusted for, MetS triglycer-
ides were no longer significantly asso-
ciated with plaque (OR [95%CI]=4.59 
[0.71–29.60], p=0.1), but the MetS 
remained related to cIMT (S β=0.17, 
p=0.05) and the number of MetS cri-
teria was still associated with cIMT 
(S β=0.21, p=0.027) and plaque (OR 
[95%CI]=2.14 [1.12–4.06], p=0.02).  
  
Discussion
In this study, African black women 
with RA experienced a markedly in-
creased metabolic risk factor burden 
compared to their Caucasian counter-
parts. However, although MetS blood 
pressure was related to cIMT, overall 
metabolic risk as reflected by the MetS 
and number of its components were not 
associated with carotid atherosclerosis 
in black women with RA. In contrast, 
overall metabolic risk was consistently 
related to carotid atherosclerosis inde-
pendently of sociodemographic char-
acteristics in Caucasian women with 
RA. As applies to previously reported 
studies that examined cardiovascular 
risk in non-RA and RA subjects, many 
relationships were assessed. However, 
our main findings were each produced 
in confounder adjusted multivariable 
analysis. To our knowledge, this is the 
first study that simultaneously assessed 
and directly compared the relationships 
of metabolic cardiovascular risk with 
atherosclerosis between patients with 
RA that belong to a developing and de-
veloped population.
African black women with RA used 
numerically more often antihyper-
tensive agents than their Caucasian 
counterparts, in the present study. This 
would appear to further support our 
observation that MetS blood pressure 
is associated with carotid atherosclero-
sis in black but not Caucasian African 
women with RA, since antihyperten-
sive agents reduce adverse cardiovas-
cular outcomes. However, the associa-
tion between MetS blood pressure and 
cIMT in African black women with 
RA should be interpreted with caution. 
CIMT and plaque represent different 
aspects of arterial pathology and are 
biologically and genetically distinct 
(47-52). The cIMT constitutes ~80% 
media and ~20% intima (48). Intima-
media thickening results mostly from 
adaptive responses of medial cells to 
blood pressure and age and associates 
mostly with stroke risk factors and 
stroke, whereas carotid artery plaque 
arises as a consequence of intimal pa-
thology and reflects an advanced stage 
of atherosclerosis that is more closely 
associated with coronary artery disease 
risk factors and ischemic heart disease 
prevalence (48-50). Therefore, the 
most striking and important finding in 
the present study is the consistent lack 
of relationships of metabolic cardiovas-
cular risk factors with plaque as well as 
the lack of associations of the respec-
Table II. Metabolic syndrome criteria in African Caucasian and black women with RA.
MetS characteristics Caucasian women Black women OR* (95% CI) 
 (n=93) (n=104)     
          
MetS waist  33.3 64.7 2.47 (0.92–6.60)
MetS blood pressure 59.1.5 83.7 1.45 (0.45–4.68)
MetS HDL-cholesterol 15.1 21.2 6.14 (1.11–33.92)†
MetS triglycerides 11.8 17.3 0.82 (0.23–2.92)
MetS glucose 5.4 20.2 2.73 (0.52–14.36)
MetS definition 9.7 30.8  10.11 (1.76–58.03)‡
   
 Caucasian women Black women p-value*
Continuous variable  mean (SD) mean (SD)
   
MetS criteria, n 1.3 (1.0) 2.1 (1.1) 0.03
Dichotomous variables are expressed as proportions or percentages. *Odds ratio and p-value for 
comparisons between African black and Caucasian African women after adjustment for age, sex and 
healthcare centres. †p=0.036. ‡p=0.009. RA: rheumatoid arthritis; MetS: metabolic syndrome; HDL: 
high-density lipoprotein.
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tive risk factors, other than MetS blood 
pressure, with cIMT in African black 
women with RA, particularly in the 
face of an overall metabolic risk factor 
burden that was larger than in their Cau-
casian counterparts. Ultrasonographi-
cally determined carotid artery plaque 
is associated with a 10-year cardiovas-
cular event rate risk of 39% in non-RA 
subjects (53) and reportedly predicts 
incident ACVD in patients with RA ir-
respective of population origin (40, 41). 
Taken together, our results indicate that 
metabolic risk factors in women with 
RA from developing groups of African 
descent do not as yet translate in severe 
atherosclerosis. Indeed, our findings 
are congruous with the distinctly low 
ACVD event rates (32-34, 38) despite 
the recent acquisition of more prevalent 
obesity, hypertension and diabetes in 
African black compared to Caucasian 
non-RA subjects (54). Furthermore, our 
data analysis indicates that the pres-
ence of RA does not alter the absence 
of metabolic risk factor related ACVD. 
Ultimately, metabolic risk may enhance 
atherogenesis in such persons, but only 
a longitudinal study will answer this 
question.
The burden of atherosclerosis was as 
large in African black compared to Cau-
casian women with RA in this study. 
Our results therefore indicate that rigor-
ous systematic cardiovascular risk as-
sessment should be performed irrespec-
tively of metabolic risk factor profiles 
in African black women with RA.                 
Caucasian patients in the present in-
vestigation had a lower BMI and less 
frequent abdominal obesity and, con-
sequently, a smaller MetS prevalence 
Table III. Recorded characteristics in African Caucasian and black women with RA with and without metabolic syndrome. 
Characteristics  Caucasian women Black women           
 MetS no MetS p-value* MetS no MetS p-value*
 (n=9) (n=84)  (n=32) (n=72)
Sociodemographics 
   Age, years 59.2 (14.5) 57.1 (11.5)    … 55.7 (9.5) 55.3 (10.3)    … 
   Public healthcare (%) 22.2  16.7     … 97.1  90.6     …
Lifestyle factors
   Pack year history smoking†, n 13.3 (5.6) 0.12 (4.7)   0.009 0.1 (1.4) 0.1 (1.5)   0.9 
   Alcohol use (%) 50.0  33.3    0.4 6.3   0.0    1.0
   Exercise, hours per week†, n 0.7 (1.9) 0.5 (2.0)   0.5 0.5 (2.9) 0.8 (2.1)   0.3
BMI, kg/m2 30.9 (4.5) 24.8 (4.6)   0.0003 32.5 (6.4) 28.9 (6.4)   0.01
Blood pressure
   Systolic blood pressure, mm Hg 150 (17) 126 (16) <0.0001 141 (23) 139 (24)   0.7
   Diastolic blood pressure, mm Hg 85 (13) 77 (8)   0.01 87 (13) 84 (15)   0.3  
Lipids
   Total cholesterol, mmol/l   5.7 (1.5) 5.1 (1.0)   0.1 4.8 (1.0) 4.7 (0.8)   0.5
   LDL cholesterol, mmol/l 3.0 (1.0) 2.8 (0.9)   0.6 2.7 (0.9) 2.6 (0.7)   0.6
   HDL cholesterol†, mmol/l 1.5 (1.5) 1.8 (1.3)   0.1 1.2 (1.3) 1.6 (1.2) <0.0001
   Total cholesterol÷HDL cholesterol 3.9 (1.4) 3.0 (0.9)   0.009 4.1 (1.3) 2.9 (0.7) <0.0001 
   Triglycerides†, mmol/l 2.1 (1.7) 1.0 (1.4) <0.0001 1.7 (1.8) 0.9 (1.4) <0.0001
   Triglycerides÷HDL cholesterol† 1.4 (2.1) 0.6 (1.6) <0.0001 1.4 (2.0) 0.5 (1.6) <0.0001
   Non-HDL cholesterol 4.0 (1.2) 3.3 (1.0)   0.03 3.5 (1.0) 3.0 (0.8)   0.006
Diabetes mellitus (%) 33.3   1.2    0.004 43.8  5.6  <0.0001
RA characteristics
   Disease duration, years 16.7 (9.0) 14.4 (8.7)   0.5 13.6 (9.9) 12.6 (8.9)   0.9
   Rheumatoid factor positive (%) 88.9  72.3    0.3 75.0  76.4    0.9
   DAS28 4.5 (1.7) 3.4 (1.5)   0.05 4.4 (1.3) 4.1 (1.3)   0.1
   Deformed joints†, n 3 (4) 3 (4)   0.8 5 (3) 6 (3)   0.6
   Prednisone ever (%) 33.3  42.9    0.5 34.4  47.2    0.2
   Current DMARD, n 1.6 (0.9) 2.2 (0.9)   0.06 2.6 (0.8) 2.5 (1.1)   0.9
   Current methotrexate use (%) 55.6  81.0    0.06 90.6  93.1    1.0
   Current chloroquine use (%) 22.2  48.8    0.1 75.0  79.1    0.7
Systemic inflammation
   ESR†, mm/hr 13 (3) 7 (3)   0.09 25 (3) 19 (3)   0.2
   C-reactive protein†, mg/l 8.2 (3.1) 3.5 (3.4)   0.06 9.0 (3.6) 6.9 (2.8)   0.2
Other 
   Education, years 12.7 (2.1) 12.8 (2.7)   0.8 8.3 (4.2) 7.1 (4.0)   0.6
   AIMS depression† 4.1 (1.5) 2.8 (1.7)   0.04 3.4 (1.4) 3.3 (1.6)   0.7
   Hypothyroidism‡ (%) 55.6  33.3    0.1 6.3   5.6    0.6
   Hormone replacement therapy (%) 22.2  17.9    0.7 9.4  4.2    0.2
Results are expressed as mean (SD) unless indicated otherwise.
*p-value for comparisons between African black and Caucasian women after adjustment for age, sex and healthcare.  
†Non-normally distributed variable for which geometric mean (SD) is given. ‡It includes subclinical and overt hypothyroidism and diagnosed when thyrotro-
pin level was >4.94 mU/L or when thyroid hormone replacement therapy was used.  RA: rheumatoid arthritis; MetS: metabolic syndrome; BMI: body mass 
index, DAS28: disease activity score in 28 joints, DMARD: disease modifying agents for rheumatic disease, ESR: erythrocyte sedimentation rate; AIMS: 
arthritis impact measurement scales; CIMT: common carotid artery intima-media thickness.
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compared to those in published reports 
on metabolic risk in RA from the US 
(20, 24) and Europe (19, 21). Neverthe-
less, our results in Caucasians add to 
the available evidence that substanti-
ates a role for metabolic risk in athero-
genesis and cardiovascular risk assess-
ment amongst patients with RA from 
developed populations (16-25). This 
includes the association of metabolic 
risk with systemic inflammation in that 
the DAS28 was, and the ESR and C-re-
active protein concentrations tended to 
be higher in Caucasians with compared 
to those without the MetS in adjusted 
analysis. However, whereas systemic 
inflammation and disease activity ex-
plained the association between meta-
bolic risk and coronary atherosclerosis 
in a study from the US by Chung et al. 
that included patients with both early- 
and long-standing RA (20), we found 
that the respective relationship was not 
materially altered by, and mostly inde-
pendent of non-metabolic risk factors. 
This discrepancy is likely due to the 
fact that only patients with established 
treated RA were included in our study. 
Since lipid lowering agents decrease 
adverse cardiovascular outcomes, the 
fact that this intervention was more fre-
quently employed in African Caucasian 
than in black women with RA further 
supports the presence of a relationship 
between MetS triglycerides and carotid 
atherosclerosis in the former but not 
the latter group.  
Our study has further limitations. Our 
patients were exclusively women, the 
cross-sectional design of our investi-
gation precludes drawing inferences 
on the direction of causality and the 
presence of less strong relationships 
between MetS characteristics and 
atherosclerosis than those found in our 
study may have eluded identification 
in view of our relatively small patient 
sample. Furthermore, we have recent-
ly reported that, compared to British 
Caucasians, non-RA black Africans 
experience much greater aortic reflec-
tive waves (54) and, therefore, possibly 
greater aortic blood pressure values for 
a given brachial blood pressure and, 
black Africans have reduced noctur-
nal blood pressure dipping that may 
produce target organ effects independ-
ently of conventional blood pressure 
(56). Consequently, central rather than 
brachial blood pressure evaluation and 
the use of ambulatory 24-hour day and 
night blood pressure recording may be 
required to adequately investigate the 
impact of the respective metabolic risk 
factor on atherogenesis in black Afri-
cans with RA.
Conclusion
In contrast to their African Caucasian 
counterparts, black women with RA 
experience a markedly increased meta-
bolic risk factor burden that is however 
currently as yet not likely to be associ-
ated with atherosclerosis. The potential 
role of metabolic risk factors in athero-
genesis in African black women with 
RA requires further assessment in lon-
gitudinal studies. Meanwhile, since the 
atherosclerosis extent was not reduced 
in African black compared to Cauca-
sian women in the present study, our 
findings call for systematic cardiovas-
cular risk management irrespective of 
metabolic risk factor profiles in African 
black women with RA.
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Paper 6 
      The previous 5 papers revealed that none of the risk factors that are 
currently recommended in cardiovascular risk stratification among patients 
with RA, are associated with atherosclerosis in black Africans with this disease.  
Another potential candidate in this context is a reduced glomerular filtration 
rate or chronic kidney disease.  Indeed, as stated in the introduction of this 
thesis, reduced kidney function is an independent cardiovascular risk factor 
and may be more prevalent in black Africans than in developed populations.   
      Paper 6 compares the frequency of reduced kidney function and its 
association with (1) endothelial activation that comprises the earliest stage in 
atherogenesis upon exposure to cardiovascular risk factors, as well as (2) 
atherosclerosis among black and white Africans with RA.  Nine reported 
estimated glomerular filtration rate equations were calculated. 
      A Chronic Kidney Disease Epidemiology Collaboration estimated glomerular 
filtration rate of <90 ml/min/1.73 m
2
 was identified in 49.1% of black and 
30.6% of white African patients with RA (p = 0.004).  In white Africans with RA, 
estimated glomerular filtration rate was related to endothelial activation.   
By contrast, in black RA patients, all except the Modification of Diet in Renal 
Disease equation were associated to a similar extent with carotid intima-media 
thickness, and plaque (p = 0.0003 to 0.08) in Receiver Operating Characteristic 
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curve analysis.  Based on optimal estimated glomerular filtration rate cut-off 
values with sensitivities and specificities ranging from 42 to 60% and 70 to 
91%, respectively, a low estimated glomerular filtration rate increased the 
odds ratio for plaque 2.2 to 4.0 fold.  The respective optimal cut-off values 
ranged from 49 ml/min/1.73 m
2
for the Cockroft-Gault equation to 82 
ml/min/1.73 m
2
 for the Chronic KidneyDisease Epidemiology Collaboration.  
      In conclusion, except for the Modification of Diet in Renal Disease equation, 
other estimated glomerular filtration rate equations comprise the first 
reported easily and in fact routinely available cardiovascular risk marker shown 
to be useful in cardiovascular disease risk stratification in black Africans with 
RA. 
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Abstract
Objective
To determine whether kidney function independently relates to endothelial activation and ul-
trasound determined carotid atherosclerosis in black and white Africans with rheumatoid ar-
thritis (RA).
Methods
We calculated the Jelliffe, 5 Cockcroft-Gault equations, Salazar-Corcoran, Modification of
Diet in Renal Disease (MDRD) and Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) estimated glomerular filtration rate (EGFR) equations in 233 (112 black)
RA patients.
Results
The CKD-EPI eGFR was<90 ml/min/1.73m2 in 49.1% and 30.6% of black and white pa-
tients, respectively (odds ratio (95% confidence interval) = 2.19 (1.28–3.75), p = 0.004).
EGFRs were overall consistently associated with monocyte chemoattractant protein-1 and
angiopoietin 2 concentrations in white patients, and with carotid intima-media thickness and
plaque in black participants. Amongst black patients, plaque prevalence was 36.7% and the
area under the curve (AUC) of the receiver operating characteristic (ROC) curve was not as-
sociated with plaque presence for the MDRD equation (p = 0.3), whereas the respective re-
lationship was significant or borderline significant (p = 0.003 to 0.08) and of similar extent
(p>0.1 for comparisons of AUC (SE)) for the other 8 equations. Based on optimal eGFR cut-
off values with sensitivities and specificities ranging from 42 to 60% and 70 to 91%
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respectively, as determined in ROC curve analysis, a low eGFR increased the odds ratio for
plaque 2.2 to 4.0 fold.
Conclusion
Reduced kidney function is independently associated with atherosclerosis and endothelial
activation in black and white Africans with RA, respectively. CKD is highly prevalent in black
Africans with RA. Apart from the MDRD, eGFR equations are useful in predicting carotid
plaque presence, a coronary heart disease equivalent, amongst black African RA patients.
Introduction
In 1974, Lindner and colleagues [1] reported that atherosclerotic coronary heart disease
(CHD) risk is increased in patients on dialysis. However, dialyzed patients experience increased
mortality due to sudden death and heart failure more frequently than from atherosclerotic
CHD [2]. Endothelial cell dysfunction comprises a central mechanism in the genesis of the dif-
ferent cardiovascular dysfunction aspects in chronic kidney disease (CKD) [2]. Mild renal im-
pairment elevates cardiovascular disease (CVD) risk [3].
Patients with RA sustain an increased risk of CVD [4,5]. Reduced kidney function develop-
ment is enhanced in patients with RA compared to non-RA persons and increases the risk of
cardiovascular events in RA [6,7]. The potential impact of impaired kidney function on athero-
genic mechanisms including endothelial activation and atherosclerosis in RA
requires elucidation.
Both traditional and nontraditional cardiovascular risk factors are associated with prevalent
and incident CVD in RA [8]. Accordingly, currently reported recommendations on CVD risk
stratification in RA include the use of multiple traditional risk factor assessment equations
such as the Framingham score and the Systematic COronary Risk Evaluation score (SCORE)
in combination with consideration of RA characteristics [9]. Nevertheless, up to 85% of white
RA patients considered to be at moderate CVD risk according to the latter approach were re-
ported to have carotid artery plaque [10], which represents a CHD equivalent [11,12]. Impor-
tantly in the present context, we recently found that both traditional cardiovascular risk factors
and RA characteristics were related to atherosclerosis in white but consistently not in black Af-
ricans with RA, this despite a similar atherosclerosis burden amongst the 2 groups [13–15].
Taken together, these findings call for additional easily available and reliable CVD risk markers
in white and even more so in black patients with RA.
Creatinine concentrations are unreliable and creatinine clearance is no longer recom-
mended to estimate kidney function as timed urine collections are cumbersome and prone to
error [16]. The iothalamate, EDTA, diethylene triamine pentaacetic acid or iohexol clearance
most accurately estimate glomerular filtration rate (GFR) [16]. However, performing these in-
vestigations is expensive and complex and not recommended in routine clinical practice [16].
The initially reported Jelliffe estimated glomerular filtration (eGFR) equation in 1973 was a
landmark in the assessment of kidney function [17]. Subsequently, a large series of other equa-
tions calculated from serum creatinine concentrations as well as age and sex with or without
the inclusion of anthropometric measures or race were reported. Amongst these, the Chronic
Kidney Disease Epidemiology Collaboration (CKD-EPI) is most recent and was most exten-
sively validated [18]. Both The Modification of Diet in Renal disease (MDRD) [19] and Chron-
ic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations were also validated in
EGFR and Cardiovascular Risk in RA
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non-RA black Africans [20]. To date, only the Cockcroft-Gault (C-G) actual body weight equa-
tion has been validated in a small cohort of white RA patients [21]. The MDRD was reported
to be less accurate than the C-G actual body weight as a measure of creatinine clearance in RA
[22]. A further complicating factor in patients with RA is that they experience excess body fat
for a given body mass index (BMI) and reduced muscle mass [23], which can result in an over-
estimation of kidney function [24–26]. In this regard, the Salazar-Corcoran equation and the
substitution of actual body weight by various other weight measures in the C-G equation can
improve kidney function evaluation in persons with an altered adiposity status [24–26].
In view of these considerations, we evaluated the independent relations of 9 different eGFR
equation values with endothelial activation and atherosclerosis in black and white Africans
with RA. We further aimed at determining the accuracy of eGFR equation results in identifying
patients with carotid plaque or high risk atherosclerosis.
Patients and Methods
Patients
The present study was conducted according to the principles outlined in the Helsinki declara-
tion. The Human Research Ethics Committee (Medical) from the University of the Witwaters-
rand in Johannesburg, South Africa approved the protocol (approval number: M06-07-33).
Participants gave informed, written consent.
This was a two-center based prospective study, comprising consecutive patients. Two hun-
dred and thirty three African patients (112 black and 121 white) that met the 1987 American
College of Rheumatology [27] and 2010 American College of Rheumatology/European League
against Rheumatism (EULAR) criteria for RA [28] were enrolled at the Charlotte Maxeke Jo-
hannesburg (n = 129) and Milpark Hospital (n = 104) in Johannesburg. All invited participants
agreed to participate. Data were missing in fewer than 5% of any of the
recorded characteristics.
Baseline characteristics
Were assessed baseline characteristics using previously reported methods (13–15). Briefly, we
recorded demographic features, and anthropometric characteristics including height, weight
and waist and hip circumference were measured employing standard approaches. The body
mass index (BMI) was calculated and abdominal obesity and fat distribution were estimated by
waist circumference and waist-hip ratio respectively. We recorded disease duration and rheu-
matoid factor status. Anti-cyclic citrullinated peptide antibody concentrations were not consis-
tently evaluated and therefore not included in the analysis. Disease activity was assessed by the
Clinical Disease Activity Index (CDAI) and the Disease Activity Score in 28 joints (DAS28).
Extra-articular manifestations included the current or previously recorded (hospital record re-
view) presence of pericarditis, pleuritis, Felty’s syndrome, cutaneous vasculitis, neuropathy,
scleritis or episcleritis, retinal vasculitis, glomerulonephritis, vasculitis affecting other organs,
amyloidosis, keratoconjunctivitis sicca, xerostomia, Sjogren’s syndrome, pulmonary fibrosis,
bronchiolitis obliterans organizing pneumonia, cervical myelopathy, subcutaneous nodules
and rheumatoid nodules in other locations. C-reactive protein concentrations were determined
using immunoturbidimetric methods. Standard laboratory blood tests of erythrocyte sedimen-
tation rate, lipids and glucose were performed.
We recorded current smoking status and systolic and diastolic blood pressure. Hypertension
was defined as an average systolic blood pressure140 or/and diastolic blood pressure90
mmHg or/and current use of antihypertensive medications. Dyslipidemia was diagnosed when
the atherogenic index, i.e. the cholesterol-HDL cholesterol ratio, was>4. Diabetes was
EGFR and Cardiovascular Risk in RA
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identified when glucose lowering agents were used or the fasting plasma glucose was7
mmol/l. The Framingham score was calculated using algorithms [12].
Endothelial activation
Wemeasured early endothelial activation molecule concentrations including those of soluble
E-selectin, vascular cell adhesion molecule-1 (VCAM-1), ICAM-1and monocyte chemoattrac-
tant protein-1 (MCP-1), as well as angiopoietin 2 and using solid-phase sandwich ELISA
(Quantikine1HS, R & D Systems, Inc., Minneapolis, MN, USA). Their lower detection limits
were 0.009 ng/l, 0.6 ng/l, 0.096 ng/l, 5.0 pg/ml and 1.2 pg/ml respectively; their inter- and intra-
assay coefficients of variation were 7.9 and 5.8, 7.0 and 3.1, 5.5 and 4.6, 5.7 and 5.8, and 8.9 and
5.9% respectively.
Atherosclerosis
BAS (see acknowledgement) and AS performed the carotid artery ultrasound measurements in
private and public healthcare patients, respectively. Both operators obtained images of at least
1cm length of the distal common carotid arteries for measurement of the intima-media thick-
ness of the far wall from an optimal angle of incidence defined as the longitudinal angle of ap-
proach where both branches of the internal and external carotid artery are visualized
simultaneously [29] and with high resolution B-mode ultrasound (Image Point, Hewlett Pack-
ard, Andover, MA, USA and SonoCalc IMT, Sonosite Inc, Bothell, Wash, USA used by BAS
and AS, respectively) employing linear array 7.5 MHz probes. The details of the methodology
used by BAS were reported previously [30]. The equipment used by AS involves the application
of a unique semi-automated border detection program that was previously found to provide
highly reproducible results [29]. The intima-media thicknesses in the left and right common
carotid artery were measured and the cIMT was defined as the mean of these. Carotid artery
plaque was defined as a focal structure that encroaches into the arterial lumen of at least 0.5
mm or 50% of the surrounding intima-media thickness value, or demonstrates a thickness of
>1.5 mm as measured from the media-adventitia interface to the intima-lumen interface [31].
Both operators were blinded to the cardiovascular risk profiles of the patients. Repeat ultra-
sound examinations by both operators on 23 patients revealed Spearman correlations between
repeat cIMT measurements of 0.983 and 0.956 for BAS and AS, respectively, and the correla-
tion between measurements made by BAS and AS was 0.926. Both operators identified carotid
artery bulb or/and internal carotid artery plaque in 11 of these 23 patients with full agreement.
Kidney function
Serum creatinine concentrations were measured using the kinetic alkaline picrate method. In
the 129 patients enrolled at the Charlotte Maxeke Johannesburg Academic Hospital, the Advia
Chemistry systems (Siemens) was used with calibration traceable to isotope dilution mass spec-
trometry (IDMS); in the other 104 patients that were recruited at the Milpark Hospital, the
Multiconstituent Calibrator (Architect) was employed which, at that time, was not traceable to
IDMS. The non-IDMS and IDMS traceable values were inter-converted using the following
equations: IDMS serum creatinine = (non-IDMS serum creatinine—0.067)/1.065 and non-
IDMS serum creatinine = IDMS serum creatinine x 1.065 + 0.067 [32]. IDMS serum creatinine
values were used in the CKD-EPI equation and non-IDMS results were employed in the other
equations, as was defined when these equations were initially formulated [17–26]. Table 1 gives
the 9 different eGFR equations [17–26] that were evaluated in the present study. The MDRD
was calculated based on 4 variables [19]. The ethnicity factor as recommended in black
EGFR and Cardiovascular Risk in RA
PLOSONE | DOI:10.1371/journal.pone.0121693 March 25, 2015 4 / 17
Americans when calculating the MDRD and CKD-EPI was not applied in the present study as
its use results in an overestimation of kidney function in black Africans living in our region
[20].
Data analysis
Dichotomous variables are expressed as proportions or percentages and continuous variables
as mean (SD) or median (interquartile range) when non-normally distributed. Non-normally
distributed characteristics were also logarithmically transformed prior to their inclusion in
multivariable statistical analysis.
The recorded characteristics were compared between black and white patients using the Stu-
dent t test, Mann-Whitney U or univariate logistic regression analysis as appropriate. To iden-
tify potential confounding variables in subsequent analysis, we assessed the associations of
baseline characteristics with eGFR equations at p0.2 in demographic characteristic adjusted
linear regression models.
The independent relationships of eGFR equations with endothelial activation molecule con-
centrations and cIMT were identified in confounder adjusted linear regression models; inde-
pendent associations between eGFR equations and carotid plaque were evaluated in logistic
regression models.
When consistent independent relations were found between eGFR equations and plaque,
sensitivity versus false positive frequency (1-specificity) for predicting plaque presence with
eGFR levels was analyzed employing receiver operator characteristic (ROC) curves. The pre-
dictive accuracy of eGFR equations was evaluated by the area under the curve (AUC). In this
analysis, we accounted for potential confounding by traditional CVD risk factors and RA
Table 1. Estimated glomerular filtration rate equations.
Jelliffe Men: (98–0.8 x (age—20)) / Scr; women: (98–0.8 x (age—20)) / Scr x 0.9
Cockcroft Gault
ABW
Men: ((140—age) x ABW) / (Scr x 72); women: ((140—age) x ABW) / (Scr x 72) x
0.85
Cockcroft Gault
IBW
Men: ((140—age) x IBW) / (Scr x 72); women: ((140—age) x IBW) / (Scr x 72) x
0.85; with IBW = 50 kg + (0.906 x (height-152.4)) in men and 45.5 kg + (0.906 x
(height-152.4)) in women
Cockcroft Gault
LBW
Men: ((140—age) x LBW) / (Scr x 72); women: ((140—age) x LBW) / (Scr x 72) x
0.85; with LBW = (9270 x ABW) / (6680 + (216 x BMI)) in men and (9270 x ABW) /
(8780 + (244 x BMI)) in women
Cockcroft Gault
ADBW
Men: ((140—age) x ADBW) / (Scr x 72); women: ((140—age) x ADBW) / (Scr x 72) x
0.85; with ADBW = IBW + (0.4 x (ABW—IBW))
Cockcroft Gault
NBW
Men: (140—age) / Scr; women: (140—age) / Scr x 0.85
Salazar-Corcoran Men: ((137—age x ((0.285 x weight) + (12.1 x height2))) / (51 x Scr); women: ((146—
age x ((0.287 x weight) + (9.74 x height2))) / (60 x Scr)
MDRD Men: 186 x Scr−1.154 x age−0.203; women: 186 x Scr−1.154 x age−0.203 0.742
CKD-EPI Women when Scr 0.7: 144 x (Scr / 0.7)−0.329 x 0.993age and when Scr >0.7: 144 x
(Scr / 0.7)−1.209 x 0.993age; men when Scr 0.9: 141 x (Scr 0.9) −0.411 x 0.993age and
when Scr >0.9: 141 x (Scr / 0.9)−1.209 x 0.993age
Ideal body weight was calculated using the formula by Devine (34) with height measured in centimeters. In
the Salazar-Corcoran equation, weight is expressed in kilogram and height in meter.
Scr = serum creatinine, AWB = actual body weight, IBW = ideal body weight, LBW = lean body Weight,
ADBW = adjusted body weight, NBW = no body weight, MDRD = Modification of Diet in Renal Disease,
CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.
doi:10.1371/journal.pone.0121693.t001
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characteristics by including as a covariate the Framingham score, this with the application of
the EULAR multiplier of 1.5 in patients with 2 of 3 criteria comprising of (1) a disease duration
>10 years, (2) rheumatoid factor positivity, and (3) the presence of extraarticular manifesta-
tion(s) and thereby giving the modified (m) Framingham score (9). To determine the optimal
cut-off values of eGFR values in predicting plaque presence, we calculated the Youden index
using the following formula: sensitivity + specificity − 1, with the maximum obtained value
corresponding to the optimal cut-off point [33]. Positive and negative predictive values were
determined by applying Bayes’ theorem [34]. We then reassessed the associations of eGFRs
with plaque using the obtained cut-off values in mFramingham score adjusted logistic
regression models.
Statistical computations were made using the GB Stat program (Dynamic Microsystems,
Inc, Silverspring, Maryland, USA) and SPSS software, version 21 (SPSS, Armonk, NY, USA).
Significance was set at p<0.05.
Results
Baseline characteristics
Table 2 gives the baseline characteristics and their comparisons between those obtained in
black and white patients with RA. As compared to whites, black participants were more often
women, experienced a larger adiposity burden, more active and severe RA except for less fre-
quent extraarticular manifestations and more prevalent hypertension and diabetes. The mean
(SD) Framingham score was 6 (7) and 5 (7) in black and white patients, respectively. However,
this characteristic was non-normally distributed with similar median (interquartile range) val-
ues of only 2 (1–5) and 3 (1–6) in the respective groups.
Endothelial activation and atherosclerosis
E-selectin and angiopoietin 2 concentrations were larger and ICAM-1 and MCP-1 levels lower
in black compared to white patients with RA. CIMT values and plaque frequency were similar
in both groups.
Kidney function
Table 2 also gives measures of kidney function in all, black and white patients. As previously re-
ported in non-RA subjects [32], in all patients, IDMS creatinine concentrations were on aver-
age 13% smaller than those of non-IDMS creatinine. The mean (SD) C-G actual body weight
and CKD-EPI eGFR values were similar (91 (28) ml/min versus 93 (17) ml/min/m2, p = 0.2).
Application of the other equations produced consistently lower values (p<0.05 for compari-
sons with CKD-EPI eGFR), as also reported in non-RA subjects [24–26,35].
The non-IDMS and IDMS creatinine concentrations were higher in black compared to
white patients. Kidney function as estimated by the C-G actual body weight equation was simi-
lar in both groups whereas application of each of the other 8 equations revealed reduced values
in black compared to white patients. Taken together, as the C-G actual body weight equation
overestimates kidney function in obese persons [24–26] and black patients experienced excess
adiposity compared to whites (see Table 2), overall, these results indicate that renal function is
impaired in the former compared to the latter group. In this regard also, CKD as defined by a
CKD-EPI eGFR of<90 ml/min/m2 (3,18) was present in 49.1% and 30.6% of black and white
RA patients, respectively; black population origin was associated with CKD (odds ratio (95%
CI) for CKD = 2.19 (1.28–3.75), p = 0.004). Amongst all patients, the eGFR was mildly (60 to
EGFR and Cardiovascular Risk in RA
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Table 2. Recorded characteristics in all 233 and 112 black and 121 white patients with RA.
Demographic characteristics All patients Black White p
Age (years) 57.1 (10.8) 55.7 (10.1) 58.3 (11.4) 0.06
Female sex 82.8 88.4 77.7 0.03
Anthropometry
Body mass index (kg/m2) 27.4 (6.0) 29.3 (6.6) 25.6 (6.6) <0.0001
Body mass index 25 (kg/m2) 58.8 69.6 48.8 0.001
Waist circumference (cm) 91 (13) 93 (13) 89 (13) 0.01
Waist/hip 0.86 (0.80–0.92) 0.85 (0.80–0.90) 0.87 (0.80–0.93) 0.2
Cardiovascular agents
Antihypertensives 46.8 52.7 41.3 0.08
Statins 28.3 19.6 36.4 0.005
Ezetimibe 0.9 0 1.7 . . .
Oral glucose lowering agents 7.7 12.5 3.3 0.01
Insulin 1.7 1.8 1.7 0.9
RA characteristics
Disease duration (years) 13.6 (9.3) 12.9 (9.2) 14.3 (9.4) 0.3
Rheumatoid factor positive 76.7 78.5 75.0 0.5
Clinical Disease Activity Index 7.2 (2.0–13.7) 10.3 (4.0–15.5) 5.1 (0.7–11.7) 0.0001
Disease Activity Score in 28 joints 3.9 (1.5) 4.1 (1.3) 3.6 (1.6) 0.01
Erythrocyte sedimentation rate (mm/hr) 12 (5–27) 21 (9–31) 7 (3–14) <0.0001
C-reactive protein (mg/l) 5.1 (2.1–12.5) 7.0 (4.0–13.8) 3.8 (1.5–10.6) 0.002
Deformed joints (number) 6 (0–15) 8 (3–14) 4 (0–17) 0.03
Extraarticular manifestation(s) 7.7 2.7 12.4 0.01
Synthetic modifying agents
Methotrexate 83.7 90.2 77.7 0.01
Chloroquine 66.1 79.5 53.7 <0.0001
Leflunomide 30.9 22.3 38.8 0.007
Sulphasalazine 18.5 24.1 13.2 0.03
Azathioprine 14.2 16.1 12.4 0.4
Tetracycline 12.0 10.7 13.2 0.6
Cyclophosphamide 3.0 5.4 0.8 0.08
Penicillamine 3.4 4.5 2.5 0.4
Number 2.4 (1.0) 2.5 (1.0) 2.2 (0.9) 0.01
Prednisone use 2.6 1.8 3.3 0.5
Tumor necrosis factor- blockade 3.9 0 7.4 . . .
NSAID 17.6 7.1 27.3 0.0002
Conventional CV risk factors
Hypertension 57.5 70.5 45.5 0.0001
Systolic blood pressure (mmHg) 133 (21) 139 (24) 128 (16) 0.0001
Diastolic blood pressure (mmHg) 82 (12) 86 (14) 79 (9) <0.0001
Total cholesterol (mM) 4.8 (1.0) 4.7 (0.9) 5.0 (1.1) 0.02
HDL cholesterol (mM) 1.5 (1.3–1.9) 1.5 (1.3–1.8) 1.6 (1.3–2.0) 0.07
LDL cholesterol (mM) 2.7 (0.9) 2.6 (0.8) 2.8 (0.9) 0.09
Triglycerides (mM) 1.0 (0.8–1.4) 1.0 (0.8–1.4) 1.0 (0.8–1.4) 0.6
Cholesterol/HDL cholesterol 3.2 (1.1) 3.3 (1.1) 3.2 (1.0) 0.5
Cholesterol/HDL cholesterol>4 19.7 23.9 16.0 0.1
Non-HDL cholesterol (mM) 3.2 (1.0) 3.1 (0.9) 3.3 (1.0) 0.2
Diabetes 12.5 17.9 7.4 0.002
(Continued)
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89 ml/min/m2 (stage 2 CKD)) and moderately (30 to 59 ml/min/m2 (stage 3 CKD)) reduced in
84 (36.1%) and 8 (3.4%) (4 black and 4 white) RA participants, respectively.
Baseline characteristics associated with kidney function
Associations between baseline characteristics and eGFR equations at p0.2 are shown in S1
Table. Demographic characteristics, adiposity indices, RA characteristics and traditional CVD
risk factors were related to kidney function equations. The Framingham score was significantly
associated with 7 of the eGFR equations and was included in subsequent analysis to account
for potential confounding by traditional CVD risk factors.
Table 2. (Continued)
Demographic characteristics All patients Black White p
Glucose (mM) 4.7 (4.4–5.2) 4.9 (4.5–5.4) 4.7 (4.4–5.1) 0.02
Smoking, current 6.9 3.6 10.0 0.07
Framingham score 2 (1–6) 2 (1–5) 3 (1–6) 0.4
Endothelial activation
Early endothelial activation
E-selectin (ng/ml) 38.6 (18.4) 41.6 (19.8) 35.7 (16.5) 0.02
VCAM-1 (ng/ml) 834 (664–1,048) 835 (696–1,043) 828 (635–1,033) 0.5
ICAM-1 (ng/ml) 277 (214–353) 247 (173–317) 305 (251–385) <0.0001
MCP-1 (pg/ml) 427 (265–683) 351 (223–679) 476 (334–684) 0.009
Angiopoietin 2 (pg/ml) 2,502 (2,044–3,307) 2,681 (2,232–3,566) 2,366 (1,924–3,130) 0.002
Carotid atherosclerosis
Intima-media thickness (mm) 0.709 (0.111) 0.703 (0.090)) 0.715 (0.130) 0.4
Plaque 40.3 36.7 43.8 0.2
Creatinine (mg/dl)
Non IDMS traceable 0.82 (0.72–0.96) 0.87 (0.75–0.89) 0.79 (0.67–0.92) 0.006
IDMS traceable 0.71 (0.61–0.84) 0.76 (0.64–0.86) 0.68 (0.57–0.80) 0.006
EGFR equations
Jelliffe (ml/min) 79 (22) 76 (19) 82 (24) 0.003
C-G ACBW (ml/min) 91 (28) 90 (27) 92 (30) 0.2
C-G IBW (ml/min) 71 (23) 65 (20) 77 (24) <0.0001
C-G ADBW (ml/min) 79 (23) 75 (20) 83 (25) 0.0002
C-G LBW (ml/min) 57 (17) 54 (14) 59 (20) 0.001
C-G NBW (ml/min) 91 (25) 87 (22) 94 (28) 0.0003
Salazar-Corcoran (ml/min) 89 (25) 85 (22) 93 (28) 0.0003
MDRD (ml/min/1.73 m2) 84 (24) 78 (20) 89 (27) 0.0003
CKD-EPI (ml/min/1.73 m2) 93 (17) 90 (17) 95 (17) 0.0005
Results are expressed as mean (SD), median (interquartile range) or proportion as appropriate.
Significant relations are shown in bold.
RA = rheumatoid arthritis, NSAID = non steroidal antiinflammatory agents, VCAM-1 = vascular adhesion molecule-1, ICAM-1 = intercellular adhesion
molecule-1, MCP-1 = monocyte chemoattractant protein-1, IDMS = isotope dilution mass spectrometry, eGFR = estimated glomerular filtration rate,
C-G = Cockcroft-Gault, AWB = actual body weight, IBW = ideal body weight, ADBW = adjusted body weight, LBW = lean body weight, NBW = no body
weight, MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.
doi:10.1371/journal.pone.0121693.t002
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Kidney function and endothelial activation
Table 3 gives the independent relations of the eGFR equations with the endothelial activation
markers MCP-1 and angiopoietin 2. In all patients, 4 eGFR equations were related to MCP-1
and 5 of them to angiopoietin 2. In stratified analysis, eGFR equations were not associated with
endothelial activation amongst black Africans; by contrast, in whites, all equations were associ-
ated with MCP-1 concentrations and all except the Jelliffe, C-G no body weight and MDRD
equation were related to angiopoietin 2 levels. Kidney function was unrelated to E-selectin,
VCAM-1 and ICAM-1 concentrations (see S2 Table).
Kidney function and atherosclerosis
Table 4 gives the independent relations of eGFR equations with atherosclerosis. In all patients,
the Jelliffe, C-G ideal body weight, C-G no body weight, Salazar-Corcoran and CKD-EPI equa-
tions were associated with cIMT, and the Jelliffe, C-G no body weight and CKD-EPI equations
with plaque. In stratified analysis, all except the MDRD equation were related to cIMT and all
equations were associated with plaque in black patients; a 1 SD increase in eGFR was associated
with an odds ratio of 0.34 (C-G actual body weight) to 0.45 (MDRD) for plaque. By contrast,
no associations between eGFR equations and atherosclerosis were found in whites.
As shown in Fig. 1, to estimate the accuracy of eGFR levels in the independent prediction of
plaque presence amongst black patients with RA, we performed ROC curve analysis with the
inclusion of the mFramingham score as a covariate. The mean (SD) and median (interquartile
Table 3. EGFR formulas and endothelial activation in all, black, white, normal weight and obese patients with RA.
All patients Black patients White patients
MCP-1 Angiopoietin 2 MCP-1 Angiopoietin 2 MCP-1 Angiopoietin 2
EGFR equation β (SE); p β (SE); p β (SE); p β (SE); p β (SE); p β (SE); p
Jelliffe −0.002 (0.001);
0.04
−0.001 (0.001); 0.2 −0.001 (0.002);
0.6
0.001 (0.001); 0.4 −0.003 (0.001); 0.02 −0.001 (0.001); 0.2
C-G ACBW −0.002 (0.001);
0.05
−0.001 (0.001); 0.05 −0.000 (0.002);
0.8
−0.000 (0.001);
0.8
−0.003 (0.001); 0.01 −0.002 (0.001);
0.04
C-G IBW −0.002 (0.001);
0.07
−0.001 (0.001); 0.02 0.000 (0.002); 0.9 −0.000 (0.001);
0.6
−0.003 (0.001);
0.009
−0.002 (0.001);
0.03
C-G ADBW −0.002 (0.001);
0.06
−0.001 (0.001); 0.03 −0.000 (0.002);
1.0
−0.000 (0.001);
0.7
−0.003 (0.001);
0.009
−0.002 (0.001);
0.04
C-G LBW −0.003 (0.001);
0.04
−0.002 (0.001);
0.006
−0.000 (0.002);
0.9
−0.001 (0.001);
0.3
−0.004 (0.001);
0.008
−0.003 (0.001);
0.01
C-G NBW −0.002 (0.001);
0.04
−0.001 (0.001); 0.1 −0.001 (0.002);
0.6
−0.000 (0.001);
0.6
−0.002 (0.001); 0.02 −0.001 (0.001); 0.2
Salazar-
Corcoran
−0.002 (0.001);
0.06
−0.001 (0.001); 0.04 −0.000 (0.002);
1.0
−0.000 (0.001);
0.8
−0.003 (0.001);
0.009
−0.002 (0.001);
0.04
MDRD −0.002 (0.001);
0.05
−0.001 (0.001); 0.2 −0.000 (0.002);
0.9
0.000 (0.001); 1.0 −0.002 (0.001); 0.02 −0.001 (0.001); 0.3
CKD-EPI −0.003 (0.001);
0.01
−0.002 (0.001); 0.04 −0.002 (0.002);
0.4
−0.000 (0.001);
1.0
−0.004 (0.002);
0.008
−0.003 (0.001);
0.04
Data were analyzed in BMI, Framingham score, ethnicity, deformed joints, CDAI, chloroquine, leflunomide, penicillamine, prednisone and non-steroidal
antiinflammatory agent use adjusted linear regression models.
Significant relations are shown in bold.
EGFR = estimated glomerular filtration rate, RA = rheumatoid arthritis, MCP-1 = monocyte chemoattractant protein-1, C-G = Cockcroft-Gault,
AWB = actual body weight, IBW = ideal body weight, ADBW = adjusted body weight, LBW = lean body weight, NBW = no body weight,
MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.
doi:10.1371/journal.pone.0121693.t003
EGFR and Cardiovascular Risk in RA
PLOSONE | DOI:10.1371/journal.pone.0121693 March 25, 2015 9 / 17
range) mFramingham scores were 6 (9) and 2 (1–8) in black African patients with RA. The
area under the curve (AUC) of the ROC curve was not associated with plaque presence for the
MDRD (p = 0.3) whereas the respective relation was significant or borderline significant and of
similar extent (p>0.1 for comparisons of AUC (SE)) for the other 8 equations. The AUC of the
ROC curve was consistently not associated with plaque presence for the mFramingham score.
To determine the optimal cut-off values for the eGFR equations in determining plaque pres-
ence we calculated the Youden index [33]. The obtained values and their corresponding sensi-
tivity, specificity, and positive and negative predictive values as determined by applying Bayes’
theorem [34] are given in Table 5. EGFR values below these cut-off levels were significantly or
borderline significantly associated with plaque with odds ratios ranging from 2.22 to 4.00.
In 108 of the black patients with RA, IDMS traceable creatinine concentrations were ob-
tained. As shown in S3 Table in a sensitivity analysis performed amongst these patients, the as-
sociations of eGFR equations with plaque were consistently numerically stronger with lower
odds ratios than in the whole group (Table 4), irrespective of whether conversion of IDMS cre-
atinine to non-IDMS creatinine results was performed (the first 8 equations) or not (the
CKD-EPI equation). This suggests that the use of converted creatinine results in eGFR equa-
tions does not affect their associations with CVD risk in RA.
Table 4. Associations of EGFRwith carotid intima-media thickness and plaque (per 1 SD increase in eGFR) in all, black and white patients with
RA.
All patients Black patients White patients
CIMT plaque CIMT plaque CIMT plaque
EGFR equation β (SE); p OR (95% CI); p β (SE); p OR (95% CI); p β (SE); p OR (95% CI); p
Jelliffe −0.001 (0.000);
0.005
0.65 (0.47–0.89);
0.008
−0.002 (0.000);
0.002
0.38 (0.20–0.69);
0.001
−0.001 (0.000);
0.3
0.88 (0.59–1.31);
0.5
C-G ACBW −0.001(0.000); 0.06 0.73 (0.52–1.02);
0.07
−0.001 (0.000);
0.006
0.34 (0.17–0.67);
0.001
−0.000 (0.000);
0.5
1.04 (0.67–1.63);
0.8
C-G IBW −0.001(0.000); 0.04 0.74 (0.54–1.01);
0.06
−0.001 (0.000);
0.003
0.37 (0.20–0.70);
0.002
−0.000 (0.000);
0.5
1.00 (0.98–1.02);
0.8
C-G ADBW −0.001 (0.000);
0.05
0.75 (0.55–1.01);
0.06
−0.001 (0.000);
0.004
0.38 (0.21–0.69);
0.001
−0.000 (0.000);
0.5
1.05 (0.71–1.55);
0.8
C-G LBW −0.001 (0.000); 0.1 0.84 (0.62–1.13); 0.8 −0.002 (0.001);
0.01
0.39 (0.21–0.72);
0.002
−0.000 (0.001);
0.6
1.21 (0.82–1.80);
0.3
C-G NBW −0.001 (0.000);
0.006
0.66 (0.48–0.90);
0.009
−0.001 (0.000);
0.001
0.39 (0.20–0.68);
0.001
−0.000 (0.000);
0.3
0.91 (0.61–1.36);
0.6
Salazar-
Corcoran
−0.0001 (0.000);
0.04
0.74 (0.55–1.00);
0.05
−0.001 (0.000);
0.003
0.38 (0.21–0.70);
0.001
−0.000 (0.000);
0.5
1.04(0.70–1.54); 0.8
MDRD −0.000 (0.000); 0.3 0.94 (0.69–1.27); 0.7 −0.001 (0.000);
0.06
0.45 (0.24–0.84);
0.01
−0.000 (0.000);
1.0
1.42 (0.94–2.13);
0.09
CKD-EPI −0.001 (0.001);
0.005
0.68 (0.50–0.91);
0.01
−0.002 (0.000);
0.004
0.44 (0.26–0.73);
0.001
−0.000 (0.001);
0.2
0.94 (0.61–1.45);
0.8
Data were analyzed in BMI, Framingham score, ethnicity, deformed joints, CDAI, chloroquine, leflunomide, penicillamine, prednisone and non-steroidal
antiinflammatory agent use adjusted linear or logistic regression models for cIMT and plaque, respectively.
Significant relations are shown in bold.
EGFR = estimated glomerular filtration rate, SD = standard deviation, RA = rheumatoid arthritis, cIMT = carotid intima-media thickness, C-G = Cockcroft-
Gault, AWB = actual body weight, IBW = ideal body weight, ADBW = adjusted body weight, LBW = lean body weight, NBW = no body Weight,
MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.
doi:10.1371/journal.pone.0121693.t004
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Fig 1. Receiver operator characteristic curves showing the accuracy of the eGFR equations (AUCs shown as dotted lines) in predicting plaque
presence independent of the mFramingham score (AUCs shown as dashed lines). The P values given are for the AUC-plaque associations. The
mFramingham score was consistently unrelated to plaque presence (AUC = 0.596 (P = 0.1) in each analysis). EGFR = estimated glomerular filtration rate;
AUC = area under the curve; C-G = Cockcroft-Gault; MDRD =Modification of Diet in Renal Disease; CKD-EPI = Chronic Kidney Disease Epidemiology
Collaboration.
doi:10.1371/journal.pone.0121693.g001
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Metabolic risk factors and kidney function in black compared to white
patients with RA
In the present study, metabolic risk factors including not only BMI but also hypertension and
diabetes were more adverse in black compared to white patients with RA (Table 2) and, at the
same time, associated with kidney function (S1 Table). Both BMI and 5 of the eGFR equations
as used in the present study contain body weight. Hence, as was previously reported in non-RA
subjects, positive associations between body weight and kidney function as estimated by the re-
spective equations is expected [36]. However, this does not accurately represent a ‘cardio-renal’
relationship [36]. As shown in S4 Table File after adjustment for metabolic risk in multivariable
linear regression models, eGFR equations that did not contain anthropometric measures (Jel-
liffe, C-G no body weight, MDRD and CKD-EPI) no longer differed amongst both groups.
BMI had a strong attenuating effect on the race-eGFR equation relation.
Discussion
Although*80% of cardiovascular disease now occurs in low or middle income countries, data
on cardiovascular risk management mostly originate in developed populations [13–15]. The
present study revealed that reduced kidney function as assessed by previously reported eGFR
equations for use in clinical settings, is independently associated with increased atherosclerosis
in black Africans with RA. EGFR equations comprise the first reported easily and in fact rou-
tinely available cardiovascular risk marker shown to be useful in CVD risk stratification
amongst RA patients from black African ancestry. Indeed, in ROC curve analysis, apart from
the MDRD, eGFR equation results that fell below optimal cutoff values with sensitivities, speci-
ficities and positive and negative predictive values ranging from 42 to 60%, 70 to 91%, 21 to
34% and 72 to 76% respectively, increased the odds ratio for plaque 2.2 to 4 fold. The relatively
high specificities and negative predictive values suggest that African black RA patients with
non-reduction in eGFR are unlikely to have plaque, whereas the low positive predictive values
are expected as the prevalence of plaque was, although clinically relevant, numerically low at
36.7%. Carotid plaque represents very high CVD risk that generally requires the preventive use
Table 5. Optimal cut-off EGFR values in ROC curves with corresponding characteristics and associations with plaque in black patients with RA.
EGFR Cut-off value Sensitivity (%) Specificity (%) PPV (%) NPV (%) OR (95% CI) * p*
Jelliffe 64 45 82 24 72 3.61 (1.43–9.11) 0.007
C-G ACBW 85 60 70 34 75 3.36 (1.46–7.75) 0.004
C-G IBW 54 42 88 22 72 2.22 (0.95–5.21) 0.07
C-G ADBW 68 55 81 29 75 2.72 (1.19–6.20) 0.02
C-G LBW 49 58 79 30 76 3.31 (1.45–7.55) 0.005
C-G NBW 73 45 84 24 72 4.00 (1.57–10.17) 0.004
Salazar-Corcoran 79 55 81 29 75 2.72 (1.19–6.22) 0.02
MDRD 64 35 91 18 70 2.49 (1.00–6.18) 0.05
CKD-EPI 82 42 91 21 73 2.22 (0.95–5.22) 0.07
Significant associations are shown in bold.
EGFR = estimated glomerular filtration rate, ROC = receiver operator characteristic, RA = rheumatoid arthritis, PPV = positive predictive value,
NPV = negative predictive value, OR = odds ratio, CI = confidence interval, C-G = Cockcroft-Gault, AWB = actual body weight, IBW = ideal body weight,
ADBW = adjusted body weight, LBW = lean body weight, NBW = no body weight, MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic
Kidney Disease Epidemiology Collaboration.
*Associations were assessed in modified Framingham score adjusted logistic regression models.
doi:10.1371/journal.pone.0121693.t005
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of CVD drugs in both non-RA and RA subjects [8,11,12,37,38]. The AUC of the ROC curve for
the C-G actual body weight-plaque relations was as large as those recently reported for rheu-
matoid factor and anti-cyclic citrullinated peptide-radiographic progression relation amongst
patients with early RA [39]. Our results are also congruent with our reported finding that
major traditional cardiovascular risk factors as well as previously investigated disease charac-
teristics are not related to atherosclerosis in black Africans with RA, as the mFramingham was
not related to plaque in these patients [13–15].
An independent association of eGFR equation values with the endothelial activation mark-
ers MCP-1 and angiopoietin 2 concentrations was found in white Africans with RA. Increased
production of MCP-1 and angiopoietin 2 was reported and is linked to inflammation and im-
plicated in the enhanced CVD risk amongst non-RA CKD patients [40–42]. Angiopoietin 2
concentrations also predict mortality in CKD [42]. Recently, angiopoietin 2 was shown to im-
pact proliferation and apoptosis of cardiac endothelial cells and promote mesenchymal transi-
tion thereby leading to cardiac fibrosis [41] and capillary rarefaction. These processes increase
the susceptibility to arrhythmias and ischemic injury in CKD [2,41].
The disparities in kidney function-CVD relations amongst black and white Africans with
RA in the present investigation require further exploration. In this regard however, black Afri-
cans experienced markedly reduced kidney function with a 2.2 fold risk of CKD when com-
pared to whites. Kidney function was reported to decrease more rapidly with age in black
persons [43]. The most important causes of CKD are hypertension and diabetes [2,4]. Addi-
tionally, obesity is associated with glomerular hyperfiltration that mediates glomerular sclerosis
[44,45]. This together with the impact of obesity on other CKD risk factors including metabolic
parameters and renin angiotensin system and sympathetic nervous system activation engen-
ders reduced kidney function over time in obese subjects (44,45). In this study, disparities in
kidney function amongst black and white Africans with RA were explained by more adverse
metabolic risk factor profiles in the former group, particularly obesity and to a lesser extent hy-
pertension and diabetes. Interestingly, BMI but not hypertension and diabetes, was recently
also shown to associate with kidney function reduction development in a predominantly white
RA cohort [4]. Compared to the present investigation, kidney function was more impaired in
previous studies that documented its impact on incident cardiovascular events in RA [6,7].
We assessed kidney function using 9 different equations [17–26]. The association of the ob-
tained results with endothelial activation was consistent across these different measures
amongst white RA patients. Overall, the same applied to the relations of the different equations
with atherosclerosis in black patients with RA. Nevertheless, the AUC of the ROC curve for the
MDRD equation was not associated with plaque presence amongst black patients with RA.
Our results suggest that the application of any of the other 8 assessed equations as examined in
the present study is more reliable and therefore preferable to the MDRD equation for CVD risk
stratification amongst black RA patients.
Can a single EGFR equation be recommended in the management of patients with RA? Kid-
ney function evaluation is important for drug dosing [46], CKD staging in delineating renopro-
tective intervention strategies to prevent end stage renal disease [16], and CVD risk
stratification and management [3]. Whereas only the C-G actual body weight was previously
validated in white patients with RA (21), the CKD-EPI equation is currently most recom-
mended in CKD staging in non-RA subjects. The C-G equations have become the standard for
drug dosing. Nevertheless, recent recommendations from the National Kidney Education Pro-
gram suggest that both the C-G and CKD-EPI equations can be used for drug dosing [46]. In
the present investigation, application of the C-G actual body weight and CKD-EPI equations
produced equivalent eGFR values that were further similarly associated with atherosclerosis in
black patients and endothelial activation in whites. Calculation of the CKD-EPI equation does
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not require information on body weight measurements, which is mostly not available to report-
ing laboratories. Taken together, although the CKD-EPI equation awaits validation in patients
with RA, our results suggest that its recommended use in non-RA subjects can be extended to
the RA population. Notably, anthropometric measures are also not include in the C-G no body
weight equation and a recent meta-analysis showed that amongst C-G equations, the C-G no
body weight equation most closely estimates creatinine clearance in non-RA patients [26].
A limitation of the present study is its cross-sectional design, thereby precluding drawing in-
ferences on the direction of causality. Kidney function was defined by estimating equations. A
large number of potential confounders were included in the models on plaque in Table 4.
When we re-assessed the associations of kidney function with plaque using a summary score of
traditional and non-traditional cardiovascular risk factors being the mFramingham score, as
currently recommended for CVD risk stratification amongst patients with RA (9) and as a sin-
gle covariate in the analysis, the results were consistent (Table 5).
Perspectives
Impaired kidney function is frequent and should therefore be routinely ascertained in RA pa-
tients. A C-G ACBW equation result of<85 ml/min, C-G NBW of<73 ml/min or CKD-EPI
of<82 ml/min comprises a useful surrogate marker of high risk subclinical atherosclerosis in
black African patients with RA. This finding can help in determining the need for enhanced
CVD risk stratification by carotid ultrasound [8,11,12] or, intensified risk management with
cardiovascular drugs including statins in black African RA patients who have no access to
cardiovascular imaging.
Conclusions
CKD is twice as prevalent in black compared to white Africans with RA. Reduced kidney func-
tion is independently associated with atherosclerosis and endothelial activation in black and
white Africans with RA, respectively. Apart from the MDRD, eGFR equations are useful in
CVD risk stratification in black African RA patients.
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S1 Table.  Baseline characteristics that were associated with estimated glomerular filtration rate equations at p<0.2. 
 
 Jelliffe CG ACBW CG IBW CG ADBW CG LBW CG NBW Salazar-C SMDRD CKD-EPI 
Characteristic   
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
Age -1.006 
(0.116); 
<0.0001 
-1.388 
(0.149); 
<0.0001 
-1.119 
(0.110); 
<0.0001 
-1.227 
(0.113); 
<0.0001 
-0.855 
(0.081); 
<0.0001 
-1.194 
(0.134); 
<0.0001 
-1.304 
(0.126); 
<0.0001 
-0.459 
(0.143); 
0.002 
-0.781 
(0.093); 
<0.0001 
Female sex 6.128 
(3.329); 
0.07 
-8.958 
(4.297); 
0.04 
-18.132 
(3.150); 
<0.0001 
-14.463 
(3.261); 
<0.0001 
-19.790 
(2.329); 
<0.0001 
2.140 
(3.841); 
0.6 
-12.475 
(3.635); 
0.0007 
-6.856 
(4.122); 
0.1 
-3.155 
(2.671); 
0.2 
Black race -9.254 
(2.509); 
0.0003 
-4.146 
(3.239); 
0.2 
-12.640 
(2.374); 
<0.0001 
-9.242 
(2.458); 
0.0002 
-5.811 
(1.756); 
0.002 
-10.623 
(2.895); 
0.0003 
-9.908 
(2.740); 
0.0004 
-11.472 
(3.107); 
0.0003 
-7.094 
(2.013); 
0.0005 
BMI -0.695 
(0.213); 
0.001 
2.375 
(0.235); 
<0.0001 
-0.792 
(0.201); 
0.0001 
0.475 
(0.212); 
0.02 
0.541 
(0.149); 
0.0004 
-0.804 
(0.247); 
0.001 
0.481 
(0.237); 
0.04 
-0.842 
(0.266); 
0.002 
-0.439 
(0.173); 
0.01 
Waist -0.213 
(0.095); 
0.03 
0.997 
(0.105); 
<0.0001 
-0.129 
(0.090); 
0.2 
0.322 
(0.092); 
0.0005 
0.300 
(0.064); 
<0.0001 
-0.244 
(0.110); 
0.03 
0.323 
(0.103); 
0.002 
-0.242 
(0.118); 
0.04 
-0.147 
(0.076); 
0.05 
Log CDAI 3.784 
(2.704); 
0.2 
0.605 
(3.506); 
0.9 
1.357 
(2.569); 
0.6 
0.605 
(3.506); 
0.9 
0.882 
(1.899); 
0.6 
4.410 
(3.120); 
0.1 
1.673 
(2.964); 
0.6 
5.546 
(3.343); 
0.1 
2.540 
(2.172); 
0.2 
Log deformed 
joints 
-0.359 
(2.424); 
0.9 
-8.630 
(3.076); 
0.005 
-0.896 
(2.293); 
0.7 
-3.991 
(2.360); 
0.09 
-3.467 
(1.681); 
0.04 
-0.438 
(2.797); 
0.9 
-4.148 
(2.633); 
0.1 
-0.312 
(3.002); 
0.9 
-0.460 
(1.944); 
0.8 
Chloroquine use -8.887 
(2.739); 
0.001 
-6.489 
(3.591); 
0.07 
-6.228 
(2.619); 
0.02 
-6.332 
(2.712); 
0.02 
-4.967 
(1.932); 
0.01 
-10.353 
(3.159); 
0.001 
-7.489 
(3.019); 
0.01 
-10.929 
(3.393); 
0.01 
-6.984 
(2.199); 
0.002 
Leflunomide use 5.588 
(2.736); 
0.04 
3.912 
(3.554); 
0.3 
3.858 
(2.600); 
0.1 
3.880 
(2.693); 
0.1 
3.015 
(1.921); 
0.1 
6.489 
(3.156); 
0.04 
4.714 
(2.999); 
0.1 
6.461 
(3.392); 
0.06 
3.690 
(2.201); 
0.1 
Penicillamine  
use 
10.180 
(6.792); 
0.1 
25.633 
(8.646); 
0.003 
6.821 
(6.444); 
0.3 
14.346 
(6.620); 
0.03 
11.193 
(4.718); 
0.02 
11.746 
(7.837); 
0.1 
15.851 
(7.380); 
0.03 
12.860 
(8.410); 
0.1 
7.120 
(5.456); 
0.2 
NSAID use 4.180 
(3.364); 
0.2 
7.504 
(4.329); 
0.08 
3.698 
(3.185); 
0.2 
5.220 
(3.289); 
0.1 
3.604 
(2.350); 
0.1 
4.697 
(3.883); 
0.2 
5.974 
(3.665); 
0.1 
5.502 
(4.165); 
0.2 
2.744 
(2.702); 
0.3 
Prednisone use 19.014 
(7.752); 
0.01 
15.390 
(10.087); 
0.1 
14.741 
(7.368); 
0.04 
15.000 
(7.630); 
0.05 
10.190 
(5.454); 
0.06 
21.788 
(8.946); 
0.01 
17.553 
(8.497); 
0.04 
23.909 
(9.596); 
0.01 
12.469 
(6.246); 
0.05 
Hypertension -6.246 
(2.637); 
0.02 
5.446  
(3.427); 
0.1 
4.846  
(2.506); 
0.05 
-0.729 
(2.615); 
0.8 
0.471 
(1.868); 
0.8 
-7.112 
(3.044);  
0.02 
-1.189 
(2.914); 
0.7 
-7.718 
(3.266); 
0.02 
-4.513 
(2.121); 
0.03 
Systolic BP -0.076  
(-0.062); 
0.2 
0.169 
(0.079); 
0.03 
-0.063 
(0.058); 
0.3 
0.030 
(0.061); 
0.6 
0.035 
(0.043); 
0.4 
-0.087 
(0.071); 
0.2 
0.028 
(0.068); 
0.7 
-0.097 
(0.076); 
0.2 
-0.067 
(0.049); 
0.2 
Diastolic BP -0.104 
(0.107); 
0.3 
0.406 
(0.136); 
0.003 
-0.053 
(0.101); 
0.6 
0.131 
(0.105); 
0.2 
0.123 
(0.074); 
0.1 
-0.117 
(0.123); 
0.3 
0.131 
(0.117); 
0.3 
-0.134 
(0.132); 
0.3 
-0.108 
(0.086); 
0.2 
 
  
 
S1 Table Continued. Baseline characteristics that were associated with estimated glomerular filtration rate equations at P < 0.2. 
 
 Jelliffe CG ACBW CG IBW CG ADBW CG LBW CG NBW Salazar-C SMDRD CKD-EPI 
Characteristic   
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
p 
  
(SE); 
P 
HDL 
cholesterol* 
9.728 
(9.827); 
0.3 
-6.195 
(12.707); 
0.6 
8.557 
(9.303); 
0.4 
2.677 
(9.648); 
0.8 
0.568 
(6.892); 
0.9 
11.658 
(11.337); 
0.3 
3.966 
(10.752); 
0.7 
12.140 
(12.170); 
0.3 
11.314 
(7.865); 
0.2 
Triglycerides* -10.312 
(6.009); 
0.9 
3.689 
(7.804); 
0.6 
-9.124 
(5.691); 
0.1 
-4.036 
(35.920); 
0.5 
-1.599 
(4.231); 
0.7 
-11.861 
(6.934); 
0.09 
-4.604 
(6.598); 
0.5 
-12.718 
(7.442); 
0.09 
-7.799 
(4.824); 
0.1 
Diabetes -6.254 
(3.790); 
0.1 
4.091 
(4.914); 
0.4 
-8.394 
(3.565); 
0.02 
-3.400 
(3.729); 
0.4 
-1.682 
(2.665); 
0.5 
-7.343 
(4.372); 
0.09 
-3.782 
(4.156); 
0.4 
-7.525 
(4.695); 
0.1 
-4.813 
(3.042); 
0.1 
Glucose* -13.212 
(10.548); 
0.2 
14.923 
(13.629); 
0.3 
-17.187 
(9.952); 
0.09 
-4.435 
(10.367); 
0.7 
-0.975 
(7.407); 
0.9 
-15.550 
(12.170); 
0.2 
-4.929 
(11.556); 
0.7 
-18.546 
(13.051); 
0.2 
-6.992 
(8.480); 
0.4 
Smoking *.083 
(4.923); 
0.07 
3.172 
(6.400); 
0.6 
10.271 
(4.645); 
0.03 
7.439 
(4.835); 
0.1 
5.425 
(3.452); 
0.1 
10.808 
(5.679); 
0.06 
8.577 
(5.387); 
0.1 
12.717 
(6.085); 
0.04 
6.255 
(3.958); 
0.1 
Framingham* -15.344 
(2.886); 
<0.0001 
9.355 
(3.927); 
0.02 
-6.319 
(3.057); 
0.04 
-7.540 
(3.162); 
0.02 
-1.107 
(2.404); 
0.6 
-16.100 
(3.359); 
<0.0001 
-9.295 
(3.433); 
0.007 
-3.914 
(3.319); 
0.2 
-8.527 
(2.337); 
0.0003 
Associations were assessed in demographic characteristic adjusted linear multivariable regression models. 
C-G = Cockcroft-Gault, AWB = actual body weight, IBW = ideal body weight, ADBW = adjusted body weight, LBW = lean body weight, NBW = no body weight, Salazar-C =  
Salazar-Corcoran, MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration, BMI = body mass index, log =  
logarithmically transformed, CDAI = Clinical Disease Activity Index, NSAID = non steroidal antiinflammatory agents, BP = blood pressure, HDL = high density lipoprotein.  
 
 
 
 
 
 
 
S2 Table.  Associations of EGFR equations with early endothelial activation molecule concentrations in all and black and white patients. 
 
 All patients Black patients White patients 
 E-selectin VCAM-1 ICAM-1 E-selectin VCAM-1 ICAM-1 E-selectin VCAM-1 ICAM-1 
EGFR  
equation 
  
(SE);  
p 
  
(SE); 
p 
  
(SE);  
p 
  
(SE);  
p 
  
(SE);  
p 
  
(SE);  
p 
  
(SE);  
p 
  
(SE);  
p 
  
(SE);  
p 
Jelliffe -0.088 
(0.067); 
0.2 
-0.001 
(0.001); 
0.05 
-0.001 
(0.001); 
0.09 
0.047 
(0.119); 
0.7 
-0.001 
(0.001); 
0.3 
-0.000 
(0.001); 
0.6 
-0.122 
(0.082); 
0.1 
-0.001 
(0.001); 
0.08 
-0.001 
(0.001); 
0.08 
CG ACBW -0.043 
(0.057); 
0.4 
-0.001 
(0.000); 
0.08 
-0.001 
(0.001); 
0.07 
0.007 
(0.099); 
0.9 
-0.001 
(0.001); 
0.2 
-0.001 
(0.001); 
0.4 
-0.036 
(0.069); 
0.6 
-0.001 
(0.001); 
0.2 
-0.001 
(0.001); 
0.1 
C-G IBW -0.043 
(0.063); 
0.5 
-0.001 
(0.001); 
0.2 
-0.001 
(0.001); 
0.06 
0.017 
(0.113); 
0.9 
-0.001 
(0.001); 
0.4 
-0.001 
(0.001); 
0.6 
-0.027 
(0.076); 
0.7 
-0.001 
(0.001); 
0.3 
-0.001 
(0.001); 
0.1 
C-G 
ADBW 
-0.044 
(0.061); 
0.5 
-0.001 
(0.000); 
0.1 
-0.001 
(0.001); 
0.07 
0.013 
(0.108); 
0.9 
-0.001 
(0.001); 
0.3 
-0.001 
(0.001); 
0.5 
-0.031 
(0.074); 
0.7 
-0.001 
(0.001); 
0.3 
-0.001 
(0.001); 
0.1 
C-G LBW -0.069 
(0.081); 
0.4 
-0.001 
(0.001); 
0.2 
-0.001 
(0.001); 
0.1 
-0.028 
(0.150); 
0.9 
-0.001 
(0.001); 
0.2 
-0.001 
(0.001); 
0.6 
-0.042 
(0.096); 
0.7 
-0.001 
(0.001; 
0.3 
-0.001 
(0.001); 
0.2 
C-G NBW -0.076 
(0.058); 
0.2 
-0.001 
(0.000); 
0.05 
-0.001 
(0.001); 
0.1 
0.029 
(0.102); 
0.8 
-0.001 
(0.001); 
0.3 
-0.000 
(0.001); 
0.7 
-0.101 
(0.070); 
0.2 
-0.001 
(0.001); 
0.09 
-0.001 
(0.001); 
0.09 
Salazar-
Corcoran 
-0.045 
(0.056); 
0.4 
-0.001 
(0.000); 
0.1 
-0.001 
(0.001); 
0.07 
0.017 
(0.099); 
0.9 
-0.001 
(0.001); 
0.2 
-0.001 
(0.001); 
0.5 
-0.040 
(0.068); 
0.6 
-0.001 
(0.001); 
0.2 
-0.001 
(0.001); 
0.1 
MDRD -0.097 
(0.059); 
0.1 
-0.001 
(0.000); 
0.05 
-0.001 
(0.001); 
0.1 
-0.012 
(0.110); 
0.9 
-0.001 
(0.001); 
0.4 
-0.000 
(0.001);0.7 
-0.114 
(0.068); 
0.1 
-0.001 
(0.001); 
0.07 
-0.001 
(0.001); 
0.08 
CKD-EPI -0.069 
(0.082); 
0.4 
-0.001 
(0.001); 
0.09 
-0.001 
(0.001); 
0.2 
0.029 
(0.130); 
0.8 
-0.001 
(0.001); 
0.1 
-0.000 
(0.001); 
0.9 
-0.097 
(0.109); 
0.4 
-0.001 
(0.001); 
0.2 
-0.001 
(0.001); 
0.2 
 
Data were analyzed in BMI, Framingham score, ethnicity, deformed joints, CDAI, chloroquine, leflunomide, penicillamine, prednisone and non-steroidal  
antiinflammatory agent use adjusted linear regression models. 
Significant relations are shown in bold. 
EGFR = estimated glomerular filtration rate, RA = rheumatoid arthritis, VCAM-1 = vascular adhesion molecule-1, ICAM-1 = intercellular adhesion  
molecule-1, C-G = Cockroft-Gault, AWB = actual body weight, IBW = ideal body weight, ADBW = adjusted body weight, LBW = lean body weight, NBW  
= no body weight, MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.  
 
 
 
S3 Table.  Associations of EGFR with carotid intima-media  
thickness and plaque (per 1 SD increase in eGFR) in 108 black patients with IDMS  
traceable creatinine results.  
 
 CIMT  Plaque  
EGFR equation  (SE)  p OR (95% CI) p 
Jelliffe -0.002 (0.001) 
 
0.004 0.34 (0.18-0.65)  
 
0.001 
C-G ACBW -0.001 (0.001)  
 
0.002 0.28 (0.14-0.60) 
 
0.008 
C-G IBW -0.002 (0.001)  
 
0.001 0.34 (0.17-0.66)  
 
0.002 
C-G ADBW -0.002 (0.000)  
 
0.001 0.33 (0.17-0.65)  
 
0.001 
C-G LBW -0.002 (0.001)  
 
0.003 0.35 (0.18-0.70)  
 
0.002 
C-G NBW -0.002 (0.000) 
 
0.0003 0.34 (0.18-0.65) 
 
0.002 
Salazar-Corcoran -0.001 (0.000)  
 
0.0008 0.33 (0.17-0.70)  
 
0.001 
MDRD -0.001 (0.000)  
 
0.02 0.40 (0.21-0.80)  
 
0.003 
CKD-EPI -0.002 (0.000)  
 
0.002 0.41 (0.24-0.71)  
 
0.001 
 
Data were analyzed in BMI, Framingham score, ethnicity, deformed joints, CDAI,  
chloroquine, leflunomide, penicillamine and non-steroidal antiinflammatory agent  
use adjusted linear or logistic regression models for cIMT and plaque, respectively. 
Significant relations are shown in bold. 
EGFR = estimated glomerular filtration rate, SD = standard deviation, IDMS =  
isotope dilution mass spectrometry, RA = rheumatoid arthritis, cIMT= carotid  
intima-media thickness, C-G = Cockroft-Gault, AWB = actual body weight, IBW =  
ideal body weight, ADBW = adjusted body weight, LBW = lean body weight,  
NBW = no body weight, MDRD = Modification of Diet in Renal Disease,  
CKD-EPI = Chronic Kidney Disease Epidemiology Collaboration.  
 
 
 
 
S4 Table.  EGFR equations without anthropometric measures in  
black compared to white RA patients after adjustment for metabolic risk. 
 
EGFR equation Black (n=112) White (n=121) p* p† p§ 
Jelliffe 76 (19) 82 (24) 0.2 0.5 0.6 
C-G NBW 87 (22) 94 (28) 0.2 0.4 0.5 
MDRD 78 (20) 89 (27) 0.01 0.04 0.05 
CKD-EPI 90 (17) 95 (17) 0.08 0.3 0.3 
  
Significant associations are shown in bold. 
EGFR = estimated glomerular filtration rate, C-G = Cockcroft-Gault, NBW = no  
body weight, MDRD = Modification of Diet in Renal Disease, CKD-EPI = Chronic  
Kidney Disease Epidemiology Collaboration.  
*adjusted for body mass index 
†additionally adjusted for hypertension 
§additionally adjusted for diabetes  
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Summary and conclusions 
      This thesis comprises of 6 controlled studies that were aimed at 
investigating the atherosclerosis burden and its risk factors in black African 
patients with RA.  The control groups included mostly white Africans with RA 
(papers 1), non-RA black African persons (paper 2) or exclusively white Africans 
with RA (papers 3 to 6).   
      Atherosclerotic cardiovascular disease risk remains lower in the sub-
Saharan black African population compared to developed populations.  
However, recent studies have documented an emergence of atherosclerotic 
risk factor profiles and disease in South African black Africans [1-4].  This is in 
keeping with the presence of a socioeconomic development induced 
epidemiological health transition in the respective population [5].  In this 
regard, South Africa is socioeconomically more developed than other sub-
Saharan African countries but vast income and health inequalities persist [6]. 
      It is now well recognized that RA enhances the risk of particularly 
atherosclerotic cardiovascular disease [7-9].  However, these data originate 
generally in studies that were performed in RA patients living in developed 
countries that are further mostly inhabited by white populations.  RA occurs as 
frequently in black as white urbanized Africans [10,11]. 
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      These reported evidences triggered the work presented in this thesis.  
Initially and as given in paper 1, we investigated whether the atherosclerotic 
cardiovascular risk burden was more favourable in black compared to other 
Africans with RA.  In keeping with the presence of an earlier health transition 
stage as reported in non RA black Africans, we found disparities in the 
prevalence of individual traditional cardiovascular risk factors amongst the 2 
groups.  Indeed, black African RA patients experienced more frequent 
hypertension and obesity and smoked less often.  Strikingly however, the 
overall traditional atherosclerotic cardiovascular risk burden was as large in 
black compared other Africans.  In addition, the burden of non-traditional 
atherosclerotic cardiovascular risk factors or RA characteristics did not differ by 
population origin.  This indicates that black African persons that have 
developed RA may no longer experience the protection against atherosclerosis 
that is reported in their non-RA counterparts.  Cardiovascular risk stratification 
and management should be performed irrespective of ethnic origin and 
epidemiological transition stage in RA. 
      Is the unanticipated large atherosclerotic cardiovascular risk burden in 
black African patients as found in paper 1, attributable to RA?  To address this 
question, we explored the impact of RA on atherosclerotic cardiovascular risk 
factor profiles and carotid intima-media thickness in black Africans with and 
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without established RA.   In contrast to the association of RA with adverse 
traditional risk factor profiles that was reported in patients from developed 
populations, RA was not independently related to either dyslipidemia, 
hypertension, diabetes or smoking prevalence.  Also, whereas RA associates 
with excess adiposity in developed populations, overall and abdominal obesity 
were reduced in black Africans with RA.  Joint derived cytokines or high grade 
inflammation mediated the adverse alterations in metabolic risk factors in 
previous RA studies [12,13].  In the African black population, we found that 
circulating C-reactive protein concentrations were unchanged and interleukin-
6 levels were reduced among patients with RA.  In line with this, systemic 
inflammation was not related to clinical RA activity parameters in these 
patients.  Finally, no difference in carotid intima-media thickness was observed 
in RA compared to non-RA black Africans.  This study indicates that RA does 
not enhance atherosclerotic cardiovascular disease risk in black Africans with 
RA.  An absent interleukin-6 release from inflamed joints into the circulation 
may account for this unaltered cardiovascular disease risk. 
Given the unfavourable atherosclerotic cardiovascular risk factor profiles in 
black Africans with RA (paper 1), is the atherosclerosis burden still smaller in 
this group compared to white Africans that constitute a developed population?  
Also, does an earlier epidemiological heath transition stage translate into a 
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potentially altered influence of cardiovascular risk factors on atherosclerosis in 
black Africans with RA?  These questions were addressed in paper 3.  The 
ultrasound determined carotid atherosclerosis burden and its relations with 
atherosclerotic risk factors were compared amongst black and white Africans 
with RA.  Disparities in cardiovascular risk factors amongst the two groups 
were overall similar to those reported in paper 1.  In demographic variable 
adjusted regression models, carotid plaque prevalence and intima-media 
thickness were as large in black as in white Africans with RA.  Systolic blood 
pressure, total cholesterol-to-high density lipoprotein ratio, extraarticular 
manifestations and C-reactive protein concentrations were associated with 
atherosclerosis in white but not black African patients with RA.  By contrast, 
the Arthritis Impact Measurement Scales tension score was related to both 
plaque and intima-media thickness only in black African RA patients.  The 
Framingham score was strongly related to intima-media thickness in white but 
not black patients.   
      This study has several clinical implications.  Firstly, it supports the 
conclusion in paper 1, i.e. that cardiovascular risk should be adequately 
addressed in patients with RA irrespective of ethnic origin and epidemiological 
transition stage.  Secondly and more challengingly, data on cardiovascular 
disease risk stratification in RA that originate in developed populations [9] 
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cannot merely be extrapolated in developing populations.  Interestingly and 
support of this interpretation, we recently documented that the Framingham 
score and SCORE at markedly low cut-off values are useful in identifying 
Spanish and South African white but not black RA patients with very high 
cardiovascular risk as represented by plaque presence [14]. 
      The above reported findings call for the identification of alternative risk 
factors that are useful in cardiovascular disease risk stratification in black 
Africans with RA.  This was the aim addressed in papers 4, 5 and 6.  
      Black African women experience a markedly large adiposity burden [15].  
We therefore performed a detailed analysis of anthropometric measures in 
paper 4.  Associations between adiposity measures and carotid atherosclerosis 
were assessed in black and white African women with RA.  The generalized and 
abdominal obesity burden were larger in black compared to white African 
women with RA.  Fat distribution as reflected by waist-to hip ratio was similar 
in both groups.  The impact of excess adiposity on metabolic abnormalities was 
not influenced by population origin.  The atherosclerosis burden was similar in 
both groups.  Despite the excess adiposity in black African patients with RA, 
associations between anthropometric measures and carotid atherosclerosis 
were consistently absent in this group.  By contrast, body mass index was 
related to carotid intima-media thickness and waist-to-hip ratio to plaque in 
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white RA patients.  These associations were explained by metabolic 
abnormalities.  Anthropometric measures should be considered in 
cardiovascular risk stratification among white patients with RA.  The excess 
adiposity experienced by black African RA patients does not translate into 
atheroma at this stage. 
      The metabolic syndrome is associated with a 2 fold increased risk of 
cardiovascular events [13].  In non-diabetic patients, this cluster of interrelated 
risk factors also increases the risk of type 2 diabetes 2 to 5 fold [13].  The 
metabolic syndrome comprises excess adiposity and its metabolic 
complications [13].  In RA patients from developed populations, metabolic risk 
factors are associated with atherosclerosis [13,16,17].  We evaluated the 
National Cholesterol Education Program Adult Treatment Panel III Metabolic 
Syndrome in black and white African women with RA [13].  The metabolic 
syndrome prevalence (30.8% versus 9.7%) and mean number of criteria (2.1 
versus 1.3) were each significantly larger in black compared to white African 
women with RA.  In white African RA women, the metabolic syndrome 
definition was associated with carotid intima-media thickness whereas the 
number of criteria and triglyceride criterion were associated with plaque.  By 
contrast, among black African RA women, the blood pressure criterion was 
related to carotid intima-media thickness, which can represent age and blood 
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pressure induced hypertrophy of medial cells rather than atherosclerosis.  
These findings indicate that cardiovascular risk stratification should be 
performed irrespective of metabolic abnormalities in black African women 
with RA. 
      Chronic kidney disease as mostly determined by reduced estimated 
glomerular filtration rate, is a strong independent cardiovascular risk factor 
and its prevalence may be much larger in sub-Saharan black Africans compared 
to persons belonging to developed populations [18,19].  Chronic kidney 
disease is associated with cardiovascular disease in RA patients from 
developed populations.  In paper 6, we calculated 9 reported estimated 
glomerular filtration rate equations in black and white African patients with 
RA.  We compared the prevalence of chronic kidney disease (Chronic Kidney 
Disease Epidemiology Collaboration estimated glomerular filtration rate <90 
ml/min/1.73 m
2
) and the associations of estimated glomerular filtration rate 
equations with endothelial activation and carotid intima-media thickness and 
plaque between black and white Africans with RA.   
      A reduced estimated glomerular filtration rate was observed in 49.1% of 
black and 30.6% of white African RA patients.  The estimated glomerular 
filtration rate was overall consistently associated with monocyte 
chemoattractant protein-1 and angiopoietin 2 among white but not black 
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African RA patients.  By contrast, all except the Modification of Diet in Renal 
Disease equation were associated to a similar extent with both carotid artery 
intima-media thickness and plaque in Receiver Operating Characteristic curve 
analysis among black but not white African patients with RA.  The area under 
the curve in Receiver operating characteristic curve analysis ranged from 0.607 
for the Chronic Kidney Disease Epidemiology Collaboration equation to 0.670 
for the Cockroft-Gault actual body weight equation.  The optimal cut-off values 
ranged from 49 ml/min/m
2
 for the Cockroft-Gaultlean body weight equation to 
85 ml/min/m
2
for Cockroft-Gault actual body weight equation.  Specificities and 
sensitivities ranged from 42% to 60% and 70% to 91%, respectively.  In 
European League Against Rheumatism modified Framingham score adjusted 
regression analysis, a reduced estimated glomerular filtration rate increased 
the odds ratio for plaque 2.2 to 4.0 fold.  A low estimated glomerular filtration 
rate comprises the first reported and in fact routinely available cardiovascular 
risk marker that was found to be clinically useful in atherosclerotic 
cardiovascular disease risk stratification. 
      Taken together, the 3 main findings in the work presented in this thesis are: 
(1) whereas black African patients with RA are currently indeed at an earlier 
epidemiological transition stage compared to their white counterparts, 
theiroverall cardiovascular risk and atherosclerosis burden arenot reduced; (2) 
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the modifiable traditional atherosclerotic cardiovascular risk factors of 
hypertension, dyslipidemia and obesity as well as RA characteristics are not 
associated with atherosclerosis in black Africans with RA and (3) estimated 
glomerular filtration rate equations are clinically useful in identifying black 
African RA patients with very high risk of atherosclerotic cardiovascular events 
as represented by plaque presence. 
      Interestingly, RA did not adversely impact on cardiovascular risk factor 
profiles and carotid intima-media thickness amongst black Africans.  A 
limitation in this study is that carotid artery plaque prevalence was not 
determined among non-RA subjects, as arterial plaque is a more definite 
marker of atherosclerosis than intima-media thickness [20-25].  Therefore, the 
potential impact of RA on atherosclerosisamong black Africans requires further 
investigation. 
Given these findings, can cardiovascular disease risk be reliably performed in 
black Africans with RA?  Although the estimated glomerular filtration rate 
equations were found to be useful in this context, the area under the curve in 
Receiver Operating Characteristic curve analysis for their relationships with 
carotid artery plaque was consistently lower than 0.700.  Clearly, other 
approaches are urgently needed to more adequately identify black African RA 
patients that are at high cardiovascular risk and therefore need intervention 
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with cardiovascular drugs and particularly lipid lowering agents.  One option 
would be to systematically perform carotid ultrasound in these patients.  
However, sub-Saharan black Africans with RA have generally no access to this 
investigation at present.  In this regard, it is of interest that we recently 
identified population origin independent relationships between novel 
cardiovascular risk biomarkers and subclinical cardiovascular disease among 
African patients with RA.  This was the case for circulating concentrations of 
interleukin-6 and several adipokines [26-32].   
      The studies presented in this thesis have strengths and further limitations.  
We comprehensively assessed potential traditional and non-traditional 
cardiovascular risk factors in relatively large groups of black African RA patients 
and controls.  Besides the infrequent and absent use of biological agents in 
white and black Africans with RA, respectively, non-steroidal anti-inflammatory 
agents, glucocorticoids and traditional synthetic disease modifying agents were 
employed to a similar extent in both groups.  Confounder adjusted 
multivariable regression analysis was applied throughout.  The most important 
limitation is that the present studies were each cross-sectionally designed.  The 
reported data require confirmation in longitudinal investigations.  Further, the 
high frequency of hypertension among black African RA patients indicates a 
need for inclusion of aortic and left ventricular function as outcomes in future 
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studies.Finally, whether RA increases cardiovascular event rates among black 
Africans requires further studies.  Notably in this regard, we found no increase 
in the cardiovascular risk factor burden and carotid intima-media thickness 
among black RA compared to non-RA subjects.  However, as the presence of 
established ischemic heart, cerebrovascular or/and peripheral artery disease 
or/and heart failure could not be consistently and reliably ascertained in non-
RA subjects, the potential impact of RA on cardiovascular events could not be 
determined. These issues are presently addressed in our setting. 
      In conclusion, the cardiovascular risk and atherosclerosis burden are 
currently as large in black compared to white African patients with RA.  
Modifiable traditional risk factors that are currently recommended for 
consideration in cardiovascular risk stratification strategies were consistently 
unrelated to atherosclerosis in black African patients with RA.  Further, disease 
characteristics were also not associated with atherosclerosis in black African 
RA patients.  Impaired kidney function comprised the only routinely available 
cardiovascular risk factor that was useful in identifying black African RA 
patients with high risk atherosclerosis.  Systematic vascular imaging and 
possibly the use of novel cardiovascular risk biomarkers may be required for 
adequate cardiovascular risk stratification among black African patients with 
RA. 
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